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1 Introduction 
The work presented in this PhD thesis is placed within translational research and focuses 
on biomarker detection in epithelial ovarian cancer. It combines research in cancer medicine 
and biology, bioorganic chemistry, glycobiology, immunology, bioinformatics and 
biostatistics. The first section of the introduction describes the main knowledge of epithelial 
ovarian cancer, including epidemiology, clinical and pathological characteristics, and 
summarizes the current state of biomarker research. The second part describes basic 
glycobiology and links aberrant glycosylation to cancer. 
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1.1 Epithelial Ovarian Cancer 
1.1.1 Epidemiology and Risk Factors 
From 2002 to 2006 the world wide average incidence (Figure 1) of malignant tumors of 
the ovary was 10.7/ 100 000 women, with a median age at diagnosis of 63 years. The risk of 
ovarian cancer increases steadily with age, with the highest risk occurring after menopause. 
Industrial countries in Europe, the USA and Israel have a high incidence of ovarian cancer with 
the lowest occurrence in Japan, compared to the low incidence observed in emerging and 
developing countries. In Switzerland epithelial ovarian cancers (EOC) are diagnosed on 
average in 589 women per year (1), and it is the sixth most common cancer affecting women 
worldwide (2). An already relative 5 year survival rate of 45.9% (Figure 1) dramatically 
decreases to only 20% survival in women with advanced EOC, which is present in 75% of all 
patients diagnosed with an EOC. Thus, EOC is associated with poor survival and represents the 
leading cause of death from a gynaecologic malignancy. 
 
Figure 1 Incidence and relative survival rate of epithelial ovarian cancer. 
Bar plots show common malignancies among women based on the Surveillance, Epidemiology, and 
End Results (SEER) Program (www.seer.cancer.gov) database. SEER incidence between 1973 and 
2006 are shown in the first bar plot. Relative survival rate as seen in the second bar plot is based on the 
November 2008 submission of data from the population-based SEER database including 17 registries 
with follow-up of patients to 2006. Malignant tumors of the ovary are highlighted in dark grey. 
Several potential risk factors of ovarian cancer have been proposed based on the SEER-
Stat Databases (www.seer.cancer.gov) epidemiological data. One theory suggests involvement 
of inflammation as a common risk factor of ovarian cancer. A recent study examined the role 
of talc use, history of endometriosis and use of non-steroidal anti-inflammatory drugs 
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(NSAIDs). It was found that the risk of ovarian cancer increased significantly with increasing 
frequency and duration of talc use. A history of diagnosed endometriosis was also significantly 
associated with a higher risk for subsequently developing ovarian cancer. Further, women who 
were talc users and had a history of endometriosis showed a 3-fold increased risk (3). Contrary 
to the initial hypothesis that risk of ovarian cancer may be reduced by use of NSAIDs, it was 
found that in fact the ovarian cancer risk rose with increasing frequency and years of NSAIDs 
application (3). Additional environmental factors such as asbestos exposure, pelvic 
inflammatory disease and mumps were compatible with the theory that inflammation may be a 
common pathway for ovarian carcinogenesis (3-6). As a path of transmission, talc and asbestos 
found in sanitary pads are suspected to ascend through the fallopian tube to the peritoneal 
cavity, which is why the preventative factor tubal ligation may reduce exposure to these and 
other external carcinogens. 
The remaining two long-held hypotheses are incessant ovulation (7) and gonadotropin 
(8) theories. Both propose that continuous ovulation and gonadotropin hormones (follicle-
stimulating hormone) stimulate cell proliferation resulting in malignant transformation of the 
ovarian surface epithelium (OSE). A protective effect of anovulatory events, such as the oral 
contraceptive pill, pregnancy and lactation are in concordance with these findings (9, 10). 
However, none of these ovulation suppression events alone is sufficient to explain development 
of EOC. Despite anovulation due to breastfeeding and pregnancy, similar cancer risk factors 
were observed in both pre- and post-menopausal women. Lifetime ovulation is suspected to be 
involved mainly in the pathogenesis of pre- but not post-menopausal ovarian cancer patients, 
whilst the protective effects of years of anovulation seem to persist till post menopause (11). 
Hereditary defects are other critical risk factors. Multiple cases of breast and ovarian 
carcinomas within an individual family are the cardinal indicators of a possible BRCA1 or 
BRCA2 gene mutation (12). Women with these mutations inherit a 5- to 20-fold increased risk 
of developing breast and ovarian cancer (13). Hereditary BRCA1 or BRCA2 mutation-related 
EOC tends to occur at an earlier age than sporadic tumors, and are more often high-grade 
serous ovarian cancers with p53 protein dysfunction (14). 
1.1.2 Screening and Management 
Despite the genetic distinction between various EOC histological subtypes (15), they 
are always treated in the same manner. The standard initial management of EOC consists of 
surgical staging or debulking including total abdominal hysterectomy, bilateral salpingo-
oophorectomy, infra-colic omentectomy and possible pelvic and para-aortic lympadenectomy 
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or appendectomy. The aim of this operation is maximal cytoreduction (16, 17) leaving no 
residual tumor or individual deposits less than 1cm in diameter. Optimal cytoreduction with 
residual volumes less than 1cm in size is associated with a markedly improved disease-specific 
and relapse-free survival (18). 
Post-operative treatment includes six cycles of intravenous Carboplatin and Paclitaxel 
chemotherapy (19-21) which in some cases of optimal debulking is partially given intra-
peritoneally. Since the introduction of platinum-based chemotherapies this class of drugs has 
shown maximal potency for ovarian cancers (19). 
Nowadays, detection of EOC is usually performed using tests that examine the ovaries, 
pelvis, blood and ovarian tissue. A pelvic assessment includes bimanual examination of the 
vagina, cervix, fallopian tubes and rectum. Further, abdominal and transvaginal ultrasound 
examinations are performed to image the internal genital organs. Biomarker CA125 levels are 
usually measured to evaluate protein concentrations in blood serum and consolidate suspect 
findings of the clinical examinations. 
Early diagnosis of EOC is difficult due to the non-specificity and vagueness of 
symptoms. Early phase symptoms are characterized by dyspareunia, abdominal pressure and 
pain. These symptoms are also present in advanced disease with additional symptoms 
including bloating, nausea, anorexia as well as abdominal distension mostly caused by 
increasing ascites. 
Despite enhancements in imaging technology, gray-scale transvaginal ultrasonography 
remains the standard in evaluation of ovarian cancer (22) which is assessed by size, mass 
characteristics (cystic, solid, or both), complexity (internal septae, excrescences and papillae), 
and the presence or absence of abdominal or pelvic fluid (ascites or blood). Gray-scale and 
Doppler ultrasound examinations can help to discriminate between benign and malignant 
adnexal masses (23, 24). Ultrasonography and computed tomography have similar sensitivity 
and specificity for evaluation of adnexal masses, but ultrasonography is generally more cost-
effective (25). 
The current tumor marker, CA125, is applied as a biochemical detection tool. It is a 
glycoprotein usually elevated in patients with ovarian tumors displaying low-malignant and 
malignant potential. Significantly increased levels of CA125 are often obscured by several 
benign conditions including cirrhosis, disease involvement of a serosal surface, endometriosis, 
pelvic inflammatory disease, uterine leiomyoma as well as malignant cross-indications caused 
by breast, lung, endometrial and pancreatic cancer (26). Nevertheless, CA125 has proved to be 
a useful serum tumor marker for the purpose of monitoring response to chemotherapy, 
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detecting disease recurrence, distinguishing malignant from benign pelvic masses, and 
potentially improving clinical trial design (27). 
1.1.3 Clinical and Pathological Characteristics of Epithelial Ovarian Tumors 
Tumors of the ovary are named according to the type of cells the tumor originated from. 
There are three main types of ovarian tumors: 
1.) stromal tumors arising from the connective tissue of the ovary, 
2.) germ cell tumors derive from the gonadal tissues, and 
3.) epithelial ovarian tumors are thought to originate from the ovarian surface 
epithelium. These tumors are the most common tumors of the ovary, representing >90% of all 
cases. 
1.1.3.1 Grading 
Based on the proliferative spectrum of epithelial ovarian tumors, and recommendations 
from the International Federation of Gynaecology and Obstetrics (FIGO) and World Health 
Organization (WHO), subgroups are categorized into benign, borderline (BL, also referred to 
as ‘proliferating tumor’ or ‘tumor of low-malignant potential’ (LMP)) (28) and malignant 
categories. Malignant tumors are classified by their histopathological grade. Grading schemes 
analyze the microscopic architectural and cellular characteristics, such as tubule formation, 
mitotic rate and nuclear pleomorphism. However, due to lack of standardization, applying one 
single grading system to all the histological subtypes of EOC is difficult and clear cell ovarian 
cancers are therefore not graded at all. EOC with well differentiated cells are classified as the 
lowest grade (grade 1). Grade 2 describes moderately differentiated cells and in highest grades 
(grade 3 and 4) tumor cells are poorly differentiated or undifferentiated. In the majority of 
these cases, a clear separation is difficult and thus grades 3 and 4 are usually combined. Higher 
grades are associated with an increased malignant potential of cancer cells, as well as the 
ability to spread faster and an increasing potential for disease recurrence. The chance of a 
better outcome or successful treatment is ameliorated if the grade of EOC is lower. 
1.1.3.2 Histological Subtypes and Their Pathological Morphology 
The heterogeneity of epithelial ovarian tumors is exhibited by the appearance of diverse 
histological subtypes classified according to their patterns of differentiation (27, 29, 30). The 
following paragraphs briefly highlight the common histotypes of ovarian tumors and their 
pathological morphology with the main focus on EOC. 
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1.1.3.2.1 Serous Ovarian Tumors 
Serous tumors of the ovary are usually classified based on the proclivity of their 
epithelium to produce fine papillary structures. Their epithelial cells resemble those of the 
native fallopian tube mucosa (Figure 2 c). Cells of moderately and poorly differentiated serous 
ovarian cancers (SOC) (Figure 2 b) are small with round to slightly oval nuclei and prominent 
nucleoli. The cytoplasm is generally scant and basophilic or amphophilic with indistinct cell 
borders (31). A characteristic of SOC is the presence of randomly distributed single 
mononuclear tumor giant cells, sometimes clustered in areas of ischemic degeneration. High 
protein expression of cytokeratins, epithelial membrane antigen (EMA) and milk fat globule-
EGF factor 8 protein (HMFG-IIIC12) are immunohistochemical features found in SOC cells 
(31). SOC accounts for approximately 60% to 80% of all EOC and is by far the most 
aggressive histological type (32). Recent findings distinguish low and high grade SOC 
subtypes. High grade SOC involves the surface of the ovary, often bilaterally, along with the 
peritoneal membranes, with rapid onset of carcinomatosis, a fact that restricts the surgical 
option for complete debulking (32). Low grade SOC often originates from a serous borderline 
tumor. These tumors can be reproducibly differentiated from high grade tumors, based 
primarily on their very uniform nuclei, using low mitotic rate as a secondary diagnostic feature 
(33, 34). 
1.1.3.2.2 Endometrioid Ovarian Tumors 
Endometrioid tumors of the ovary are very rarely found in benign and low-malignant 
conditions. It is the second most common subtype of EOC representing approximately 20% of 
all cases (Figure 2 d). The majority of reported cases of endometrioid histotype are well or 
moderately differentiated endometrioid EOC (EnOC) (Figure 2 b). Low grade EnOC are 
strongly associated with endometriosis. Similar molecular genetic alterations, including loss of 
heterozygosity at 19q23 and mutations in PTEN, have been reported in endometriosis, atypical 
endometriosis and EnOC in the same specimen (35-38). EnOC are macroscopically 
characterized by cysts with a smooth outer surface and soft masses or papillae partly filling 
cystic spaces. EnOC display histological variability showing microglandular or trabecular 
patterns and elongated nuclei with coarse granular chromatin. Their morphological patterns 
tend to resemble those of proliferative endometrium (Figure 2 c). Using immunohistochemical 
techniques, EnOC also stain positive for cytokeratins and epithelial membrane antigen (31). 
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1.1.3.2.3 Mucinous Ovarian Tumors 
Benign mucinous tumors are mostly cystadenomas and are characterized by a uniform 
single layer of tall columnar cells with pale, amphophilic cloudy cytoplasm and small basal 
nuclei. Mucinous ovarian cancers (MOC) are much less common than was previously 
assumed, as historically, many case series included specimen of metastatic carcinoma with 
mucinous differentiation which were found to be primary gastrointestinal or hepato-biliary 
cancers (39). The morphology of benign as well as (low-) malignant mucinous cells resemble 
those of the endocervix and gastrointestinal mucosa (31) (Figure 2 b, c). The large size of MOC 
and their unilateral presentation underscores the fact that they grow slowly (40). It has been 
suggested that MOC develop slowly, in a stepwise fashion from benign precursors. This was 
emphasized by molecular genetic studies which have shown that the most common molecular 
genetic alterations in mucinous BL and MOC is a point mutation in KRAS (41-43). MOC are 
estimated to make up maximally 10% of all EOC. Malignant tumors of mucinous subtype are 
predominantly multilocular cystic neoplasms. They consist of solid areas and luminal nodules 
which are more common than in the less proliferative lesions, as haemorrhage and necrosis are 
(31). Microscopically, MOC show proliferating and benign areas. Invasive areas usually 
resemble mucin-secreting adenocarcinomas of intestinal origin. Their architecture varies with 
the amount of mucin produced, cellular differentiation and prominence of stroma (31). 
1.1.3.2.4 Clear Cell Ovarian Tumors 
Clear cell tumors share the same proliferative characteristics as other epithelial ovarian 
tumor histotypes do. However, benign tumors and proliferating clear cell tumors are extremely 
rare (2-5%) (Figure 2 d). Clear cell ovarian cancers (ClCOC) are macroscopically characterized 
by large thick-walled unilocular cysts containing blood-stained fluid with polyploidy nodules. 
They usually consist of small to large layers of polyhedral clear cells separated by delicate 
fibro- vascular septa. Their cells have distinct cell borders and eccentric rounded or slightly 
angular nuclei (31). ClCOC are also strongly associated with the presence of endometriosis 
(39). Using immunohistochemistry, high grade ClCOC diffusely stains for cytokeratins, the 
CA125 antigen, as well as for vimentin. 
1.1.3.2.5 Less Common Histotypes of Epithelial Ovarian Tumors 
Transitional cell tumors seem to derive directly from the OSE which undergoes 
metaplasia to form uroethelial-like epithelium. They share cytological as well as 
immunohistochemical similarities with the epithelium lining the urinary tract (44). It resembles 
those of the Walthard rests, which are epithelial inclusions found most commonly beneath the 
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serosal surface of the fallopian tubes. Transitional cell ovarian cancers (TCOC), also referred 
to as malignant Brenner tumors, show a heterogeneous solid malignant proliferation with 
variable amounts of intervening stroma. 
Mixed epithelial tumors are defined by the presence of two or more of the epithelial 
elements described above. They are found throughout the full proliferative spectrum from 
benign tumors to invasive carcinomas. A mix of serous and endometrioid characteristics is 
most commonly observed in benign tumors, whereas malignant tumors with mixed histotypes 
consists of SOC/ EnOC and EnOC/ ClCOC (31). 
Undifferentiated ovarian carcinomas (Figure 2 d) include tumors with minimal 
differentiation such as occasional endometrial glands, psammoma bodies and droplets or pools 
of mucin. Macroscopically, tumors tend to be large and solid with haemorrhage and necrosis 
commonly present. Several histopathological features are detectable with epithelial cell 
markers such as cytokeratins staining positively in following immunohistochemical 
examination (31). 
1.1.3.3 Heterogeneity and Determination of Morphological Identity 
A paradigm shift has happened in EOC during the last decade in that this formerly 
uniform disease was recognised to be of heterogeneous nature. Classification of these already 
heterogeneous tumors is further complicated by the presence of fallopian tube and primary 
peritoneal cancers. In some cases, at advanced stages, it is difficult to determine if the cancer 
originated from the ovary, tube or peritoneum. Their morphological and clinical similarity to 
EOC is possibly due to the OSE, the peritoneal, and the fallopian tube epithelia all sharing the 
same embryonic precursor (Figure 2 a, c). Observations suggest that some EOC originate from 
the fimbria of the distal tubes (45). OSE and the Mullerian ducts, a tissue of mesodermal origin 
that develops to form the fallopian tubes, uterus, and the upper portion of the vagina, are 
derived from the embryonic coelomic epithelium (46, 47). OSE is a simple cell surface 
monolayer that resembles the mesothelial lining of the abdominal cavity, whereas Mullerian 
epithelium is organized in tubal or glandular structures. The development of the reproductive 
tract is tightly regulated by homeobox genes (48). Many morphologic characteristics present in 
EOC are similar to those of the Mullerian lineages, e.g. EnOC are characterized by 
endometrial-like structures, SOC resemble malignant tumors of the fallopian tube (Figure 2 b, 
c), and MOC are composed of intestinal- or endocervical-like cells (49, 50) (Figure 2 b, c). This 
theory was confirmed by gene expression analysis on homeobox genes (Table 1). Genes that are 
exclusively expressed in Mullerian duct cells were also found in EOC subtypes according to 
Francis Jacob  Introduction 
 9 
the pattern of Mullerian-like differentiation, but were not expressed in OSE (51, 52) (Table 1). 
The lack of an explanation for the Mullerian-like features of EOC has stimulated the debate 
challenging the traditional notion that the OSE is the cell-of-origin of these cancer types (53, 
54). 
homeobox gene usually 
expressed in * 
EOC 
expression 
stable expression in transformed 
mouse OSE induces formation of 
HOXA9 
fallopian tube, 
endometrium, 
endocervix 
SOC, EnOC, 
MOC 
cystic, papillary tumors resembling 
SOC 
HOXA10 endometrium, 
endocervix MOC, EnOC glandular tumors resembling EnOC 
HOXA11 endocervix, lower 
uterine segment MOC tumors resembling MOC 
Table 1 HOX gene expression in epithelial ovarian cancer. 
*Weak or no staining for homeobox proteins is present in healthy OSE cells. Abbreviations: serous 
(SOC), endometrioid (EnOC), and mucinous (MOC) ovarian cancer; Table is adapted from Hennessy et 
al. 2009 (18). 
Several mouse genetic models have supported OSE as the origin of EOC (55, 56). 
Auersperg et al. 2001 have speculated that Mullerian metaplasia is possibly connected to 
ovarian neoplasia, and that OSE cells gain a growth advantage by acquiring Mullerian-like 
phenotypes. They have speculated that Mullerian-like differentiation of OSE cells may increase 
hormone responses, because estrogens have mitogenic effects on Mullerian epithelium but not 
on OSE. Unlike Mullerian epithelium, OSE only has a fragile attachment to underlying stromal 
components, and therefore Mullerian-like differentiation may enhance epithelial–stromal 
interactions. These explanations for Mullerian-like involvement in differentiation of OSE cells 
is interesting but has yet not been investigated further. 
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Figure 2 Histopathology and morphological features of common epithelial ovarian cancer subtypes. 
Hematoxylin–eosin-stained sections of (a) normal human ovary surrounded by a monolayer epithelium 
(arrow) and containing an inclusion cyst (i.c.), (b) sections of ovarian carcinomas: serous, with papillary 
features; endometrioid, with glandular features; and mucinous. (c) Tissue sections of normal fallopian 
tube epithelium, endometrium and endocervix. (d) Distribution of histological subtypes. Figure adapted 
from Naora et al. 2007 (50). Black bar (a) indicates 50 µm. 
1.1.3.4 Staging 
The FIGO staging system has been structured to uniformly represent the major 
prognostic factors in predicting patient outcome and lending order to the complex dynamic 
behaviours of gynaecologic cancers. The FIGO system offers a classification of gynaecologic 
cancers in a unique setting and thus allows comparisons between clinical cases (57). 
Proliferating and invasive malignant tumors of the ovary are staged (FIGO) as: Stage I A-C, 
Stage II A-C, Stage III A-C, and Stage IV. Briefly, Stage I tumors are confined to one or both 
ovaries. Tumors that have spread to pelvic organs (e.g. fallopian tubes, uterus) without 
metastasis to abdominal regions are defined as Stage II. At Stage III, one or both ovaries are 
affected by malignant tissue with additionally at least microscopically confirmed peritoneal 
metastasis outside the pelvis and/ or regional lymph node metastasis. Stage IV tumors of the 
ovary have metastases in other organs outside the peritoneal cavity. 
1.1.4 Genetic Profiling Leads to Development of New Epithelial Ovarian Cancer Models 
Based on the strong heterogeneity of EOC and its unknown cell of origin, it is not 
surprising that new hypotheses are continually arising. Due to the human genome project and 
the era of high-throughput profiling technologies we now have indications that certain 
histological subtypes have a genetically distinct profile (58). Based on recent findings, this 
d 
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section describes the main manifested theories regarding epithelial ovarian cancer 
development. 
One of the most important recent observations is that low grade serous carcinoma 
(LGSC) and high grade serous carcinoma (HGSC) are different tumor types (59, 60). In 70% 
of all investigated cases serous BL tumors and LGSC were characterized by specific mutations 
in BRAF and KRAS. Additional patterns of p53 mutations separate serous BL tumors and 
LGSC, compared to HGSC and support a new model of ovarian carcinogenesis (40, 60, 61). 
P53 gene mutations were shown to be associated with a serous BL components and do not 
seem to be linked to HGSC (62-65). 
Experimental findings have led to the creation of a new model for classifying EOC. In 
this model, two main subclasses have been proposed- Type I and Type II tumors. This 
categorization comprises distinct patterns of tumor progression and molecular genetic changes 
(61, 66). Type I tumors include LGSC, low grade EnOC, MOC, and a subset of ClCOC, which 
evolve in a stepwise fashion from well recognized precursors, in most cases, BL tumors. They 
are mostly characterized by slow growth. The latter, in turn, appear to develop from the OSE or 
inclusion cysts (Figure 2 a) as is the case for SOC and MOC. In this model endometriosis is an 
associated precursor of EnOC and ClCOC (35-39). In contrast, Type II tumors are high grade 
and have generally spread beyond the ovaries at presentation. HGSC, high-grade EnOC, 
undifferentiated EOC and malignant mixed mesodermal tumors are considered to comprise 
Type II group tumors. It is thought that Type II tumors are rarely associated with 
morphologically recognizable precursor lesions and may arise from “dysplasia” in inclusion 
cysts or serous intraepithelial carcinoma in the fallopian tube (67). Type I is usually associated 
with mutations in BRAF, PIK3CA, ERBB2, KRAS, CTNNB1 and PTEN. Type II tumors are 
generally characterized by a high frequency of p53 mutations which occur rarely in Type I 
tumors. This definition is consistent with a recent publication, but indicates that changes 
between different histological subtypes are associated with specific gene expression patterns 
regardless of the substage and grade of the disease (68). 
Another model focuses primarily on MOC, which appears to have weaker associations 
with reproductive factors (69), a positive relationship with smoking that is not observed for 
other histological subtypes (70), and no association with BRCA mutations (71). Their clinical 
and morphological distinction was described and compared to other histological types of EOC. 
Initial gene expression profiling using oligonucleotide arrays and validation by real time 
polymerase chain reaction (PCR) revealed a distinct increase in gene expression of galectin 4 
in MOC compared to other EOC histotypes comprising SOC, EnOC and ClCOC (72). Recent 
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findings based on immunohistochemical analysis support these observations. Zinc finger-
containing GATA transcription factors GATA4 and GATA6 were found to be lost (80%-90%) 
in all histological subtypes except MOC (11/12 cases), where the presence of both transcription 
factors were observed (73). Gene expression patterns of early stage EOC also revealed a clear 
distinction between MOC and other EOC histological subtypes (68). 
1.1.5 Ovarian Cancer Biomarker Detection 
One of the most promising aims to manage EOC is early detection. Early stage EOC can 
be cured with at present available cytoreductive surgery and adjuvant chemotherapy in more 
than 90% of treated patients. So far, CA125 is currently the best biomarker for early detection. 
It is a heavily glycosylated mucin (MUC16) recognized by a murine monoclonal antibody 
(mAb) OC125 (74). This mAb is used in a blood serum-based immunoassay to detect elevated 
CA125 protein levels preferentially in non-mucinous EOC patients (75). To increase 
sensitivity, an advanced second-generation CA125 II sandwich Enzyme-Linked 
Immunosorbent Assay (ELISA) has been widely accepted. It utilizes a distinct mAb to capture 
the protein followed by the use of the original OC125 antibody for detection (76), which 
improves measurement characteristics at low CA125 levels. 
During recent years, enormous effort has been made in the field of early detection of 
EOC. Due to the lack of sensitivity and specificity, CA125 as a sole biochemical biomarker is 
not recommended to screen asymptomatic women for EOC (77). Therefore, novel biochemical 
candidates alone and in combinations which have been previously reported are mentioned and 
described in this chapter. 
1.1.5.1 Single Biomarker Detection 
During the last 20 years, a large number of serum tumor markers have been evaluated 
for their ability to detect EOC at an early stage (Table 2). They were discovered through 
multiple approaches, cDNA and oligonucleotide arrays have identified a number of novel 
biomarkers, including HE4 (78, 79), prostasin (80) and osteopontin (81) (Table 2). 
Another study used a cDNA database mining strategy followed by real time 
quantitative reverse transcription PCR, which identified VTCN1 (B7-H4) (Table 2) as a novel 
gene overexpressed in EOC compared to normal tissue samples (82). Immunohistochemistry 
revealed concordant findings and observed a predominant plasma membrane staining of B7-
H4. Thus, sandwich ELISA was developed by applying two mAbs to two different B7-H4 
protein epitopes (82). Ovarian tissue lysates from 251 women with EOC, benign tumors of the 
ovary, and normal ovaries were investigated and it was found that B7-H4 expression was low 
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in normal and benign ovaries as opposed to high in malignant tumors, with compatible 
sensitivity and specificity compared to CA125 (83). 
Another strategy to identify biomarkers used hybridoma technique to generate mAbs 
that bind to antigens which were found to be present on the surface of mesothelial 
mesothelioma and ovarian cancer cells (84). Mesothelin, a glycosyl-phosphatidylinositol-
anchored glycoprotein present on the cell surface, was discovered via this method. Detection of 
its soluble form using receiver operating characteristics (ROC) analysis showed similar 
detection ability to that of CA125. Improved detection of EOC was achieved using a 
combination of both mesothelin and CA125 (85). Recent findings support an association of 
mesothelin expression to poor survival when examined by real-time quantitative reverse 
transcription PCR (86) and ELISA (87). 
A laboratory investigation into the biology of the epidermal growth factor receptor 
(EGFR) found that decreased expression of a soluble fragment of EGFR is present in serum 
samples obtained from EOC patients (88). Measured concentrations of its 110kDa fragment 
were found to be more effective in discerning advanced from early stage EOC, as well as from 
healthy women, however, no comparison to CA125 was made (89). 
During the last 25 years, despite the intensive screening for other single promising 
biomarkers of EOC, CA125 still holds the leading position in this field. Single biomarker 
candidates are selected by their ability to detect EOC with comparable sensitivity and 
specificity to CA125 (Table 2). Novel single biomarkers and CA125 have been combined by 
different statistical algorithms and reveal a slightly better discrimination than either marker 
alone (85, 90-92). Biomarker validation was predominantly performed on biological fluids, e.g. 
serum, plasma, and urine. To date sandwich ELISA is the leading technique in single 
biomarker measurement, which can be explained by its antigen accessibility. It is also less time 
consuming and more affordable. Using sandwich ELISA, studies have measured the amount of 
antigen between two layers of antibodies; mostly two mAbs directed to different antigenic sites 
of a single biomarker protein. Interestingly, all ten highlighted candidates consist of multiple 
post-translational modifications, however only glycosylation is present in all candidates (Table 
2). 
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Ref. Protein 
name 
Gene name PTM Molecular function 
(75) CA125 MUC16 disulfide bond, glycoprotein, phosphoprotein protein binding 
(90, 
91) HE4* 
WAP5, 
WFDC2 disulfide bond, glycoprotein 
serine-type endopeptidase 
inhibitor activity 
(82, 
83) B7-H4* VTCN1 
disulfide bond, glycoprotein, 
lipoprotein 
negatively regulates T-
cell-mediated immune 
response 
(93) (total) Inhibin* 
INHA & 
INHB(A-C) 
disulfide bond, glycoprotein, 
lipoprotein 
growth factor, hormone, 
cytokine, signal transducer 
(94) Kallikrein8 KLK8 disulfide bond, glycoprotein, 
zymogen 
protein binding, serine-type 
endopeptidase activity 
(95) Mesothelin+ MSLN 
cleavage on pair of basic 
residues, GPI-anchor, 
glycoprotein, lipoprotein 
protein binding 
(96) Nidogen-2* NID2 disulfide bond, glycoprotein calcium ion binding, 
collagen binding 
(81) Osteopontin+ SPP1, BNSP, OPN glycoprotein, phosphoprotein cytokine activity 
(80) Prostasin* PRSS8 disulfide bond, glycoprotein, 
zymogen 
serine-type endopeptidase 
activity 
(88, 
89) c-ErbB-1 
EGFR, 
ERBB1 
disulfide bond, glycoprotein, 
isopeptide bond, phosphoprotein, 
ubiquitin conjugation 
broad spectrum 
Table 2 Potential biomarkers for the detection of epithelial ovarian cancer. 
Biomarkers that compete with CA125 for early detection of EOC are shown. Despite different ways of 
biomarker identification, all listed proteins were measured by sandwich ELISA. All proteins contain 
glycosylation as their main post-translational modifications (PTM). Protein names, gene names, PTM 
and molecular function were taken from UniProt (http://www.uniprot.org/). Reported to complement 
CA125 in the same study* or in a later study+. 
1.1.5.2 Strategies to Improve Biomarker Detection 
Novel technologies have been developed to detect new biomarkers for early detection 
of EOC. In a recent publication, concentrations of leptin, prolactin, osteopontin, insulin-like 
growth factor II, macrophage inhibitory factor, and CA125 were examined using a multiplex, 
bead-based immunoassay system. All six biomarkers exhibited the same pattern for both the 
ELISA and multiplex system. Several models using biomarker combinations revealed a higher 
sensitivity (84%-98%, specificity 95%) than CA125 alone (sensitivity 72%, specificity 95%) 
(97). Another study simultaneously investigated 204 molecules in 294 serum samples by 
multiplex, bead-based immunoassay. A panel of putative biomarkers was found, including 
CA125 which showed the best discriminative power (98). 
To improve the diagnostic performance of single biomarkers, new technologies based 
on high-throughput profiling have emerged during recent years. Serum profiling is mostly 
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based on proteomics (58), the study of an entire set of proteins expressed by its genome. 
Proteomic approaches display a broad spectrum of technical and biological variables. Mass 
spectrometry (MS) is one of the main technologies employed in this field. Surface-enhanced 
laser desorption and ionization (SELDI) for detection of novel cluster patterns of low-
molecular-weight moieties in serum samples from EOC patients has been reported in ROC to 
yield 100% sensitivity and 95% specificity (99), unfortunately no comparison to CA125 
detection was made for final conclusions. Studies on pre-selected peptides employing different 
protein chips (e.g. IMAC3, WCX2 or SAX2) and/ or additional experimental steps are used to 
investigate a sub proteome with defined physiological or chemical properties. For example, a 
publication using a protein chip (IMAC3) with affinity selection for metal-binding proteins 
coupled to SELDI MS demonstrated that a combination of four peptides complement CA125 
performance (100). Another MS approach revealed a putative tumor marker, an 11.7kDa serum 
protein amyloid A1 in pre-selected thermo stable plasma fractions (101). A phosphorylated 
fibrinogen-α-chain isoform was identified as a potential biomarker by 2-dimensional 
polyacrylamide gel electrophoresis (2D-PAGE) and phosphoprotein specific staining (102). 
Another study identified 14 putative tumor markers in serum, pre-processed by biomarker 
enrichment reagent to capture high-abundant carrier proteins in blood (103). Despite promising 
results, MS approaches did not perform better than CA125 in the identification of biomarkers. 
Serological analysis of recombinant cDNA expression (SEREX) is another auspicious 
method to profile EOC biomarkers. To identify ovarian tumor antigens a papillary serous 
carcinoma cDNA library isolated from ascites was transferred into Escherichia coli via a 
bacteriophage expression system. Nitrocellulose transferred plaques were screened against a 
serum pool consisting of serum from 20 patients with advanced EOC. After stripping and re-
probing with pooled normal sera, true-positive immunoreactive clones were identified by 
sequence alignment. SEREX data indicated that interleukin 8 (IL-8) could be a potential target 
for the host immune response, resulting in the generation of anti-IL-8 antibodies. An 
immunofluorescent bead-based assay was subsequently developed to detect IL-8 and 
corresponding anti-IL-8 antibodies. ROC analysis revealed acceptable detection performance 
but did not reach the same levels as those for CA125. Combining IL-8, anti-IL-8 IgG and 
CA125 resulted in an increased classification power compared to markers analyzed 
individually (104). 
High-throughput profiling technologies using serum antibodies are also tools for 
biomarker discovery with good prospects. Recent findings demonstrated the accessibility of 
serum circulating antibodies to tumor-associated antigens in EOC. This is based on recent 
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knowledge of circulating autoantibodies related to EOC-associated antigens, e.g. p53, HOXA7, 
HOXB7, cathepsin D, MUC1, IL-8 and S100A7. These proteins are potential screening tools 
because they are secreted by tumor cells and are detectable by autoantibodies even when the 
tumor is very small and antigen expression is low (105, 106). In EOC it has been shown that 
p53 specific autoantibodies are present and associated with high grade disease (107). These 
findings support the theory of human immune recognition to known and unknown tumor-
associated antigens of any type of biomolecule. 
In 2006, An et al. published the first study, which investigated the role of the glycome 
in EOC, profiling the entire complement of glycans (108). Firstly, oligosaccharides covalently 
linked to human serum proteins and human ovarian cancer cell lines were released chemically. 
Changes in glycosylation were then monitored by matrix-assisted laser desorption/ ionization 
Fourier transform ion cyclotron resonance mass spectrometry (MALDI-FTICR-MS). Mass 
spectrometric analysis of purified oligosaccharides identified 15 unique serum glycan markers 
in all patients, but not in any of the normal controls. This publication was the first EOC 
biomarker detection study using a high-throughput setup to profile changes in glycosylation. 
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1.2 Glycobiology and Cancer 
1.2.1 Glycosylation as the Main Post-Translational Modification Event 
The term “Glycobiology” was first coined in 1988 by Rademacher, Parekh and Dwek 
and is defined in its broadest sense as the study of the structures, biosynthesis, and the biology 
of saccharides (sugar chains or glycans) which are widely distributed in nature. In eukaryotic 
cells, the main mechanisms by which cell surface associated components become glycan-
coated occur in the endoplasmic reticulum–Golgi biosynthetic pathway (109). Glycans on cell 
surfaces, usually named ‘glycocalyx’ (Figure 3 A) were first mentioned by a electron 
microscopists (110). All forms of molecular modifications by oligosaccharides have the 
inherent potential to add new information to the carrier molecule which usually comprises a 
lipid or protein backbone. More than half of all proteins are glycosylated as estimated from the 
SWISS-PROT database (111). Oligosaccharide trees are not primary gene products, but are 
instead built by catalytic reactions of glycan processing enzymes, glycosidases and 
glycosyltransferases, in complex with high energy sugar nucleotide donors. Human cells 
possess a repertoire of about 250 glycan related enzymes, and the co-ordinated action of as 
many as thirty enzymes may be involved in the synthesis of a single complex oligosaccharide 
(112). 
The most common monosaccharide units of animal glycoconjugates (=carbohydrate 
covalently linked to other chemical compounds) appear naturally linked to proteins as N- or O-
linked saccharides, or to lipids via a glycan bridge between phosphatidylinositol and a 
phosphoethanolamine named glycosphingolipids. An N-linked oligosaccharide is a sugar chain 
covalently linked via N-acetyl glucosamine (GlcNAc) to an asparagine residue of a folded 
polypeptide chain within the consensus sequence, Asn-X-Ser/Thr. The synthesis of such an 
oligosaccharide is performed on the cytoplasmic side of the endoplasmic reticulum (109). An 
O-glycan is typically linked to a polypeptide with motif Ser/Thr, via N-acetyl galactosamine 
(GalNAc). There is no defined consensus sequence regarding O-linked glycosylation, however, 
glycosylated Ser/Thr residues are often located in Prolin-rich sequences. O-linked 
glycosylation of glycoproteins is based on post-translational modifications (PTM) which begin 
in the cis-compartment of the Golgi apparatus. Other glycopeptide linkages have been 
described, and thirteen different monosaccharides and eight amino acids are known to be 
involved in glycoprotein linkages among all organisms. If the anomeric configurations, the 
phosphoglycosyl linkages, as well as the GPI (glycophosphatidylinositol) 
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phosphoethanolamine bridge are also considered, the observation results in a total of at 41 
possible bonds (113). 
The genome encoding deoxyribonucleic acid (DNA) is a double-stranded, helical 
polymer of nucleotides (=phosphate group + deoxyribose sugar + heterocyclic nucleotide base) 
that is held together by two or three hydrogen bonds between the nitrogenous bases, adenine-
thymine and cytosine–guanine, respectively. In comparison, a protein (=entire set of proteins is 
named proteome) is a linear polymer of twenty common amino acids linked via a peptide bond. 
Additional biochemical information in proteins lies in various intra- and inter-molecular bonds 
(e.g. disulfide bridges, hydrogen bonds) and in the numerous post-translational modifications 
(PTM). All these interactions and modifications, together with the final tertiary structures of a 
protein, dramatically enhance their functional diversity (Figure 3 B). Among the PTM, protein 
and lipid glycosylation is the major class, and the glycans represented in the glycome (=entire 
repertoire of glycans and glycoconjugates of the organism) provide biological access to vast 
amounts of information at minimum genetic cost (114). Various branched or linear 
glycosylation trees of yet unknown length are assembled from ten monosaccharides: sialic or 
neuraminic acid (Neu5Ac), hexoses glucose (Glc), galactose (Gal), fucose (Fuc) and mannose 
(Man), hexosamines GlcNAc and GalNAc, and less commonly xylose (Xyl), glucuronic acid 
(GlcA) and iduronic acid (IdoA) (Figure 3 C). Generally, most of these monosaccharides are 
linked via alpha (α) or beta (β), 1-2, 1-3, 1-4 or 1-6 glycosidic linkages. In conclusion, 
glycosylation is therefore more abundant and structurally diverse than all other types of PTM 
combined (115, 116). Based on the potential chemical information content of the glycome 
(Figure 3) due to its structure and biological involvement, it is not surprising that glycosylation 
has been linked to a variety of cancers. 
Glycosylation is a common biochemical modification of proteins and lipids, it is 
important for stability, solubility, secretion of signals, regulation of interactions, extracellular 
recognition, and folding (117). Glycan involvement in host-pathogen or -virus interactions 
occurs over a broad biological spectrum. For example, adaptation of hemagglutinin binding of 
avian influenza A viruses to α2-6 sialylated oligosaccharides located in the upper respiratory 
epithelia (118); and glycosaminoglycans and proteoglycans presented on host cell surfaces as 
substrates for the attachment of bacterial pathogens (119, 120). Interestingly, in this context, 
Lewis blood group antigens which are usually located in human gastric mucosa are also present 
on Helicobacter pylori lipopolysaccharide structures to camouflage the bacterium and facilitate 
their initial colonization (121). Glycans have also been described in inherited diseases, e.g. Tn 
(GalNAcα) polyagglutinin syndrome (122) or Wiskott-Aldrich syndrome which are 
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characterized by markedly increased branching of O-glycans on sialophorin, also known as 
leukosialin or CD43, a major glycoprotein of lymphocytes (123). 
 
Figure 3 Relative information content of the glycome. 
Scanning electron microscopy of the villous surface of the mouse small intestine shows the 
‘glycocalyx’ (A). A1- layer of enteric surface glycosylation (x 200 000), A2- glycan surface coat on the 
microvilli (M) of the villous epithelial cells (x 77 000) (124). Glycome enhancement of the molecular 
and functional diversity of the proteome on a log scale of potential chemical information content (114) 
(B). Glycan structures consist of common monosaccharides which appear in higher mammals (C). 
C 
A 1 
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1.2.2 Tumor-Associated Carbohydrate Antigens 
 Glycosylation is a universal feature of all cancer cells, but only certain distinct glycan 
alterations are frequently associated with oncogenic transformation. Aberrant glycosylation 
occurs in essentially all types of human cancers, and many glycosyl epitopes constitute tumor-
associated carbohydrate antigens (TACA) (125). 
1.2.2.1 O-linked Core Structures 
 To date, there are only a few known cancer-related glycans including the ‘core’ O-
glycan family structure Tn (GalNAcα) antigen, one of the most specific human cancer-
associated structures. ‘Core’ structures are short O-linked glycans with the largest being 
trisaccharides (Figure 4). Frequently exposed Tn is caused by increased gene expression of 
ppGalNAc-transferase that attaches the first GalNAc to a polypeptide. High Tn antigen 
expression also correlates with decreased activity of β1-3 galactosyltransferases, catalyzing the 
common core 1 O-glycan structure Galβ1-3GalNAc-Ser/Thr. The core 1 is the precursor for 
mucin-type O-glycan structures in animal cell surfaces and secreted glycoproteins (109). 
Association of breast and colon cancer with sialylated Tn antigens (sTn/ Neu5Acα2-
6GalNAc) (Figure 4) was described as a result of observed competition between α2-6 
sialyltransferases and β1-3 galactosyltransferases (126, 127). Sialylated Tn 
immunohistochemical expression is highly variable in breast cancer. However, it is commonly 
accepted that at least 25-30% of breast tumors are sTn antigen positive. Its expression has also 
been proposed to be an independent predictor of poor prognosis in breast cancer patients (128). 
The Thomsen-Friedenreich antigen (core 1, T antigen, TF/ Galβ1-3GalNAc) is another 
glycan belonging to the ‘core’ structures (Figure 4). This antigen is usually only an intermediate 
structure which is catalyzed to a core 2 (GlcNAcβ1-6(Galβ1-3)GalNAc). Due to its aberrant 
glycosylation, TF has been described as a common glycan of malignant transformation with 
strong immunohistochemical expression in several cancer cell membranes (129). In contrast, 
normal cell surfaces revealed discrete expression of TF. Another study performed on colon 
cancers found that increased expression of TF and core 2 is associated with decreased core 3 
expression (130). MS and nuclear magnetic resonance analysis independently confirmed that 
core 3 structures are expressed in mucins of the descending normal colon (131). 
Other ‘core’ structures are less common, like core 5 antigen which was described in a 
rectal adenocarcinoma mucin-type glycoprotein (132) and in human meconium (133). 
Controversially, a recent study found core 5 glycan structures in mucins from different parts of 
the normal human intestinal tract. Therefore, they suggested that core 5 can not be used to 
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diagnose a pathological case (134). Core 6 O-glycan formation was reported in human 
embryonic gut and mucins in ovarian cysts (109). 
 
Figure 4 Pathway of O-linked ‘core’ structures. 
Increasing length of O-linked ‘core’ structures descended from Tn. Additional monosaccharides are 
added in a stepwise manner to build glycan chains of various length and complexity. Cancer association 
(red) was described on Tn, sTn and TF. Normal cells (blue) exclusively express core 3. 
1.2.2.2 Lewis Blood Group Antigens 
 The term Lewis refers to the family name of individuals who suffered from a red 
blood cell incompatibility that helped lead to the discovery of this frequently called “histo-
blood group antigens” (109). Lewis antigens are widely distributed in human fluids and tissues 
(135). Expression of Lewis antigens depends on alleles inherited on two independent loci, 
FUT3 (Lewis; LE gene) and FUT2 (Secretor SE gene). Both alleles encode different 
fucosyltransferases that interact to form Lewis type 1 and 2. The family of Lewis blood group 
antigens consists of ten naturally occurring glycans with a similar structure which is based on a 
α1-3(4) linked fucose (Figure 5). Lewis structures are receptors for pathogenic bacteria, e.g. 
Helicobacter pylori (136), Candida spp. (137) and uropathogenic Escherichia coli (138). Their 
clinical significance has been described in cardiovascular disease (139), leukocyte adhesion 
deficiency syndrome (140), and renal transplantation (141). 
An association of type 1 (α1-3 fucosylated glycan) Lewis structure and cancer has been 
described. Increased expression of Lewis x (Lex/ Galβ1-4(Fucα1-3)GlcNAc) was found in 
immunohistochemical analysis of colorectal cancers (142), renal cancers (143), and transitional 
carcinoma of the bladder (144). Its sialylated form, sialylated Lex (sLex/ Neu5Acα2-3Galβ1-
4(Fucα1-3)GlcNAc) was identified as a prostate specific antigen, and is a serum marker for 
prostate cancer (145). The presence of sLex was described in poorly differentiated non-small 
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cell pulmonary cancer and in primary liver cancer with significantly higher levels of sLex 
expression compared to low grade cancers (146). 
The malignant transformation of sLex was further investigated by examination of a 
related carbohydrate determinant belonging to 6-sulfation (6’ sulfo sLex). Glycan 6-sulfo sLex 
was preferentially expressed in nonmalignant colonic epithelial cells surrounding cancer cells, 
which is in contrast to non-sulfated sLex, expressed in cancer cells. A possible function of 
sulfated carbohydrate determinants in normal epithelial cells is the absorption of pathogenic 
microorganisms such as viruses and bacteria. The metabolic conversion of sialyl 6-sulfo Lex 
into cyclic 6-sulfo sLex by a calcium dependent enzyme, sialic acid cyclase, occurs as well in 
nonmalignant colonic epithelia (147), probably driven by epigenetic changes. 
Lewis y (Ley/ CD174, Fucα1-2Galβ1-4(Fucα1-3)GlcNAc), another member of the type 
1 Lewis glycan structures, has been found in poorly differentiated carcinomas of the liver, 
colorectum and uterus (148-150). When conjugated to an adjuvant, Ley has been tested as a 
potential vaccine in ovarian cancer and has produced good immune response (151). 
Involvement of type 2 (α1-4 fucosylated glycan) Lewis structures, particularly sialyl 
Lewis a antigen (sLea/ NeuAcα2-3Galβ1-3(Fucα1-4)GlcNAc), also called clinically 
carbohydrate-antigen 19-9 (CA19-9), is associated with a variety of gastrointestinal epithelial 
malignancies and is used as a tumor marker. A gradual increase in the amount of sLea was 
found in colon and rectal tissue during neoplastic transformation and progression (152). Cells 
derived from human lung cancer were tumorigenic in nude mice only when sLea was present 
on the cell surface (153). Sialyl Lea is expressed strongly in cancers of the digestive organs and 
is known to serve as a ligand for vascular E-selectin in haematogenous cancer metastases (125, 
154). Clinicopathological studies have revealed the prognostic potential of sLea expression in 
colorectal carcinoma and their association with a high incidence of relapse and reduced 
survival time (155). 
Other non-sialylated versions of Lewis members were observed to be of importance due 
to their cancer association. Immunohistochemical analysis revealed a significant higher Lewis 
y/b
 (Ley, Leb) expression level in a large set of breast carcinomas and were associated with their 
histological grade, tumor type and Nottingham Prognostic Index (156). 
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Figure 5 Lewis type 1 and 2 glycan structures. 
Lewis glycan structures differ in the linkage of the outermost Gal (β1-3, β1-4) and in the linkage of the 
fucose to the GlcNAc (α1-3, α1-4). Background grayed R, N-, O- or glycolipid- linkage to 
biomolecules. Lewis glycan structures associated to cancer (red), disialylated Lea (di-sLea) and 6’sulfo 
sLex (blue) are preferentially expressed in non-malignant epithelial cells. 
1.2.2.3 Other Tumor-Associated Carbohydrates 
Glycan epitopes such as sTn, Tn and TF in O-linked structures, sLex, sLea and Ley are 
well described in different cancer models. This section describes other known tumor-associated 
carbohydrate structures. 
Increased sialylation is one of the most commonly reported alterations in the 
glycosylation of cancer cell surface glycoproteins and often manifests with an increase in 
sialylated Lewis or sialylated ‘core’ O-linked structures. Accumulation of N-glyconeuraminic 
acid (Neu5Gc) has been reported (1) in melanoma (157) and colorectal cancer (158); on (2) O-
linked glycans in MUC1 in the breast cancer cell line MCF-7 (159); and on (3) N-linked 
glycans in the metastatic lymphoma cell line MDAY-D2 (160). Neu5Gc is produced by 
another type of sialylation, and differs from Neu5Ac by the addition of a single oxygen atom. 
A well known phenomenon of glycan association is altered N-glycan branching. In 
cancer cells an increase of β1-6 branching is caused by upregulated gene expression of GlcNAc 
transferase V. This change occurs at the transcriptional level and is induced by a variety of 
mechanisms including viral and chemical carcinogenesis. High expression of GlcNAc 
transferase V results in an increased metastatic potential of cancer cell lines (109). Increased 
β1-6 branching can be measured by a specific lectin known as leukocytic phytohemagglutinin 
(L-PHA). It does not bind to non-diseased breast epithelial cells, but during the progression to 
invasive carcinoma, cells display an enhanced ability to L-PHA. Immunohistochemical 
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staining of L-PHA identified β1-6 branching as an independent prognostic indicator for poor 
outcome in primary node-negative tumors (161). 
Another family of TACA is comprised of ganglioside members. These are sialic acid-
bearing glycolipids involved in modulating transmembrane signalling which is essential for 
tumor cell growth, invasion, and metastasis. The mayor gangliosides GM2 (Neu5Aca2-
3(GalNAcβ1-4)Galβ1-4Glcβ) and GD3 (Neu5Aca2-8Neu5Aca2-3Galβ1-4Glcβ) are known to 
be expressed by most human cancers of neuro-ectodermal and epithelial origin (162). In 
melanoma cells, ganglioside expression correlates with metastatic potential. They are also 
selectively exposed on tumor cells with invasive potential (163, 164). Two randomized trials 
have used a vaccine against GM2 in advanced stage melanomas (165), bladder cancer (166) 
and colorectal cancer (167). Patients immunized with GM2 developed naturally occurring IgM 
antibodies and showed a significant improvement in relapse-free survival (165). A second 
study confirmed these findings despite use of a different GM2 vaccine (168). GD3 is a minor 
glycan expressed in most normal tissues (169), its expression has also been described on the 
surface of normal human peripheral blood T cells (170). GD3 is highly expressed only during 
development or in pathological conditions like arteriosclerosis and tumors of neuro-ectodermal 
origin (171). 
Globo H (Fucα1-2Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ), a linear 
glycosphingolipid, is another well described TACA. A variety of epithelial carcinomas such as 
colon, ovarian, gastric and lung cancers showed Globo H overexpression (172, 173). High 
expression was also detected by immunohistochemistry in small cell lung cancers with short 
overall survival (174). More than 60% of ductal, lobular and tubular breast cancers showed 
high Gobo H expression whilst no expression could be found in non-epithelial breast tumors 
(175). Recently, Globo H revealed immune response shown by significantly higher levels of 
human anti-glycan antibodies (AGA) in breast cancer serum samples than compared to healthy 
controls (176). 
1.2.3 Naturally Occurring Anti-Glycan Antibodies 
Apart from secreted glycoproteins most cellular glycoconjugates are found in the 
plasma membrane, exposing the glycan moiety to the extracellular space. Due to this location 
and their structural variability, glycans were thought to have a role in cellular “social 
functions” like recognition (177). It is therefore reasonable to hypothesize that the body has 
evolved a recognition system to detect and monitor self and pathogenic glycan profiles. In 
mammalian cells, fungi and parasites carbohydrates or their related glycoconjugates possess 
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unique structural elements specific to their environment, with some serving as a basis for the 
recognition of host proteins. 
Natural antibody producing B cells, natural killer cells, macrophages and dendritic cells 
remove all foreign and potentially harmful substances, e.g. bacteria and viruses, cellular waste, 
modified molecules, and most importantly, cancer cells (178). These natural antibodies are 
made by special types of lymphocytes which play a large role in the humoral immune 
response. Mature B cells, preferentially B1 or CD5+ cells (179, 180) located in body cavities, 
are the major source of naturally occurring antibodies. Natural antibodies encoded by their 
genes during germline maturation (181) are defined as antibodies that circulate in normal 
individuals in the absence of endogenous or mostly exogenous antigen stimulation. Many 
natural antibodies are directed to carbohydrate antigens found in normal human tissues and can 
be called naturally occurring anti-glycan (auto-) antibodies. They are polyreactive (182) belong 
to immunoglobulin subtypes IgA and IgM, and are present in serum of all individuals even in 
the absence of previous immunization (183). Thus, they are a part of the innate immune system 
(184) and probably contribute to the homeostasis of the immune system. Naturally occurring 
AGA appear in a number of human pathologies, e.g. ganglioside GT3 (Neu5Acα2-8Neu5Acα2-
8Neu5Acα2-3Galβ1-4Glc) in sera of patients with type 1 diabetes mellitus (185) or cranial 
dysfunction (186), in sera of patients with multiple sclerosis containing anti-Glcα1-4Glcα 
(glycogen fragment) antibodies (187), antibodies directed against oligomannose sequences are 
markers in Crohn’s disease (188), and anti-GlcNAcβ antibodies in rheumatoid arthritis (189). 
Involvement of natural IgM antibodies has been described in the early recognition of 
exogenous organisms (190), but these antibodies also seem to participate in recognition and 
elimination of precancerous and cancerous lesions (191, 192). Nearly all investigated tumor-
reactive antibodies present in cancer and healthy serum samples are bound to tumor-specific 
PTM cell surface antigens, later identified as carbohydrate epitopes (192-194). Natural IgM 
antibodies are also able to induce apoptosis in malignant transformed cells (192, 195). The 
human mAb SAM-6 was isolated from a gastric cancer patient and exclusively binds to 
malignant tissues via an O-linked glycan epitope on receptor GRP78, inducing apoptosis via 
lipid accumulation (196, 197). Another mAb PAM-1, which is directed to an integral 
membrane receptor homologue of CFR-1, has been described (191, 198, 199) and binds to a 
tumor-specific N-linked glycan located on CFR-1 that is specifically expressed on malignant 
cells. PAM-1 induces in vitro as well as in vivo apoptosis probably via blockage of CFR-1 
(199). 
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Investigation of intravenous immunoglobulin preparations bound to a printed glycan 
array (Consortium for Functional Glycomics) containing 377 glycan structures showed that 
sera pools contain a much wider range of IgG antibodies than expected. Nearly half of the 
glycans were bound by IgG, with the highest level of binding to structures of human 
pathogenic and non-pathogenic bacteria. Little to no binding activity to human endogenous 
glycans, including TACA, was detected (200). Serum levels of natural AGA of IgG subtype 
bound to TF antigen and were significantly elevated in gastric cancers (201). 
In a recent publication extracellular mucin exposed glycans identified MUC1 with 
aberrant glycosylation patterns in many cancer types. The microarray hydrogel-based platform 
was developed in order to detect MUC1 O-glycopeptide-specific antibodies. Cancer-associated 
IgG autoantibodies that bound to several O-glycopeptide epitopes were found, not including 
IgG antibody signals to MUC1 peptide epitopes. Human cancer sera (breast, prostate and 
ovarian) revealed IgG antibody signals directed to Tn-MUC1, sTn-MUC1 and truncated core 
3-MUC1, which were not found in healthy control sera (202). Results on core 3 structures are 
controversial because former studies found higher core 3 expression in normal colon tissue 
(130, 131). 
Globo H is another member of a family of antigenic glycans and is highly expressed on 
the cell surface of prostate, ovarian, and breast cancer cells (203). Investigations on Globo H 
and its truncated carbohydrate structures revealed significantly elevated anti-Globo H antibody 
levels in breast cancer serum samples compared to healthy controls (176). A cancer vaccine 
based study investigated the potential of Globo H-keyhole limpet hemocyanin (204). They 
measured a remarkably broad polyclonal antibody activity with a significantly higher IgG level 
in sera after immunization. Substantial quantities of IgG and IgM antibodies were elicited with 
a clear indication of a class switch to IgG. Unfortunately, it could not be demonstrated that the 
IgG antibody levels alone were responsible for the anti-vaccine activity (205). 
1.2.4 Distinct Glycosylation in Epithelial Ovarian Cancer (State of Research) 
Aberrant glycosylation is a well described hallmark of cancer development and 
progression. Over 50% of cancers are known to express TACA which includes glycolipids, 
Lewis blood group antigens, and ‘core’ glycan structures (206). Some indications exist that 
EOC is also reflected by aberrant glycosylation or distinct glycosylation patterns. Therefore 
this section highlights the most important findings in EOC and their associated glycan 
structures. 
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A recent mass spectrometry study screened oligosaccharides secreted by cancer cell 
lines and found specific changes in glycosylation without any protein information content. 
Several oligosaccharides as found in the supernatants of EOC cell lines were concordant with 
the oligosaccharides detected in serum samples. Moreover, it was found that anionic oligomers 
were composed of several series of hexuronic acid (108). 
In another pilot study, the total serum glycome of patients with advanced EOC was 
examined. A number of changes were found including increased levels of ‘core’ fucosylated, 
agalactosyl biantennary glycans (FA2) and sLex. A similar study of glycosylation and 
glycoprotein levels revealed that acute-phase proteins, haptoglobin, α1-acid glycoprotein, and 
α1-antitichymotrypsin mostly contain elevated levels of sLex. IgG heavy chains from patients 
contained twice the level of FA2 compared to healthy controls (207). A subsequent study 
showed that decreased galactosylation and sialylation of IgG heavy chains increased cytotoxity 
of natural killer cells and complement activation via mannose-binding lectin (208). 
Even CA125, the best current single biomarker for the detection of EOC contains up to 
30% molecular weight in glycan structures, mostly O-linked glycans (209). Lewis family 
carbohydrate structures, including Lex have been found to be expressed on CA125 (210). A 
two-step isolation of CA125 from an ovarian cancer cell line and sequencing of 
oligosaccharides is present in O-glycan structures in both core 1 and 2 glycans. An unusual 
feature was the expression of branched core 1 antennae in the core 2 glycans. It has also been 
found that CA125 contains N-linked glycans, primarily expressing high mannose and complex 
bisecting type of N-linked glycans (211). 
Differentiation of EOC histotypes has been studied based on the carbohydrate antigens 
belonging to O(H) (H type 1, H type 2), Lewis blood group families (Lea, sLea, Lex, sLex, Leb 
and Ley), and the mucin- ‘core’ family (Tn, sTn and TF) using mAbs on fresh frozen sections. 
Clear differences in antigen expression were observed between MOC and other histotypes of 
EOC, particularly as MOC tended to express sTn, Lea and sLea strongly and homogeneously. 
Strong immunostaining of Ley and H type 2 antigens were observed in SOC and EnOC only. 
Based on these findings it has been suggested that MOC and non-MOC tumors are of distinct 
biology (212). 
Tn antigen expression (defined by Vicia villosa lectin) was associated with EOC patient 
survival (213). Its sialylated structure, sTn is elevated in serum samples and correlated with a 
more aggressive malignant status, metastatic progress and low patient survival (214). Both Tn 
and sTn expression were also found to be higher in EOC patients than in benign tumors and 
correlated with shorter overall survival (215). Other new potential TACA were recently 
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suggested in a study on EOC which revealed that enzyme GlcNAc 6-O-sulfotransferase-2 is 
specifically expressed in MOC, ClCOC and SOC. Other new ovarian TACA reported in this 
study were 6-Su-LacNAc, 6-Su-Lewisx and 6-Su-SialylLewisx (216).  
EOC correlated TACA have consistently proven to be promising biomarkers for cancer. 
Also, the immune response in cancers is clearly and predominantly related to the carbohydrate 
moiety, independent of their expression as glycoproteins or glycolipids (206). As shown within 
the results section, using the covalent printed glycan array, the immune response against 
TACA is indeed far more abundant than previously demonstrated and can be detected in 
microliters of serum in the form of AGA (176). 
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2 Thesis Aim and Structure 
2.1 Background 
Due to a poor prognosis in ovarian cancer patients our translational research group 
focuses on the detection of early cancer biomarkers in this devastating disease. In this PhD 
thesis we concentrate on past, present and future high-throughput technologies for the detection 
of ovarian cancer. After a primary literature analysis we have performed a world-wide new 
discovery approach facilitating a printed glycan array in non-mucinous borderline tumors and 
ovarian cancer patients compared to healthy controls. Our aim was to investigate the immune 
response in the form of anti-glycan antibodies towards ovarian cancer-associated glycans in 
order to improve the detection rate of this disease, group it in biologically sensible subtypes 
and improve our knowledge about origin and progression of ovarian cancer. 
2.2 High-Throughput Profiling in Epithelial Ovarian Cancer 
In the first part of this PhD thesis, we assessed the current situation of high-throughput 
profiling technology biomarker studies in epithelial ovarian cancer. The aim was to see which 
studies have been performed from both a technical and a results point of view. A systematic 
online database search was performed on all published high-throughput technologies (‘omics’) 
which focused on epithelial ovarian cancer. The goal was to bring the state-of-the-art 
proteogenomic studies into translational context, showing the co-evolution of ovarian cancer 
knowledge based on the results of profiling technologies. We summarized the data and 
reviewed the clinical questions addressed in the published studies, highlighting the most 
promising novel biomarkers (1). We also described directions for future research, based on 
technical limitations and identified needs. Using this approach, we identified the emerging field 
of glycomics as a new potential for epithelial ovarian cancer biomarker research. Glycomics 
has not been used for this purpose yet, but is rapidly progressing into the mainstream of 
biology and biomedicine. The glycome represents the main class of post-translational 
modifications and provides access to circulating anti-glycan antibodies in a patient’s blood (2-
5). This observation could have two major clinical applications in epithelial ovarian cancer: (A) 
novel biomarker detection and (B) targets for immunotherapy. 
In order to perform a discovery approach we established a biobank including 
prospective sample and data collection. Collection and processing of blood serum, ascites and 
tissue has been performed at the Department of Gynaecology (University Hospital Zurich), 
after written informed consent (Ethical Approval 2006, SPUK, Canton of Zurich, Switzerland) 
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was granted. For each sample, comprehensive clinical and experimental parameters were 
stored in our PEROV- database. 
2.3 Biomarker Research Using Printed Glycan Array 
Aberrant glycosylation of proteins and lipids during malignant transformation results in 
the appearance of specific glycan structures known as Tumor Associated Carbohydrate 
Antigens, or TACA, on cell surfaces and serum components (6, 7). Combinations of TACA are 
always present during malignant transformation. Potential cancer tumor markers which can be 
detected in serum of ovarian cancer patients are based on the observation that some TACA are 
shed into or present in the bloodstream, reflecting the pathological state. Our immune system 
constantly surveys the body for such aberrant carbohydrate structures and generates a response 
against them. Consequently, naturally occurring anti-glycan antibodies binding to these 
structures are promising targets for detection of epithelial ovarian cancer. 
The second part of this PhD thesis we detected individual patient anti-glycan antibody 
signatures as well as multivariate patterns in the form of ovarian cancer-associated anti-glycan 
antibodies with an identified diagnostic value. Using printed glycan array technology, we 
screened 57 well-defined and prospectively collected serum samples of patients with either 
non-mucinous ovarian cancer or borderline tumor, and healthy control patients at the time of 
surgery. 
The three essential key features we were using are: (1) in-house printing of custom 
glycan arrays, (2) established experimental development of printed glycan arrays and (3) 
printed glycan array-dedicated mathematical data processing tools (Figure 6). The production of 
standardized PGA slides for simultaneous profiling of anti-glycan antibodies involved also the 
development of a glycan library containing over 200 glycans, including TACA, natural 
oligosaccharides, blood group antigens and their related structures. The printing protocol 
implemented quality control of glycan arrays, such as print spot quality, batch-to-batch 
reproducibility and standardization of printed glycan array slides. We developed standard 
operating procedures for serum development and profiling of anti-glycan antibodies of 
immunoglobulin subtype IgM, IgG and IgA. Standardization of serum development also 
included bar-code and tracking systems to link printed glycan slides to individual serum 
samples. Each serum incubated slide was proved after fluorescence scan and low quality 
developments were repeated. For technical validations approximately 75% of all samples were 
screened in duplicates. Mathematical algorithms were developed and software implementation 
was used for pre-processing of printed glycan array data. Data pre-processing included 
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transformation and normalization of raw glycan array data to minimize technical variability 
and maximize performance. Data validation and statistical examination for biomarker detection 
as well as study of glycan-binding motifs were performed using the open source software 
CRAN R –project. Statistical analysis included detection of univariate and multivariate 
discriminative sets of glycans (biomarkers) and was further evaluated in terms of predictive 
precision, sensitivity and specificity. Glycan-binding motifs were studied by unsupervised 
learning. 
 
Figure 6 Process of printed glycan array experiment. 
Essential key features are in-house printing of glycan arrays (1), serum development of printed glycan 
arrays (2), and data processing (3), including scanning, quantification/ data preprocessing and statistical 
analysis for clinical and biological interpretation. 
2.4 Study of Glycan-Binding Motifs 
The study of glycan-binding motifs is a major field in glycobiology which is necessary 
to understand molecular recognition events. A number of glycan-based immunoassays for 
high-throughput investigations of the glycome have been developed recently to analyze the 
binding between glycans and glycan-binding proteins (e.g. lectins). To our knowledge, no 
study has examined the binding motifs of anti-glycan antibodies to immobilized glycans in 
healthy and ovarian cancer samples. Within our study cohort we aimed to identify specific 
glycan-binding patterns of naturally occurring anti-glycan antibodies. We further performed a 
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comprehensive analysis by applying different glycan-based immunoassays to study chemically 
synthesized glycans displayed by different ways to human anti-glycan antibodies. In this third 
part of the PhD thesis we examined human serum samples for their detection rates in three 
glycan immunoassays: printed glycan array, custom made sandwich ELISA technique and 
multiplex flow cytometric suspension array. In all three assays we aimed for the detection of 
anti-blood group A/B antibodies using A/B trisaccharides, known to be AB0 blood group 
minimal determinants. Related antigens of AB0 blood group were used as biological validation 
technique for our new PGA approach because it is widely used in immunochemical studies and 
well known for biological pathways. We did also assess the detection rate of our PGA 
generated candidate with the highest ovarian cancer detection rate, P1 (Galα1-4Galβ1-
4GlcNAcβ) on all glycan-based immunoassays. 
2.5 Identification of Glycan-Binding Proteins 
Oligosaccharides presented on eukaryotic cell surfaces are known targets for anti-
glycan antibodies as well as other glycan binding proteins, such as galectins or siglecs. Glycan- 
binding proteins specifically recognize and interact with carbohydrates, and can be found in 
every type of known organism. They play major roles in biological processes such as immune 
recognition and regulation, inflammatory responses, cytokine signaling, and cell adhesion. As 
fourth part of this PhD thesis, we tried to identify specific proteins that bind to a high-purity 
chemically synthesized oligosaccharide. We established an experimental strategy to study 
functionality and a complex hierarchical system of specific glycan-protein interactions. This 
includes affinity purification of potential glycan-binding partners from pooled ascites, 
validation of eluted proteins by SDS-PAGE followed by silver staining, immuno-detection of 
glycan-binding immunoglobulins, and validation of anti-glycan antibodies by sandwich ELISA 
and printed glycan array methodology. Final identification of potential glycan-binding proteins 
was performed by liquid chromatography mass spectrometry (LC-MS/MS). 
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3 Results 
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3.1.1 Summary 
There has been a concerted effort over the last decade to improve our understanding of 
the complex biology of ovarian cancer. A linear growth in published proteogenomic studies 
has addressed a variety of questions regarding its molecular pathogenesis. A number of genes 
have been identified by transcriptomic approaches, some of which are being investigated as 
putative tumor markers (HE4, OPN, Ep-CAM, Mesothelin), whilst others are potential targets 
for molecular therapeutic approaches (VEGF, IO4, EGFR, MUC1, CLDN4, SLPI). 
Proteogenomics has the potential to further change our current characterization and treatment 
of ovarian cancer. Additional advances will depend on integrated study designs, 
interdisciplinary collaborations, use of robust high-throughput platforms, as well as uniform 
guidelines for bio informatic analyses. 
Keywords: ovarian cancer, ovary, proteomics, transcriptomics, glycomics, profiling, 
microarray, diagnostics, biomarkers, post-translational modifications 
3.1.2 Introduction 
Epithelial ovarian cancer is the fourth most common cause of cancer death in women in 
the Western world and the leading cause of death from gynecological malignancies [1]. The 
majority of women have advanced stage disease at initial diagnosis and a five-year survival of 
10 – 30% [2]. The median survival after recurrence is only two years despite advances in 
chemotherapy and secondary debulking surgery in selected patients [1, 3, 4]. We clearly need 
better insights into the biology of the disease in order to detect the disease at an earlier, 
potentially curable stage and to develop more targeted and effective treatment strategies. 
Epithelial ovarian cancers are made up of five main histological subtypes that vary in 
their biological behavior, response to treatment and overall prognosis [5]. However, even 
within specific histological subtypes there is considerable heterogeneity, particularly within the 
more common serous cancers [6, 7]. Although FIGO stage and grade are still used to classify 
all ovarian cancers, it has been recently recognized that there are two separate and quite distinct 
subgroups of serous cancer: Type 1, which are low grade and indolent and have a distinct 
molecular pathogenesis, and the more common Type 2 serous cancers, which are high grade 
and disseminate rapidly [8, 9]. Type 1 tumors appear to arise from the ovarian surface 
epithelium or inclusion cysts [10] and follow a stepwise progression through micro invasive 
tumors and tumors of low malignant potential. They commonly have mutations in KRAS and 
BRAF [9]. In contrast, Type 2 serous tumors  appear to arise from the fimbrial end of the 
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fallopian tube [11-14] and p53 mutations occur early. BRCA1/2-associated ovarian cancers in 
particular appear to arise from the fimbrial end of the fallopian tube and have a better response 
to platinum-based chemotherapy [15-17]. 
Despite the genetic distinction between the various ovarian cancer histological subtypes 
[18], they are commonly treated in the same manner: namely, with maximal cytoreductive 
surgery [19-22] followed by platinum- and taxane-based chemotherapy [4, 23, 24]. It would be 
valuable if we could use molecular expression profiles to classify ovarian tumors into distinct 
subtypes based on the biological behavior and to better predict individual patient outcomes 
based on a such a personal molecular “biosignature” [25, 26]. Good examples of this approach 
are given already for breast cancers and lymphomas [27, 28]. 
There has been a concerted effort over the last decade to identify specific molecular 
profiles of ovarian cancers using cDNA microarrays and oligonucleotide arrays [29, 30]. These 
high-throughput technologies for transcriptomics or genomic expression profiling permit the 
analysis of the expression of thousands of genes in one experiment examining a specific 
biological system [31]. The resulting patterns allow researchers to investigate important 
biological questions that have not been easily addressed with traditional gene expression 
technologies such as Northern blots, in situ hybridization or RNase protection assays. 
Following the development of large-scale profiling technologies, the first high-throughput 
studies examining protein expression levels were performed using serological analysis of 
autologous tumor antigens by recombinant cDNA expression cloning (SEREX) [32]. Within 
the growing spectrum of proteomic technologies, most techniques were based on two-
dimensional polyacrylamide gel electrophoresis (2D-PAGE) mainly in combination with mass 
spectrometry techniques such as matrix-assisted laser desorption/ionization-time of flight 
(MALDI-TOF), surface-enhanced laser desorption/ionization-time of flight (SELDI-TOF), 
electrospray ionization (ESI) or with liquid chromatography (LC). 
There has been a linear growth in the number of publications on ‘biomic’ studies of 
ovarian cancer. Since the initial studies on transcriptomics of ovarian cancer in 1999 [33-35] 
237 studies were published until the end of 2007 using various –omic technologies. A vast 
amount of data has been amassed over the last decade, providing greater insight into the 
heterogeneous genetic background of ovarian cancer. This has lead to the identification of 
novel markers as well as new diagnostic, prognostic and therapeutic targets. 
The aim of this study is to provide a comprehensive summary of the totality of 
published studies pertaining to functional genomics of ovarian cancer. We attempt to put the 
state of the art of proteogenomic studies in ovarian cancer into context, showing the co-
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evolution of ovarian cancer knowledge and technologies for new assays, which provide the 
basis for our view of the direction of future research.  We also summarize the data and review 
the clinical questions addressed in the published studies and highlight the most promising 
novel tumor markers. We briefly describe new technical possibilities [36], which have the 
potential both to improve the early detection and better predict prognosis of patients with 
epithelial ovarian cancer, and take a glimpse at the future of ovarian cancer biomarker research. 
3.1.3 Identification of genomic profiling studies. 
We performed an electronic search of the online databases PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed/), Cochrane (http://www.cochrane.org/) and Medline 
(http://medline.cos.com/) to identify publications on ovarian cancer proteogenomic profiling 
during the 9 year period 1999-2007. Keywords used to search the databases were in changing 
combinations: “ovarian cancer”, “ovary”, “human ovarian” in combination with “mass 
spectrometry”, “MS”, “serial analysis of gene expression”, “SAGE”, “SEREX”, “cDNA 
microarray”, “DMH”, “CGH”, “array CGH”, “expression profiles”, “oligonucleotide array”, 
“proteomics“, “transcriptomics“, “genomics“, or “expression profiling”, “array”, “microarray” 
and “SNP array”. Only published studies that used human-derived cell lines or human clinical 
samples were included. Articles were excluded when (a) the term “microarray” was related to 
tissue microarrays without further mentioning expression profiling within the paper; (b) the 
data were from another, already published proteogenomic study; and (c) publications in 
languages other than English. 
The identified publications were divided into three categories: transcriptomics, 
proteomics, and other profiling technologies. Transcriptional profiling includes cDNA and 
oligonucleotide microarray studies and SAGE; proteomic profiling includes studies using 
SEREX, 2D PAGE, MALDI-TOF, SELDI-TOF, ESI and LC; and other profiling technologies 
cover differential methylation hybridization (DMH), single nucleotide polymorphism (SNP) 
arrays and (array) comparative genomic hybridization (aCGH) studies. The publication data are 
summarized according to year of publication, high-throughput technology used, number of 
profiled samples, sample type, sample preparation, aim of study, and main study findings. 
`Numbers of studies’ as listed in the supplementary data do not reflect the numbers of 
published studies but the research questions addressed within studies, with multiple questions 
possibly arising from individual proteogenomic datasets. 
Data summaries were further descriptively analyzed for the overall time of 9 years and 
for three individual time periods of 3 years each. We evaluated the whole time period in order 
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to study the trend of profiling studies performed per year and method used (Figure 7). 
Individual 3 year periods were used to demonstrate trends within sample types (Figure 8), high-
throughput technologies (Figure 9), and research questions addressed (Figure 10). Individual 
research questions were also further sub-classified into thirteen main categories: (a) tumor 
marker discovery (Cancer vs. Normal), (b) treatment effects (Treatment; wild type vs. knock 
out or treated vs. untreated), resistance (Drug Resistance), patient outcome (Outcome), (c) 
distinction of different histological subtypes (Subtypes), histological grades (Grades), the 
International Federation of Gynecology and Obstetrics (FIGO) stage (Stages), primary versus 
metastatic site (Metastasis), ovarian vs. non-ovarian cancers (EOC vs. non-EOC), (d) aberrant 
chromosomal patterns (Chromosomes), epigenetics (Epigenetics), hereditary diseases 
(Hereditary), and (e) specificity of technique (Technical Optimization) (Figure 10). Ovarian 
cancers subtypes as defined by histology, stage, grade, organ of origin and outcome were 
further studied in order to assess whether a genetic distinction between groups would be 
justified. Taken together, Figures 7- 10 trace the history of clinical biomarker identification 
using genomic and proteomic technologies. These figures also serve to emphasize the point 
that although the amount of data is increasing, we still face the daunting challenge to translate 
the information contained therein to clinically relevant knowledge that will benefit patients. 
We incorporated published lists of new candidate tumor markers derived from 
transcriptomic approaches for distinguishing between healthy individuals and patients with 
ovarian cancer into our previously described automated over-lapping ovarian (OLOV) database 
[37]. All published candidate gene lists were screened for gene overlaps across individual 
studies, with overlaps identified by matching gene symbols, accession numbers and UniGene 
identifiers. We used Gene Cards (http://www.genecards.org) and the Human Protein Reference 
database (http://www.hprd.org) to further enhance the list of most frequently identified 
potential tumor marker genes, with the addition of information regarding cellular localization, 
translational modifications, molecular class, glycosylation as post-translational modification, 
available treatment options and clinical testing status (Phase I-III trials). The numbers of 
studies demonstrating a significant difference between research question groups are presented 
graphically using OLOV as described previously [37]. OLOV-incorporated genes were ranked 
by previously described gene identifiers and sorted in decreasing order by number of 
reoccurrence across studies.  
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3.1.4 Development of high-throughput profiling studies 
Between the years 1999-2007, 237 primary studies addressing functional ‘biomics’ in 
ovarian cancer have been published. During the first five years, there is a roughly linear growth 
in number of publications using profiling techniques, after which the number of publications 
reaches a plateau (Figure 7). Two thirds of studies between 1999 and 2004 used transcriptomic 
(rather than proteomic or other) methods. After a clear increase in 2005 a steady decline in 
number of transcriptomic studies can be observed, which is linked to a nearly linear increase in 
proteomic and other methods since 2004. These other methods were used as frequently as 
proteomics methods. Although MIAME (minimal information about a microarray experiment) 
[38, 39] guidelines state the need to openly distribute microarray raw data for further validation 
or meta-analysis, most frequently only lists of significant gene expressions are published, 
especially for the earlier time periods. Unfortunately, such lists are of limited utility for 
integrating information across studies. 
3.1.5 Profiling technologies used in ovarian cancer 
We have grouped profiling technologies into three major classes: (1) transcriptomics 
(63.7% of studies): e.g. cDNA and oligonucleotide microarrays and SAGE technology, used to 
study gene expression; (2) proteomics (20.3% of studies): 2D PAGE, typically in conjunction 
with mass spectrometry technologies, SEREX, and protein microarray; and (3) other 
technologies (16.0% of studies), including: (array) CGH, SNP array and DMH. Multiple 
techniques were used in 15.6% of studies, most of which combine either transcriptomics with 
CGH (29.7%), or proteomic technologies with transcriptomics (5%) (Figure 9). 
The majority (63.7%) of ovarian cancer-specific questions were addressed using 
technologies to identify gene expression patterns, including cDNA microarrays (51.3%) and 
oligonucleotide (46.3%) arrays, most commonly produced by Affymetrix (Santa Clara, 
California, USA; HuGeFL, U95-, U133-series).  
Robust transcriptomic technologies and analysis methodologies have led to the detection of 
several new ovarian cancer biomarkers. In contrast, even with advances in mass spectrometry, 
proteomic approaches have led to only a few protein biomarkers which are used clinically. 
Despite technical complexity, various recent reviews have discussed the great potential of 
proteomics in clinical biomarker discovery [40-44]. Proteomic approaches applied to detecting 
clinical biomarkers typically involve a broader spectrum of samples and larger chemical 
information content on the protein level than other types of biomic studies [45], but technical 
challenges have hindered development. Due to the broad and complex diversity of proteins, the 
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field of proteomics has to deal with a wide range of differences in molecular size, relative 
abundance, concentration, polarization and ionization as well as the high dynamic 
concentration range of proteins in complex samples like tissues and body fluids. Since there is 
not at present a single, optimal instrument that satisfies all proteomics research needs, there is a 
wide variety of mass spectrometry instrumentations, including an extensive assortment of 
modular arrangements of different types of mass analysers [46]. The current standards in 
bioinformatical analyses [47] and normalization procedures [48] are rather limited. 
Recent advances in mass spectrometry-based quantitative proteomics permit the 
identification of differentially expressed proteins in cells, tissues and body fluids in a high-
throughput manner [49, 50]. Quantification of proteins by mass spectrometry is currently most 
commonly performed by differential isotopic labeling of samples, separation of the peptides by 
liquid chromatography and identification as well as quantification of the peptides by shotgun 
mass spectrometry and database searches [51-54]. Major improvements during recent years 
have been achieved by (a) label-free quantifications that integrate the total ion current of 
peptide signals as quantitative measure of original peptide concentration [55-58], (b) selected 
reaction monitoring for quantitative protein identification [59-61], and the development of (c) 
protein microarrays as protein-detecting microarrays, sandwich immunoassays with spotted 
antibodies, antigen capture immunoassays and direct immunoassays [62]. 
3.1.6 Variation of biological sample types 
The most commonly profiled samples in transcriptomic studies consisted of human 
tissue (48.3%), cell lines (41.7%) or both tissues and cell lines (9.3%), with a small minority 
(0.7%) using body fluids. During recent years a change in sample selection has taken place; 
individual samples were required to be more uniform so that tumors with mixed histological 
appearances would tend to be excluded. This constraint facilitates laser capture micro 
dissection (LMD) [63] for paraffin-embedded or fresh-frozen tissue specimens in cancer as 
well as for normal controls [64], e.g. particularly ovarian surface epithelium. However, the rate 
of studies incorporating LMD in order to allow homogenous messenger RNA generation was 
only 8.9%. Proteomic experiments were performed on tissue specimens (14.6%), cell lines 
(31.2%), and body fluids, e.g. blood serum, ascites or pleural effusions (54.2%). The first 
studies examining ascites and ovarian cyst fluid have only just recently been published [65].  
The selection of normal control tissue is a major concern in most of the studies 
published. Whilst in earlier studies whole ovaries were used as a normal control or human 
ovarian surface epithelial cell lines were used in comparison to tissue samples, improvements 
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have been under way using laser capture microdissection for human ovarian surface 
epithelium. Whilst quantities of ovarian surface epithelial cells are a major problem, new 
proposed precursor lesions like inclusion cysts and, more recently, the tubal epithelium [10-12, 
14, 66] have so far only rarely been incorporated into biomic studies. 
3.1.7 Study aims within genomic profiling 
Study aims for all 237 publications were characterized and grouped, and are shown as 
absolute numbers in a bar graph (Figure 10). As study aims have changed during the years, they 
are presented in three-yearly intervals (1999-2001, 2002-2004, 2005-2007), thus demonstrating 
the general interest shift over time. During these three time periods, most studies investigated 
the differentiation between cancer vs. normal in order to find new biomarkers (82 studies), 
experimental treatment settings (48 studies), histological subtypes (44 studies), tumor grades 
(20 studies) and chromosomes (20 studies) aberrant in ovarian cancer (Figure 10). The search 
for a new tumor marker in ovarian cancer (cancer vs. normal) was the most studied aspect 
during 2005-2007 in 38 studies, nearly the same as during the previous three year period 
(2002-2004, 30 studies). The other most commonly addressed topics during the most recent 
three years included treatment effects (33 studies), drug resistance (31 studies), histological 
subtype distinction (28 studies), technical optimization (23 studies), grades (15 studies) and 
chromosomes (13 studies). There is a growing diversity during this most recent period, with the 
emergence of new fields such as technical optimization of experimental procedures. 
3.1.8 Distinct ovarian cancer biology identified by high-throughput profiling 
Clinico-pathological characteristics of ovarian cancer were examined on the molecular 
level to define distinct proteogenomic patterns. Studies aimed to identify a pattern for 
histological subtypes, stage, grade, organ of origin and disease progression. Distinctions 
identified for particular subgroups of ovarian tumors are shown in Figure 11. These results 
show that there is a clear molecular difference between histological subtypes of mucinous, 
clear cell and endometrioid ovarian cancers. Further, endometrioid cancers of either ovarian or 
endometrial origin seem to have a distinct molecular pattern, even when expressing the same 
histological phenotype. Serous ovarian cancers of different grades, especially serous borderline 
tumors, are biologically different from serous ovarian cancers, which have been further 
molecularly distinguished as early (FIGO stage I/II) or late (FIGO stage III/IV) stage disease. 
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3.1.9 Aberrantly expressed genes identified across multiple transcriptomic studies 
Candidate genes differentially expressed in ovarian cancer compared to normal 
controls, detected by all transcriptomic studies independent of specific research question, are 
listed in order of their number of overlaps across studies (Table 3). Most transcriptomic 
profiling studies identified OI4, VEGF and TFCP2, from which especially OI4 and VEGF have 
interesting implications. Both gene products are extracellulary localized, are glycosylated and 
are used as targets for therapies which are either already clinically used (Imatinib for OI4;  
Bevacizumab for VEGF; Gefitinib for EGFR) or in clinical phase II/III trials, targeting VEGF, 
EGFR, CLDN4 and HER3. Other less frequently identified biomolecules show involvement of 
either cellular communication, adhesion or immune response. Post-translational modifications, 
especially glycosylation modifications, can be found in 55% of these biomolecules.  
We have also identified overexpressed genes overlapping across studies addressing the 
same specific research question. Our approach was only possible for analyses (1) Carcinoma 
vs. normal, (2) Subtypes, (3) Grades and (7) Treatment. In this sub question examination, a 
maximum of 5 overlaps across studies could be identified for individual genes (Table 4). A 
reason for this low number is the diversity of clinical questions which makes it difficult to give 
question-specific markers. Interestingly, there are some genes which persist across a number of 
different specific aims, namely HE4 for Carcinoma vs. normal and Grades, and OPN for 
“Carcinoma vs. normal” and “Subtypes”. Genes identified in the “Treatment” research question 
analysis were unique to this question only (Table 4). 
3.1.10 Established knowledge due to proteogenomics 
The aim to improve upon early screening techniques and to develop more effective, 
targeted treatments for ovarian cancer has driven the field of high-throughput technologies 
since their inception 10 years ago. The success of the intensive international efforts to improve 
outcomes, with new targeted therapies being tested in phase III trials (e.g. VEGF inhibitors as 
the most advanced therapeutics), has now become evident. Moreover, the first diagnostic 
marker, HE4, is commercially promoted by Fujirebbio Inc. and is increasingly being used in 
conjunction with CA125. Particularly notable today is the appreciation of the heterogeneity of 
ovarian cancer, necessitating its re-categorisation into multiple distinct entities. It is thus 
recognized that we must treat especially mucinous and clear cell ovarian cancers differently 
from serous and endometrioid histological subtypes. The careful reflection on the employment 
of proteogenomic technologies and the critical assessment of the benefits gained from them 
compared to their costs has also become an unquestionable factor. It is equally important to 
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learn from mistakes and to carefully design future studies in order to maximise the benefit from 
these costly technologies (Table 5). 
3.1.11 Future Perspectives 
New, more specific high-throughput technologies under development target the 
biological products of the gene-protein network, namely glycosylation, phosphorylation and 
metabolisation. These reflect post-translational modifications of ovarian cancer and therefore 
carry important biological information. Most of our current clinical tumor markers are 
glycosylated proteins (CA125, CEA, CA19-9), 55% of all newly identified biomarkers (Table 
3) show glycosylation. Technical simplification and standardisation of these new methods will 
improve the uniformity and comparability of results across cohorts and is expected to 
massively improve our knowledge of ovarian cancer. 
During this last decade, biomics in the field of ovarian cancer has undergone a 
paradigm shift away from the single disease theory towards the acceptance of disease 
heterogeneity. This implies the presence of different biological mechanisms and precursor 
lesions for the development of ovarian cancer and the requirement for differential 
classifications and individualized disease subtype-specific treatments. One significant 
consequence is that shortcomings of previous studies, such as heterogeneity of samples and 
methods, application of inadequate methodologies or missing bioinformatics expertise in 
analysing the datasets, have been largely overcome. Another consequence is that numerous 
tumor markers have been proposed and are now under evaluation in combination with or 
without CA125, the still unbeaten tumor marker for ovarian cancer. 
Advantages of previous proteogenomic studies include the wealth of data available 
within the scientific community, the lessons learned from mistakes, and subsequent 
improvements in technologies and study design and analysis techniques. A far-reaching aspect 
of the increased data acquisition is an accompanying increase in data sharing. There are now 
several prominent publicly accessible databases of genomic information. These include general 
microarray data repositories such as the Gene Expression Omnibus (GEO) [67, 68], 
ArrayExpress [69], and the Stanford Microarray Database (SMD) [70] and cancer-specific data 
repositories such as the Expression Project for Oncology (expO, 
http://www.intgen.org/expo.cfm) and ONCOMINE [71, 72]. 
The experimental design and statistical analysis of microarray studies has evolved 
greatly from the early days of simplistic, single-sample comparisons [73]. In addition to the 
ordinary considerations of any scientific study, important aspects more specific to design of 
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microarray studies include pairing of samples for dual-channel arrays and sample processing 
protocols to avoid confounding and increase precision of inferences [74]. The analysis of 
microarray data generally includes a technology-specific component (so-called ‘low-level’ 
analysis) and a study aim-specific (‘high-level’) analysis. Low-level analysis consists of data 
preprocessing (image analysis and normalization), required to reliably quantify fluorescence 
intensities for each transcript. For a review of methods for cDNA arrays, see Smyth and Speed 
2003 [75]; for Affymetrix and other single-channel arrays, the most widely used methods are 
MAS 5 [76] and RMA [77, 78]. The most commonly carried out type of higher level analysis is 
identification of differential expression. Many methods exist for this, but the most reliable ones 
involve computing a type of t-statistic (or F-statistic) based on (log) fold change and a 
moderated standard deviation. A widely used method is the linear modeling approach [79]. 
As data sharing becomes the new standard, we gain increased opportunities for 
knowledge synthesis. Among these is the ability to carry out statistically sound meta-analysis 
for clinically relevant questions. Integrated analysis of high-throughput transcriptomic studies 
is complex. The ONCOMINE web tool (http://www.oncomine.org/) has some meta-analytic 
capabilities, however it provides limited flexibility. We have created a more adaptable 
approach for combining information across gene expression studies [80, 81] but, like 
ONCOMINE, it still relies on having access to primary data (not just a summary p-value or 
ranked gene list). An extension of our methodology should allow for combination of 
heterogeneous data types (such as gene expression and glycomic data) rather than across just 
gene expression, thereby making fuller use of existing data resources.  
Despite widespread acceptance and requirement of MIAME guidelines [38], data 
sharing is still incomplete, limiting the possibility to quantitatively combine and critically 
reflect on all research results. 
Based on this timeline examination of recent ovarian cancer research and current 
technological trends it is of major concern that only a limited number of genes are detectable in 
an overlap approach. This minimal number of overlaps can be explained by the limited number 
of available datasets, variation in study design and platforms used and diversity of research 
questions studied. For this field to be of more efficient assistance in identifying clinically 
usable biomarkers individual studies need to be comparable within each other. Based on our 
examination we suggest that future biomic studies meet the following requirements: 
(A) adequate number of samples, depending on the research question preferably from 
different continents (in order to avoid or address population-specific effects),  
(B) prospective inclusion of patients where appropriate for the study question,  
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(C) inclusion of all presumed precursor lesions, namely ovarian surface epithelium, inclusion 
cysts, fimbrial end of fallopian tube epithelium,  
(D) inclusion of other cancers to distinguish ovarian specificity,  
(E) absence of mixed pathological histotypes,  
(F) clear-cut study question (or hypothesis) and study groups, and  
(G) microdissection in all tissue samples.  
Of particular importance is that  
(H) qualified analysts (e.g. bioinformaticians, statisticians) perform the data analyses 
according to  
(I) internationally accepted guidelines.  
Such guidelines need to be developed to establish clear requirements for data analyses. At 
present, MIAME compliance is widespread but not universal. The research community will 
need to adapt quickly to new scientific insights in ovarian cancer to avoid costly, unnecessarily 
repetitive studies. To this end, we encourage the establishment and support of internationally-
driven programs and open access platforms that guarantee the sharing of data, especially for 
the new technologies under current development. 
3.1.12 Executive Summary 
Epithelial ovarian cancer is the leading cause of death from gynecological malignancies 
• Survival rate of 20% in advanced stage disease has not changed over the last 10 years, 
even with improvements in chemotherapy regimen 
• Increasing acceptance of the heterogeneity of ovarian cancer, which requires a disease 
subtype-specific treatment regimen 
• Proteogenomics will be the basis for improvements in ovarian cancer diagnosis and 
management in the future 
High-throughput profiling technologies and their development in ovarian cancer 
• 237 proteogenomic primary studies were published on ovarian cancer during 1999-
2007 
• Most studies focused on the detection of new clinical biomarkers for ovarian cancer  
• Transcriptomic (gene expression) approaches were most commonly used 
• Proteomic methods are gaining stability and reproducibility during the last few years 
and will have major potential in the future 
Heterogeneity as the main ovarian cancer biology finding using proteogenomic high-
throughput profiling 
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• A distinct genomic background was found for mucinous, clear cell and endometrioid 
ovarian cancers as compared to serous ovarian cancers 
• Serous borderline tumors demonstrate a distinct genetic origin from high grade, high 
stage serous ovarian cancers 
• The potential ovarian cancer precursor lesion has been defined as either ovarian surface 
epithelium, inclusion cysts, fallopian tubal epithelium, or tubal epithelium at the 
fimbrial end of the fallopian tube 
Overexpressed genes identified across multiple transcriptomic studies 
• Most transcriptomic profiling studies identified OI4, VEGF and TFCP2 as 
overexpressed genes in ovarian cancer 
• 55% of all identified transcriptomic biomarkers express glycosylation 
• Multiple identified biomarkers are already used as new targeted treatments and for 
diagnostic purposes 
Conclusions 
• Development of new high-profiling technologies targeting the biological products of 
the gene-protein network 
• Glycomics will be an area of particular interest in the development of new biomarkers 
in the future as most so far identified tumor markers show glycosylation changes 
• Establishment and support of internationally-driven, multidisciplinary programs joining 
datasets and cohorts 
• Study design requirements are: question-driven prospectively collected clinical samples 
incorporating all proposed precursor lesions, clear histological subtypes generated 
using microdissection 
• Definition of bioinformatical analysis standards and integration of different data types 
• Development of internationally accepted guidelines for bioinformatical analyses using 
qualified analysts 
• Open access platforms requiring full data distribution  
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Figure 7 Development of biomics in ovarian cancer from 1999-2007. 
Absolute numbers of profiling experiments published over the last 9 years. All incorporated techniques 
are grouped within the “Biomics” graph and individually for “transcriptomics” (cDNA microarray, 
oligonucleotide array and SAGE), “proteomics” (SEREX, 2D PAGE, protein microarray, SELDI -, 
ESI- and MALDI-TOF MS and their modified techniques) and “other technologies” (SAGE, SNP array, 
CGH and DMH). 
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Figure 8 Variation of profiled biological samples using high-throughput technologies. 
Samples used for profiling experiments analysed within this study: tissue samples (“tissue”, n=114), 
ovarian cancer cell lines (“cell line”, n=80), and a mix of both (“mix”, n=16). “Body fluids” (n=27) 
stands for biological samples from blood, pleural effusions or ascites. 
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Figure 9 Ovarian cancer profiling studies using high-throughput technology. 
Numbers of publications using specific high-throughput technologies are shown in bar graphs. 
Technologies are grouped into transcriptomics (black bars), proteomics (white bars), and other 
technologies of proteogenomics (shaded graphs). “Combined techniques” represents the publications 
using more than one high-throughput technique. 
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Figure 10 Categorization of investigated aims in EOC proteogenomic studies from 1999-2007. 
Research questions addressed within proteogenomics studies on ovarian cancer are grouped within 
three-yearly time periods as (a) tumor marker discovery (Ca vs. Normal), (b) treatment effects 
(Treatment; wild type vs. knock out or treated vs. untreated), resistance (Drug Resistance), patient 
outcome (Outcome), (c) distinction of different histological subtypes (Subtypes), grades (Grades), 
stages (Stages), primary versus metastatic site (Metastasis), ovarian vs. non-ovarian cancers (EOC vs. 
non-EOC), (d) aberrant chromosome patterns (Chromosomes), epigenetics (Epigenetics), hereditary 
diseases (Hereditary), and (e) specificity of technique (Technical Optimization). Numbers within graphs 
represent numbers of studies within time period and question addressed. 
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Figure 11 Genomic profiling in ovarian cancer demonstrating distinct entities. 
Number of genomic profiling studies showing a genetic difference within groups of diseases studied 
(arrow with number of studies expressing a difference in brackets). Analyses are performed for (A) 
histological subtypes of ovarian tumors, (B) organ of disease origin, (C), grade and stage of ovarian 
cancer, (D) benign and malignant tumors within possible progression models of ovarian cancer. EOC, 
epithelial ovarian cancer; MOC, mucinous ovarian cancer; SOC, serous ovarian cancer; ClCOC, clear 
cell ovarian cancer; EnOC, endometrioid ovarian cancer; MBL, mucinous borderline tumor; SBL, 
serous borderline tumor. 
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3.1.15 Tables 
 
Table 3 Overlapping genes most commonly identified in functional transcriptomic studies of ovarian 
cancer. 
Most commonly identified overexpressed ovarian cancer genes (OLOV) using transcriptomics. Studies 
in which genes are overlapping, gene symbol (gene), location of analogous protein (localization), post-
translational modifications (PTMs), glycan modifications, treatment and treatment options (mechanism 
of potential treatment) and trial status are listed. Genes which are already in clinical trials are underlined 
in grey. 
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Research aim Top candidates and number of overlaps in studies 
1. Carcinoma vs. 
Normal 
max. overlaps 5 
POSTN (5); HE4 (5); OPN (5); Ep-CAM (5); ERBB3 
(5); CD24 (5); MUC1 (5); UBE2C (5); CPLA2 (5); 
KLK7 (5); PRAME (5) 
2. Subtypes 
max. overlaps 4 
OPN (4); POSTN (4); C7 (4); CR (4) 
3. Grades 
max. overlaps 3 
HE4 (3); IBP5 (3); Col6A1 (3); PAX8 (3), ALP (3) 
7. Treatment 
max. overlaps 3 
CCN1 (4); CYR61 (4); GIG1 (4) 
Table 4 Overlapping overexpressed genes per individual research question. 
 
OPTIMI- 
ZATION 
STUDY 
DESIGN 
SAMPLE 
SELECTION 
BIOMICS 
PLATFORM 
SELECTION 
BIO-
INFORMATICAL 
ANALYSIS 
1 Experimental 
design in 
collaboration with 
statistician 
Histological review 
by a specialized 
gynaecological 
pathologist 
Established 
/robust 
technique 
Full datasets available 
for analysis 
2 Interdisciplinary 
team approach 
involves: 
biologist, 
gynaecological 
oncologist, 
statistician, 
bioinformatician, 
pathologist 
Avoidance of mixed 
pathologies 
(histological 
subtypes or grades) 
Technique able 
to address the 
study question 
Analysis by a 
specialised 
bioinformatician 
3 Prospective 
collection of study 
cohort  
Microdissection of 
tissue (preferably by 
a gynaecological 
pathologist) 
Reproducible 
results 
Translational 
communication 
throughout complete 
process 
4 Result validation 
within 
independent 
cohort (different 
continent) 
Selection of adequate 
controls in tissue and 
serum 
No inter-
personal 
variation 
Distribution of full 
datasets after analysis  
5 Inclusion of 
adequate 
statistically 
significant 
numbers 
No group 
combination of 
proven distinct 
entities  
 Inter-study validations 
and meta-analyses 
6 Definition of 
study question 
reflects the 
selection of 
profiling 
technique 
   
Table 5 Optimization for future profiling studies. 
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3.2 Serum anti-glycan antibody detection of non-mucinous ovarian cancers using 
printed glycan array 
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3.2.1 Abstract 
Ovarian cancer has the highest mortality rate among gynaecological cancers. Altered 
glycosylation of proteins and lipids is associated with oncogenic transformation producing 
tumor-associated carbohydrate antigens. We investigated the potential of anti-glycan antibodies 
in the diagnosis of ovarian cancers using a printed glycan array containing 203 glycans. Serum 
samples were collected from healthy controls (n=24) and non-mucinous borderline/ovarian 
cancer patients of various FIGO stages (n=33). Anti-glycan antibodies bound to printed 
glycans were detected via biotin-streptavidin fluorescence. Data were validated measuring 
blood group associated di-, tri and tetra- saccharide antigens on known AB0 blood groups. 
High reproducibility in measuring anti-glycan antibodies was found overall with cluster 
analysis demonstrating repetitive patterns of specific core carbohydrate structures within 21 
clusters: N-linked (n=11) O-linked (n=3), glycosphingolipids (n=2), not clearly sub-specifiable 
structures. Binary classifiers revealed 24 glycans including P1 (Galα1-4Galβ1-4GlcNAcβ; 
p<0.001) significantly discriminating between ovarian cancers, borderline tumors and healthy 
controls. Higher sensitivity and specificity than CA125 was achieved by a panel of multivariate 
selected and linear combined anti-glycan antibody signals (83.3% and 84.8%, respectively). 
Using anti-glycan antibody profiles we detected malignant tumors with a higher sensitivity and 
specificity than CA125, indicating a potential for the development of a new generation of 
biomarkers for ovarian cancer. 
Keywords: Glycan array, microarray, ovarian, cancer, anti-glycan antibodies, glycan, 
biomarkers 
3.2.2 Introduction  
Epithelial ovarian cancer is the fourth most common cause of cancer death in women in 
the Western world and the leading cause of death from gynecological malignancies1. This 
phenomenon is caused by the delay of initial diagnosis due to non-specific symptoms and non 
existent screening methods, leading to 75% of patients being detected in late stage disease, 
with a five-year survival of 10-20%2. During the last ten years a large amount of research has 
focused on transcriptomics and proteomics to detect a more sensitive and specific tumor 
marker than CA1253,4. Although this has advanced the biological understanding of the 
heterogeneity of ovarian cancer and has detected various potential biomarkers, so far, none of 
these seems to overcome the poor sensitivity and specificity of CA125. 
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Glycans are essential partners in many biological recognition processes, and the 
characterization of the “glycome” of cells, tissues and organisms has become one of the 
frontiers in the post-genomic era. The immense biological potential of altered glycosylation has 
been demonstrated during malignant transformation by the occurrence of tumor-associated 
carbohydrate antigens5,6 as well as in diseases like rheumatoid arthritis7 and Crohn's disease8. 
Cancer associated carbohydrates are mostly located on the surface of cancer cells and are 
therefore potential targets for new diagnostic biomarkers9. Beside their oncogenic role, 
naturally occurring antibodies seem to play an important part in anti-tumor surveillance, 
probably by binding to the repetitive motif of carbohydrate epitopes10,11. Anti-glycan 
antibodies in their malignancy-defining role identified by glycan array technology has been 
first described in breast cancer12,13 and Hodgkin’s lymphoma14. 
Carbohydrate arrays promise to be usable and powerful tools as they offer the potential 
to profile hundreds of glycan structures simultaneously. This diverse repertoire of 
oligosaccharides immobilized on solid matrices has the potential to map out glycan-protein 
interactions in a high-throughput manner15. Carbohydrate arrays allow determination of the 
specificities of glycan binding proteins16,17, examination of microbiologically relevant 
glycans18, study of carbohydrate-processing enzymes19, and anti-glycan immune responses20,21. 
Most recent carbohydrate array studies have focused on the development of solid platforms 
validated by individual proteins, e.g. lectins or monoclonal antibodies. Microarray-based 
analysis of glycan–binding proteins in complex biological fluids are complicated but of highest 
biological relevance. To date only few publications study a small cohort of glycans and 
glycoconjugates within a specific biological system22, screening anti-glycan antibodies within 
human serum for diagnostic purposes20,23,24 or detecting the immune response to bacterial 
pathogens25,26. 
In this study we used a recently described, standardized printed glycan array to 
characterize discriminating carbohydrate antibody recognition in 57 human blood serum 
samples from healthy controls, ovarian borderline tumors and non-mucinous ovarian cancer 
patients of various FIGO stages. The library of printed glycans20 contains a large number of 
chemically synthesized carbohydrate structures of high purity, e.g. blood group antigens, 
pathogen related oligosaccharides, lactosamines, sulphated-, sialylated-, fucosylated-
carbohydrates and known as well as expected tumor associated carbohydrate antigens. 
As the field of glycan-arrays is just evolving, to our knowledge there are currently only 
three publications describing anti-glycan antibody binding towards glycans under 
healthy20,24,27, and two publication under cancer conditions, hereby detecting anti-glycan 
Francis Jacob  Results 
 70 
antibodies to truncated versions of globo-H in breast cancer serum samples28. No anti-glycan 
antibody microarray profiling for the detection of ovarian cancer biomarkers has been 
published so far. 
Application of glycan array enables the study of biomarkers in a specific disease at the 
level of post-translational modifications and therefore displays potentially in magnitude the 
presenting features of the individual state of disease29. Thus, this approach is capable of 
opening access to a broad range of novel biomarkers for ovarian cancer for diagnostic as well 
as therapeutic purposes. The monitoring of changes in the profiles of specific antibodies 
enables also the observation of the immune response of an organism against a specific disease 
at a specific point in time. 
3.2.3 Experimental Section 
Clinical cohort. Serum samples were prospectively collected from 57 women at the 
Department of Gynaecology University Hospital Zurich after written informed consent (Ethical 
approval 2006, SPUK, Canton of Zurich, Switzerland). Serum samples were collected at 
primary diagnosis immediately prior surgery from patients with a suspicious ovarian mass but 
subsequently proven negative intra-operative status (n=24) and from non-mucinous epithelial 
ovarian borderline tumor and cancer (EOC) patients of various FIGO stage (n=33) (Table 6). 
Patients with a past history of cancer or with chronic infectious diseases of non-gynaecological 
and gynaecological origin were excluded from the study. Routine imaging and CA125 serum 
tumor marker measurements (standardized ELISA, Fujirebbio Inc, Sweden) were obtained for 
all patients within the clinical setting. Histopathological diagnosis was independently 
determined by a second pathologist specialized in ovarian cancer (R.C.), with inconsistent 
diagnoses, mixed or mucinous histotypes being excluded. Although age-matched control 
patients were envisaged, the median age of women within the healthy control cohort was ten 
years younger than the ovarian cancer cohort (54 versus 63 years) (Table 6). Venous blood 
samples (12ml) were collected per patient in EDTA blood tubes (BD Vacutainer®, 0.184M 
EDTA, BD Diagnostics, Franklin Lakes, US) and stored on ice for a maximum of three hours 
until further processing. Blood samples were centrifuged at 3000xg at 4°C for 10 minutes, and 
aliquots of the supernatant plasma frozen at –80 °C. Comprehensive present and past medical 
and gynaecological history data, diagnostic imaging and serum marker measurements, surgical 
data including pathological results, grading, staging and residual disease were collected per 
patient and stored in a database. 
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Printed glycan array. Printed glycan array slide fabrication and high-throughput 
profiling was performed as previously described20,30. Glycans were diluted in 300mM 
phosphate buffer pH 8.5 containing 0.005% Tween 20 and printed by robotic pin deposition on 
N-hydroxysuccinimide activated glass slides (Nexterion Slide H, Schott, Jena, Germany). The 
entire glycan library containing 203 structures of 95-98% purity (Lectinity Holdings, Moscow, 
Russia) was printed in 50µM concentration in eight replicates. To create images documenting 
the deposition of each feature, printed glycan library slides were scanned for salt deposition 
using a ProScanArray HT Microarray Scanner (PerkinElmer) with the red reflect scan protocol 
(633nm excitation, neutral density filter). Following salt scan, free N-hydroxysuccinimide 
activated groups were blocked with 50mM ethanolamine in 50mM borate buffer at a final pH 
of 9.2. Slides were then rinsed with deionized water, dried and stored at room temperature in a 
desiccator. 
Sample preparation. Each serum sample was diluted 1:15 with PBS containing 0.1% 
v/v Tween20 and 3% w/v BSA, thoroughly vortexed for 15 seconds and incubated at 37°C for 
15 minutes to dissolve potential lipid aggregates. Insoluble residual sample components were 
centrifuged for 30 seconds in a table-top centrifuge at maximum speed. Samples were 
transferred to the array slides and gently rocked in a sealed humidified incubator for 2h at 
37°C. Unbound sample components were washed with a series of 0.1% and 0.001% Tween 20 
in PBS. ImmunoPure goat anti-human IgA + IgG + IgM conjugated to long chain biotin 
(“Combo”, Pierce, Rockford, IL) 1:100 in PBS containing 0.1% Tween20 and 3% BSA was 
added and slides were incubated at room temperature in a humidified chamber for 45 minutes. 
Following washing steps as described above, bound antibodies were visualized by incubating 
slides with fluorescent dye streptavidin Alexa Fluor555 (Molecular Probes, Invitrogen, 
Carlsbad, CA), 1:1000 in PBS/0.1% Tween 20 at room temperature for 30 minutes. 
Data quantification. Fluorescence signals corresponding to glycan-bound antibodies 
were measured and quantification of images was carried out using ImaGene analysis software 
version 6.1 and 7.5 (BioDiscovery, El Segundo, US). Salt scan and fluorescence image of each 
slide were aligned to assure quantification accuracy in case of weak signals. Signals were 
measured as medTSI per glycan and were expressed as median across eight within-array 
replicates. 
Statistical analysis. Data analysis was performed using the open source statistical 
programming language R (http://CRAN.R-project.org/, version 2.8.1). All p-values < 0.05 
were taken as significant. Epitopic and structural preference of antibody binding to individual 
carbohydrate structures was carried out using hierarchical clustering. We performed 
Francis Jacob  Results 
 72 
unsupervised agglomerative hierarchical clustering using Ward’s method31 with 1-correlation 
distance on the signals from the 50µM prints, including both the 203 glycans and the 8 biotin 
controls. Cancer-specific glycans were identified by univariate linear modeling implemented in 
the R package limma32. For multivariate classification, sets of glycans were selected by a 
support vector machine algorithm (R package GALGO)33 ranked by their stability within 700 
independent statistical runs. The most stable glycans were further combined in a linear 
discriminant model (R package ‘MASS’)34 and analyzed by ROC curves (R package ROCR)35 
for each binary classifier to determine the sensitivity and specificity of selected models. These 
models were further used to compare glycan-based classifiers to the standard tumor marker 
CA125. The best cut-off between observed false negative and false positive rates was 
determined with two independent methods: “best cut-off point” (Method A), defined as the 
largest value of sensitivity plus specificity, selected from each individual classifier in ROC 
curves; and “precision-recall break even point” (Method B)35, the point at which precision 
equals recall and predictions are made due to the prevalence within given data. 
Variability and reproducibility. Quality control intra-chip analysis using replicates and 
inter-chip reproducibility were previously determined as described20. To assess the 
experimental variability of the array, samples from 32 patients (13 controls and 19 tumors) 
were randomly chosen for replicate profiling in two independent experiments on different days. 
In order to detect technology based systematic errors, mean, s.d., and CV were assessed. 
Biological and technical controls. As biological controls, α-rhamnose and 
aminoglucitol were used. Alpha-rhamnose was used as a “positive biological control” due to 
the known high expression levels of anti-rhamnose antibodies in healthy control individuals21. 
Aminoglucitol, an opened reduced form of D-glucose which is not present as a structural 
component of regular glycosylation, has been shown to be negative for anti-glycan binding at 
similar values to the technical background binding control20, which is why we used it as a 
negative biological control. 
3.2.4 Results 
Reproducibility of the printed glycan array. Comparing independent experimental 
settings, we found a high concordance correlation coefficient (CCC) for the mean (across 
patients) of the median total signal intensity (medTSI) of eight within-chip replicates 
(CCC=0.957; Figure 12 A). Standard deviations (CCC=0.940; Figure 12 B) within all measured 
samples with the coefficient of variation (CV) were concordant to these findings (CCC=0.966; 
Figure 12 C). The CV across mean signal intensities for repeats had a mean of 14.6%, with a 
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median of 14.2% and interquartile range 8.9% - 19.0% (Figure 12 D). Two independent 
experimental repeats showed a similar maximal CV for the same oligosaccharides: NeuAcα2-
3Galβ1-3(NeuAcα2-6)GalNAcα (CVexp.1 433.3%; CVexp.2 463.6%), Galβ1-4GlcNAcβ1-
3(Galβ1-4GlcNAcβ1-6)Galβ1-4GlcNAc (CVexp.1 442.8%; CVexp.2 371.9%) and (SA2-6G-GN-
M)2-3,6-M-GN-GNβ (CVexp.1 415.2%; CVexp.2 393.8%; Figure 12 C). The “biological positive 
control” α-rhamnose showed a CVexp.1 49.7% and CVexp.2 46.8%, respectively. We examined 
intra-slide variability using the carbohydrate structure Fucα1-2(GalNAcβ1-3)Galβ, which was 
represented twice on the array in two different positions and had a CV of less than 10% in each 
experiment (CVexp.1 8.7%; CVexp.2 9.9%). 
AB0 blood group antigens as proof of principle. Anti-A and anti-B blood group 
antibody binding to corresponding AB0-blood group antigens printed onto the array was used 
as an attempted validation. Investigated ligands for blood group antibodies were A and B di-, 
tri- and tetrasaccharides. Corresponding antibody patterns in sera of patients with known blood 
groups were defined by standardized clinical agglutination tests and compared to array-based 
results. The highest levels of statistical significance (p<0.05 for 19 glycans) were detected for 
A and B tri- and tetrasaccharides. Two printed trisaccharide structures known to be minimal 
blood group determinants, GalNAcα1-3(Fucα1-2)Galβ, A trisaccharide/ Atri and Galα1-
3(Fucα1-2)Galβ, B trisaccharide/ Btri showed a highly significant difference (p<0.001). Low or 
no signals were detected in the case of Atri in blood groups A and AB and against Btri in blood 
groups B and AB. In contrast, high levels of antibodies were found for both trisaccharides in 
blood group O, for Atri in blood group B and for Btri in blood group A (Figure 13). The most 
significant difference in antibody levels (p<0.001) was observed for the tetrasaccharides 
GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ (Atype 2) and Galα1-3(Fucα1-2)Galβ1-4GlcNAcβ (Btype 
2), known to be major AB0 antigens on erythrocytes. In addition to expected differences in 
antibody profiles to Atype 2 in blood groups O and B versus A and AB, it was noted that the 
level of antibodies differed highly significantly between blood groups B and O (p<0.001). A 
similar result was found for Btype 2 with low antibody levels in blood groups AB and B 
compared to A and O, which significantly differed from lower antibody levels in blood groups 
A versus O (p=0.005). Differentiating antibody binding across blood groups was not possible 
using the disaccharides GalNAcα1-3Galβ (Adi; p= 0.0841) and Galα1-3Galβ (Bdi; p= 0.9189), 
which are lacking fucose residues. Although high levels of antibody binding could be detected 
to Adi with lower signals against Bdi across all profiled blood groups (Figure 13), the highest 
levels were found in blood group O individuals against A and B tri- and tetrasaccharides. 
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Anti-glycan antibody distribution across printed glycans. The highest anti-glycan 
antibody levels (mean ± s.d. in medTSI) were observed for glycan 3’-O-Su-Galβ1-3GlcNAcβ 
(146*105 ± 68*105), GlcNAcβ1-4Mur-L-Ala-D-i-Gln-Lys (94.6*105±53*105) and Neu5Acα2-
3Galβ1-3GlcNAcβ (87*105±37*105) (Figure 14). The “biological positive control” α-rhamnose 
(50*105±24*105; Figure 14 A) showed high signals whilst the “negative control” aminoglucitol 
(2.5*105±4.2*105; Figure 14 C) had a low mean result. The glycan which was examined twice 
on the array to analyze any intra-slide variability (Fucα1-2(GalNAcβ1-3)Galβ; Figure 14 B) 
showed close levels in both analyses. 
A large spectrum of anti-glycan antibody signals was detected within the whole patient 
cohort, composing of healthy controls, non-mucinous borderline tumors and ovarian cancers 
(Table 6). The mean medTSI for all carbohydrate-bound antibody levels per patient varied 
between 8.59*105 and 38.21*105 medTSI. The interquartile range varied from 8.08*105 to 
49.7*105 medTSI and the CV from 79.7% to 188.4%. All individual serum samples showed 
mild and extreme outliers (Figure 15). Observed biological variability of anti-glycan antibodies 
was hereby not associated with any clinical or experimental covariates, namely antibody levels 
in cancer patients were not as a whole altered as compared to healthy control patients. 
Anti-glycan antibodies bind to specific epitope core structures. Cluster analysis 
revealed 53 clusters, each containing at most eight oligosaccharides that show similarities in 
carbohydrate structures. Glycans that are structurally identical but printed using different 
spacers, clustered together, as did the eight biotin controls and the blood group A and B 
antigens. Distinct structural similarities were found for 21 clusters (Table 7): N-linked glycans 
(11 clusters), O-linked glycans (3 clusters), glycosphingolipids (2 clusters) and not clearly sub-
specifiable structures (5 clusters). N-linked carbohydrates included a. linear lactosamine 
structures [Galβ1-4GlcNAcβ]1-3; b. linear glucosamine structures [GlcNAcβ1-4]3-6; c. sulfated 
lactosamine structures 4’ or 6’-O-Su Galβ1-4GlcNAcβ; d. single core lactosamine structures 
Galβ1-4GlcNAcβ with terminally coupled “monsters” 20, representing artificial carbohydrates 
which are not present in biological objects, namely β2-6Neu5Gc, β2-6Neu5Ac or Galα1-
4Galβ1-4GlcNAcβ; e. single core lactosamine structures Galβ1-4GlcNAcβ modified by Galα or 
O-sulfation; f. Lewis c (Galβ1-3GlcNAcβ) structures; g. single core lactosamine structures 
modified by neuraminic acid (NeuAcα2-3Galβ1-4GlcNAcβ; h. single core lactosamine 
structures with additional N-acetylglucosamine  (GlcNAcβ1-6Galβ1-4GlcNAcβ; and i. single 
core N-actelylglucosamine structures (GlcNAcβ). Interestingly, within this cluster four out of 
eight carbohydrate structures (Fucβ1-3GlcNAcβ, Galβ1-3GlcNAcβ, 3’-O-Su-Galβ1-3GlcNAcβ 
and NeuAcα2-6Galβ1-3GlcNAcβ) were highly correlated in their signal intensities, with 
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correlation coefficients ranging from 0.76 to 0.90. O-linked carbohydrates included: a. 
Thomson-Friedensreich structures Galβ1-3GalNAcα; b. sialylated Tn antigen structures 
Neu5Acα2-6GalNAcα; c. lactosamine on Tn antigen Galβ1-4GlcNAcβ1-3GalNAcα. The last 
specific structure group consisted of glycosphingolipids including Galβ1-3GlcNAcβ1-3Galβ1-
3Glcβ. 
Non-mucinous ovarian cancer biomarker detection. Linear modeling revealed 24 
carbohydrate structures for which the amount of anti-glycan antibodies was significantly lower 
in the non-mucinous ovarian borderline and cancer cohort as compared to the healthy patient 
cohort. The glycan structure with the most significant discriminatory ability was P1 (Galα1-
4Galβ1-4GlcNAcβ; p=0.0008). Compared to the presently used tumor marker CA125, which 
had a sensitivity of 64/76% (Method A/B) and specificity of 95.6/73.9% (Method A/B) in our 
cohort, the identified anti-glycan antibodies revealed comparable values, particularly the top 
candidate P1 (sensitivity 79.2/70.8% (Method A/B) and specificity 75.7/78.8% (Method A/B)) 
(Figure 16). A combination of both P1 and CA125 did improve neither sensitivity nor specificity 
(82.6/76.0% (Method A/B) and 72.0/73.9% (Method A/B), respectively). 
We next aimed to identify a panel of anti-glycan antibodies that could generate a higher 
sensitivity and specificity for the differentiation between non-mucinous ovarian borderline and 
cancer patients from healthy control patients. Interestingly, the top candidate P1 was again the 
most stable glycan using this selection algorithm. In comparison to the univariate approach, the 
first three multivariate selected and linear combined glycans (svmLDA03) improved the 
sensitivity by 5-10% and the specificity by 0-3% (Table 8). Combination of a panel of six 
glycans generated the highest sensitivity (79.2%; Method A/B) and specificity (84.8%; Method 
A/B): Galα1-4Galβ1-4GlcNAcβ, Neu5Acα2-3Galβ1-4-(6-Su)GlcNAcβ, Neu5Acβ2-6GalNAcα, 
Neu5Acβ2-6Galβ1-4GlcNAcβ, Neu5Acα2-3Galβ1-3-(6-Su)GalNAcα and Galβ1-4GlcNAcβ1-
6Galβ1-4GlcNAcβ (svmLDA06) (Figure 16; Table 8). The combination of the highest 
significant ten glycans in the multivariate selection model (svmLDA10) only improved 
sensitivity by 4% (Method A) (Table 8). Interestingly, these ten glycans share similar 
carbohydrate motifs, namely eight structures containing core single lactosamine (Galβ1-
4GlcNAcβ) and two structures with Tn antigen (GalNAcα) (Table 9). In contrast, different 
monosaccharides, e.g. Galα-, Fucα- as well as sulfated and sialylated structures were observed 
at the terminal regions of these ten glycans. So called “Monster” structures presented as 
Neu5Acβ2-6 were also observed, but do not seem to play a biological role compared to core 
structures. 
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3.2.5 Discussion 
Using printed glycan array technology, we identified patterns of core carbohydrate 
structures in ovarian cancer patients which are specifically recognized by anti-glycan 
antibodies. Most glycan binding proteins are able to recognize glycan epitopes36, and non-
glycan moiety of the glycoconjugate is discussed to be involved in this binding. This is 
concordant with our findings, as we identified certain core structures which seem to recognize 
specific anti-glycan antibodies. Based on this observation we assume that the core of identified 
carbohydrate structures, as well as terminal or peripheral sugars, could play an important role 
in antibody recognition. The binding affinity or specificity of anti-glycan antibodies seems to 
be higher in the case of specific core structures20, especially containing GalNAcα-, Galβ1-
4GlcNAc- or Galβ1-4Glcβ-. Potentially, benign human cell core structures could be occupied 
by interactions of different types of membrane- associated proteins as well as other 
carbohydrate structures. Therefore, binding of anti-glycan antibodies seem to be limited to 
these potential cell surface carbohydrate epitopes. During oncogenic transformation of cells 
and rearrangements of extra-cellular matrix, these encrypted binding sites could become 
available for circulating anti-glycan antibodies. This means that glycans and their molecular 
environment are presenting epitopes and signal the status of a cell to the immune system 
leading to a corresponding response. Various functional studies have been performed in the 
field of detection of naturally occurring and anti-glycan antibodies and their carbohydrate-
binding, e.g. for anti-α-galactosyl antibodies37,38, antibodies bound to negatively charged 
glycans20,39, or GlcNAc-terminated carbohydrate chains20,40. This could reflect a natural 
antigenic mimicry, described as anti-idiotypic antibodies41 which are peptides that mimic 
tumor-associated carbohydrate antigens or their glycosphingolipid constituent. 
At present no technologies are available to study anti-glycan antibody reactions as 
sensitive and reproducible as within this high-throughput glycan array technology. Other 
technologies as ELISA and suspension array are under evaluation, but the main advantage of 
an array is obviously the unlimited number of glycans which can be screened in a high-
throughput manner. We have therefore used the well established AB0 blood group 
carbohydrate antigens as an attempted method to validate the glycan array results. AB0-
specific antibodies (isohemagglutinins) belong to a group of naturally occurring antibodies 
which can be determined by hemagglutination, ELISA42 and FACS43. Although in our 
experimental setting anti-glycan antibodies were determined using a pool of immunoglobulin 
subtypes, our results on blood groups detected by glycan array are concordant with classical 
hemagglutination data. However, only anti-tri/tetra-saccharides, and no disaccharides, were 
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able to discriminate within blood groups, whilst anti-disaccharide antibodies seemed to be less 
specific and bound to corresponding blood group antigens independent of AB0 blood groups, 
as previously described20,24. In contrast, A/B tri- and tetrasaccharides showed highly specific 
binding with appropriate antibodies in concordance with basic distribution of anti- A/B 
antibodies within blood groups. Affinity of AB0 blood group antibodies increased due to the 
number of sugar units in A/B antigens, being lowest in A/B disaccharides and highest in A/B 
tetrasaccharides, with fewer outliers observable in longer carbohydrate structures. Some degree 
of auto-reactivity could be found in our experiments in concordance with the literature, 
probably due to the heterogeneity of the A and B blood groups43. These findings on the AB0 
blood group system, although used as an attempted validation is the first published experiments 
on the AB0 blood group system using a glycan array approach. 
Since there are no carbohydrates that are yet established as truly positive and negative 
antibody binding reference structures, α-rhamnose is used in this study as positive and 
Aminoglucitol as a negative biological control. The overall variability of signals for anti-
glycan antibodies bound to carbohydrate antigens measured in this study are similar to the 
literature as is the coefficient of variation for the proposed positive biological control α-
rhamnose24,44. Minor discrepancies can be explained by different technical set-ups, including a. 
differences in carbohydrate presentation on individual platforms, as monomeric structures on 
bovine serum albumin coupled to a platform24,27 versus monomeric structures coated 
covalently to a surface matrix20,28 ; b. differences in generation of  individual serum samples; 
and c. one-step detection24,27,28 versus two-step detection methodology20. Although the amount 
and concentration of spotted glycans can also influence the data, the printed glycan array has 
shown high reproducibility in measuring anti-glycan antibodies bound to spotted carbohydrate 
structures20,24. 
Ovarian cancer biomarker discovery using glycan array. Previously, the printed 
glycan array was used to study immunoprofiles of serum anti-glycan antibodies in 106 healthy 
female blood donors20, detecting a broad variety of antibody profiles, independent of clinical 
parameters. Although similar individual anti-glycan antibody patterns have been shown in 
another group of patients27, other studies have observed discrepancies due to differing age 
groups45 or varying antibody titres against the carbohydrate mannan of Candida albicans, 
causing variations as much as 6.000-fold within a healthy donor group46,47. Therefore, 
interpretations on one single cohort which moreover has no information regarding their clinico-
pathological characteristics, could harvest mistakes. In this study we have therefore used the 
printed glycan array as a method to identify particular anti-glycan antibodies discriminating 
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between the clinically most important screening setting, namely non-mucinous ovarian 
borderline and cancer patients from unaffected women. P1, a member of the P blood group 
system demonstrated the highest significance and similar sensitivity/specificity levels as 
CA125 in detecting non-mucinous ovarian tumors in this setting. The P blood group system 
has two common phenotypes, P1 and P2, P1 and Pk (CD77; Galα1-4Galβ1-4Glc) share a 
common structure, namely Galα1-4Galβ1-4Glc(NAc). The physiological function of P1 and the 
P blood group system in general is still unknown. Pk antigen has been associated with acute 
leukaemia48, whilst P1 is present in hematopoietic49 and mesothelioma cell lines50. The 
presence of P1 in epithelial cells has been correlated to urinary tract infections due to the 
terminal part of P1, Galα1-4Gal, being a bacterial adhesion molecule in a pyelonephrotic strain 
of Escherichia coli51. The detection of P1 within this experimental setting as a tumor-associated 
carbohydrate antigen in ovarian cancers could implement that similarly to mesothelioma cells 
also ovarian cancer cells contain a P1 epitope. In this case the lowered levels of anti-P1 
antibodies in the serum of cancer patients could be explained due to the higher amount of P1 
cell-bound antibodies. 
Except for P1, no other anti-glycan antibody in this experimental approach has reached 
a similar performance as CA125. This could be due to the current limited panel of synthetic 
carbohydrates within the printed glycan array. It certainly reflects the heterogeneity even in a 
non-mucinous ovarian cancer cohort, and further clear-cut cohort selections will be necessary 
to improve sensitivities and specificities. Further, a panel of markers as suggested in 
proteogenomic studies52,53 and as confirmed in our data with already the combination of two 
anti-glycan antibodies improved sensitivity and specificity compared to the identified 
univariate candidates, including the top candidate P1. An improved differentiation could be 
reached with a minimum of six selected glycans with only minor gains by combining an even 
higher number of glycans. Panels of anti-glycan antibodies did not, however, reach a better 
sensitivity and specificity than 84%. When using a combination of eight candidates containing 
the structure Galβ1-4GlcNAcβ in the top ten selected antibodies, a sensitivity of 83.3% and 
specificity of 87.8% could be reached, which is clearly better than CA125 (76%/ 73.9%, 
respectively). Possible explanations why sensitivities and specificities above 90% could not be 
reached are a. the heterogeneity of the patient cohort; b. unknown clinically relevant diseases in 
the healthy controls; c. background binding effects which are not necessarily cancer-associated; 
d. low-titer reactivities of potential tumor-associated signals; e. vast variety of serum anti-
glycan antibodies expressing cross-reactivity, and f. limited number of synthesized glycans on 
the array. We also need to be aware that using anti-glycan antibody detection via array 
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technology cannot offer information about inducing stimuli, neither are we able to define the 
affinity or specificity of a collective of antibodies binding to individual glycan structures. A 
positive binding signal of human immunoglobulins to glycans demonstrates therefore only a 
variety of polyclonal antibodies binding to a saccharide that possibly represents different forms 
of biological epitopes. 
3.2.6 Conclusions 
Aberrations in well programmed glycosylation occur very early during malignant 
transformation and result in the appearance of specific glycans known as tumor-associated 
carbohydrate antigens on cell surface and serum components. They are also known to trigger 
an immune response resulting in the generation of anti-glycan antibodies. This is the first study 
publishing the identification of patient-specific anti-glycan antibody patterns in non-mucinous 
ovarian cancer. We found a discriminating anti-glycan antibody panel including the top 
candidate P1 which can diagnose ovarian borderline tumors and cancers with higher sensitivity 
and specificity than CA125. Except for P1, no other individual anti-glycan antibody in this 
experimental approach has reached a similar performance as CA125. This could be due to the 
current limited panel of synthetic carbohydrates within the printed glycan array. It certainly 
also reflects the heterogeneity even in a non-mucinous ovarian cancer cohort, and further clear-
cut cohort selections will be necessary to improve sensitivity and specificity studies. Printed 
glycan array technology has the potential to detect individual and panels of anti-glycan 
antibodies and is therefore a highly promising tool for future ovarian cancer biomarker 
discovery. 
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3.2.9 Figures 
 
Figure 12 Overall inter-slide variability. 
Results of two independent printed glycan array experiments on 32 patients for A. means; B. standard 
deviation (s.d.); C. coefficient of variation; D. summarized coefficient of variation. Number in each plot 
refers to concordance correlation coefficient (CCC), red line indicates IQR, blue dashed line indicates 
median, green dot indicates α-rhamnose; red dot indicates aminoglucitol, light and dark blue dot 
indicate Fucα1-2(GalNAcβ1-3)Galβ printed in double on different positions across the array. NeuAcα2-
3Galβ1-3(NeuAcα2-6)GalNAcα, Galβ1-4GlcNAcβ1-3(Galβ1-4GlcNAcβ1-6)Galβ1-4GlcNAc and (SA2-
6G-GN-M)2-3,6-M-GN-GNβ are highlighted as carbohydrate structures with highest coefficient of 
variation (red star; C). 
 
 
Figure 13 Validation using AB0 blood group anti-glycan antibody detection. 
Boxplots demonstrate the distribution of medTSI within each blood group independent of disease 
status, demonstrating the binding of anti-glycan antibodies against A and B blood group antigens. 
Comparisons were measured using the Kruskal-Wallis test. Carbohydrate structures presented are: Adi 
p=0.064; Bdi p=0.898; Atri p<0.0001; Btri p<0.0001; Atetra p<0.0001; Btetra p<0.0001. 
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Figure 14 Median total signal intensity of anti-glycan antibody profile per glycan (n=203). 
Pattern of median total signal intensities (medTSI) of AGA binding for 57 serum samples; medTSI x 
105 on x-axis and individual carbohydrate structures sorted by median on y-axis. Grey lines indicate α-
rhamnose (A); Fucα1-2(GalNAcβ1-3)Galβ (B); aminoglucitol (C). 
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Figure 15 Anti-glycan antibody profiles for individual serum samples. 
Profiles of antibody signals bound to 203 individual carbohydrate structures. Anti-glycan antibody 
distributions are grouped by disease status and are sorted by median per group. 
 
 
Figure 16 Receiver Operating Characteristics (ROC). 
for the univariately selected top candidate P1, standard tumor marker CA125 and multivariately selected 
and linearly combined glycan models. Number in svmLDA identifier indicates the number of glycans 
selected by support vector machine (svm) algorithm and combined in a linear discriminant model 
(LDA): svmLDA03, svmLDA06, svmLDA10. Carbohydrate structures involved in the linear model are 
described in order in Table 9. 
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3.2.10 Tables 
 No. of patients % of patients 
Healthy control 24 42.1 
Ovarian borderline tumor 2 3.5 
Ovarian cancer 31 54.4 
Age (yrs) (n=57)   
< 50 11 19.3 
≥ 50 46 80.7 
Tumor Stage (FIGO)(n=32)   
I 4 12.5 
II 3 9.4 
III 17 53.1 
IV 8 25.0 
Tumor Grade (n=30)   
G1 1 3.3 
G2 9 30.0 
G3 18 60.0 
Histological subtype (n=33)   
Serous 19 57.6 
Endometrioid 7 21.2 
Clear cell 1 3.0 
Transitional cell 4 12.1 
Undifferentiated 2 6.1 
Residual disease (n=23)   
< 1cm 12 52.2 
≥ 1cm 11 47.8 
Preoperative CA125 (n=53)   
< 35 U/ml 18 34.0 
≥ 35 U/ml 35 66.0 
Blood group (n=52)   
A 22 42.3 
B 9 17.3 
AB 2 3.8 
0 19 36.6 
Table 6 Clinicopathological characteristics of the patient cohort. 
Number of patients and percentage for patient cohort incorporating age, stage, grade, histological 
subtype, residual disease after primary cytoreduction, preoperative standardized CA125 measurements 
(ELISA), and routine clinical blood group detection (ELISA) for a cohort of 57 patients. 
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1 6 Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ 4-6 * core 0.78-0.98 GSL 
9 8 [Galβ1-4GlcNAcβ]n 2-6 - varying 0.48-0.96 N 
10 3 [GlcNAcβ1-4]n 3-6 - varying 0.91-0.96 N 
15 3 3’-O-Su-Galβ1-4 2 - terminal 0.69-0.84 GSL, N 
16 5 Galβ1-4Glc or GlcNAcβ 2 - core 0.15- 0.62 GSL, N 
17 4 6’-O-Su-Galβ1-4GlcNAc 2 - varying 0.43-0.81 N 
26 4 4’-O-Su-Galβ1-4GlcNAc 2 - varying 0.78-0.98 N 
28 2 [Glcα-]n 3,4 - varying 0.94 GSL 
30 3 Galα1-3(Fucα1-2)Galβ 3-4 - varying 0.87-0.97 GSL, N 
31 3 GalNAcα1-3(Fucα1-2)Galβ 3-4 - varying 0.59-0.92 GSL, N 
32 2 Neu5Gcβ or Neu5Acβ 2-6 Galβ1-4GlcNAcβ 3 - core 0.87 N 
33 4 Galβ1-3GalNAcα- 2-4 * varying 0.66-0.86 O 
34 8 Fucα1-3, Fucβ1-3 or Galβ1-4GlcNAcβ 1-4 * core 0.44-0.90 N 
35 2 Neu5Acβ2-6GalNAcα 2,4 - varying 0.67 O 
36 2 Galα1-4Galβ1-4GlcNAcβ 3,4 * varying 0.64 N 
37 2 Galβ1-4GlcNAcβ1-3GalNAcα 3,5 * varying 0.82 O 
38 4 (6,6’Su2; Neu5Acα2-6; Galα1-3; Galα1-4) to Galβ1-4GlcNAcβ 2-4 * varying 0.25-0.63 N 
40 3 Fucα/Neu5Acα1/2-2/3/4-Galβ1-3GlcNAcβ 3 * core 0.46-0.64 N 
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42 2 Neu5Acα2-3Galβ1-4 GlcNAcβ 3 - varying 0.70 N 
44 2 GalNAcα 4 + varying 0.96 N, O 
47 2 GlcNAcβ1-6Galβ1-3GlcNAcβ 3,4 - varying 0.69 N 
Table 7 Selected clusters with structural similarities. 
Cluster identifiers, number of glycans within each cluster, core structure of cluster, glycan length 
(number of monosaccharides in cluster) are listed for structurally similar glycan clusters. Glycan 
architecture occurs as a linear tree (-), branched tree (+) or linear/ branched together (*). Localization of 
core carbohydrate substructures describes where the common sub-structure occurs; at core (directly 
after the spacer), at terminal part, or varying location. Pearson correlation coefficients for glycans are 
summarized by within-cluster range of values. Expected natural glycan linkage is described as 
Glycosphingolipid (GSL); N-linked (N); O-linked glycan (O). 
 
A) “Best cut-off point” B) Precision- recall break even 
point 
 
Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%) 
CA125 64.0 95.6 76.0 73.9 
P1 79.2 75.7 70.8 78.8 
Chitobiose-Asn 66.7 84.4 66.7 75.0 
GNb6’LN 66.7 84.8 66.7 75.7 
GlcNAcβ1-6’LN 66.7 66.7 66.7 54.2 
Pk 62.5 75.7 62.5 72.7 
svmLDA03 87.5 69.7 75.0 81.8 
svmLDA06 79.2 84.8 79.2 84.8 
svmLDA10 83.3 84.8 79.2 84.8 
LDA/P1-CA125 82.6 72.0 76.0 73.9 
Table 8 Discriminative power of univariate/multivariate selected candidates. 
Sensitivity and specificity for “best cut-off point” and “precision-recall break even point” calculated for 
tumor marker CA125, individual discriminative anti-glycan antibodies and anti-glycan antibody panels 
for 3 (svmLDA03), 6 (svmLDA06) and 10 (svmLDA10) glycans; LN = Galβ1-4GlcNAc. 
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Rank Carbohydrate Structure 
1. Galα1-4Galβ1-4GlcNAcβ 
2. Neu5Acα2-3Galβ1-4-(6-Su)GlcNAcβ 
3. Neu5Acβ2-6GalNAcα 
4. Neu5Acβ2-6Galβ1-4GlcNAcβ 
5. Neu5Acα2-3Galβ1-3-(6-Su)GalNAcα 
6. Galβ1-4GlcNAcβ1-6Galβ1-4GlcNAcβ 
7. Galβ1-4(6-O-Su)GlcNAcβ 
8. Galα1-3Galβ1-4(Fucα1-3)GlcNAcβ 
9. Galα1-3(Galα1-4)Galβ1-4GlcNAcβ 
10. GlcNAcβ1-3Galβ1-4GlcNAcβ 
Table 9 Multivariate selected discriminating glycan structures. 
Glycans ranked by their stability after 700 independent runs 
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3.3 Comparison of three glycan-based immunoassays: suspension array, ELISA and 
printed glycan array in the detection of human anti-glycan antibodies. 
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3.3.1 Abstract 
Anti-glycan antibodies incorporate a vast and yet insufficiently investigated 
subpopulation of naturally occurring and adaptive antibodies in humans. Glycan-specific 
antibodies and their glycan ligands regulate various important biological processes, including 
cancer. The role of glycan-antibody interactions in cancer progression is still poorly 
understood. Recently, a variety of glycan-based microarrays were generated, allowing high-
throughput profiling of the entire repertoire of glycans and glycoconjugates within one 
organism. There is, however, no platform established which would allow for comparison and 
evaluation of glycan-microarray generated candidates. In the present study we compare the 
three currently available ‘glycan-based immunoassays’, namely printed glycan array, 
fluorescent microsphere-based suspension array and ELISA. Our aim was to investigate 
glycan-based immunoassays for their efficacy and selectivity in profiling anti-glycan 
antibodies in a cohort of 31 patients with and without gynecological cancer. For estimation of 
sensitivity and specificity in the detection of anti-glycan antibodies, the AB0 blood group 
glycan antigens were used as ligands. All three methods reflected the known blood groups 
serology, as confirmed by Bland-Altman plot and receiver operating characteristics. From 
moderate to high concordance correlations coefficient were detected for A/B trisaccharides 
within all assays (CCC 0.41-0.83). A previously identified glycan candidate, which potentially 
allows ovarian cancer detection, P1 trisaccharide (Galα1-4Galβ1-4GlcNAcβ), was explored 
within all three assays. In contrast to the observations on AB0-blood group determinants, anti-
P1 antibody binding profiles displayed a variety of weak but positive results. Our results 
demonstrate that each assay presents unique characteristic features, presumably reflecting the 
difference in glycan presentation, assay conditions and detection technique. This indicates that 
an individual assay has to be used depending on the aspect of interest within a particular 
glycan-antibody interaction. 
3.3.2 Introduction 
Interactions of glycans, complex oligosaccharides attached to a protein or lipid, with 
glycan-specific antibodies mediate many important biological processes, such as pathogen 
recognition (1), malignant transformation (2), autoimmune disease (3), neurological disorders 
(4) and host-versus-graft rejection (5). Currently, a vast subpopulation of naturally occurring 
and adaptive anti-glycan antibodies are under investigation. We have previously performed 
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experiments identifying antibody answers to a new ovarian cancer marker, P1, which can 
reflect a variety of antibody binding as well as non-specific binding. 
In recent years, a number of glycan based microarray platforms, based on specific 
(covalent or non-covalent) immobilization of chemically conjugated glycans on a chemically 
modified surface, have been developed for high-throughput investigations of the glycome (6). 
Glycan-based arrays vary in glycan presentation, origin, assay conditions, detection methods 
and immobilization on flat surface or microspheres, contributing ultimately to the affinity and 
selectivity of glycan-binding proteins (7, 8). There is a crucial need for standardization and 
comparison between various forms of glycan microarrays, especially taking into account their 
proven scientific potential for translational research and subsequent clinical applications. The 
increasing number of high-throughput glycan-array studies requires the application of different 
bioinformatical analyses for validation and comparison of datasets. However, to date, only a 
few reports compared glycan microarrays and conventional ELISA, most of them only in terms 
of sample size and detection limitations (2, 9, 10). 
In the present study we compared three independent custom-developed glycan-
immunoassays in their potential and efficacy for the detection of anti-glycan antibodies in 
human serum; (1) printed glycan array; (2) multiplex flow cytometric suspension assay (SA); 
and (3) ELISA, the most established method. Printed Glycan Array (PGA) as one of the newest 
high-throughput microarray technologies (11, 12) allows the automated detection of an 
unlimited number of natural and synthesized glycans in one experimental setting. It is 
characterized by high sensitivity and a significant reduction of reagent consumption. Multiplex 
flow cytometric suspension assay (SA) (13), incorporating fluorescent microspheres with 
distinct spectral addresses as a solid support for ligands, was recently developed for profiling 
of anti-glycan antibodies (14). This type of assay combines the flexibility of ELISA with the 
simultaneous detection of multiple ligands in one sample with minimal reagent consumption. 
Standard ELISA (9, 15-17), allows screening of a limited number of ligands, is well 
established and widely used. Naturally occurring or chemically synthesized glycans are 
displayed in various ways throughout the three technologies of ‘glycan-immunoassays’. In 
both the PGA and ELISA glycans are positioned on a flat surface. On PGA glycans are 
covalently attached to the surface of a glass slide in a monovalent form as ω-alkyl glycosides 
(Glyc-sp-NH2), in ELISA they are physically absorbed to polystyrene as conjugates with a 
poly[N-(2-hydroxyethyl)acryl amide] carrier (Glyc-PAA). In the case of SA, glycans are 
coupled as end-biotinylated glycopolymers (18) via streptavidin-biotin reaction to pre-modified 
fluorescent beads [14]. All three glycan immunoassays display various detection specificities 
Francis Jacob  Results 
 93 
resulting in certain advantages and limitations (Table 10). ELISA is more relevant for the 
investigation of a limited panel of glycans, PGA allows broad glycan library screening, and SA 
is ideal for the rapid multiplex detection of up to several dozens of samples. Therefore, all three 
glycan-assays could be used to study different aspects of glycan-antibody interactions. 
We performed a comparative analysis of all three ‘glycan-immunoassays’ within a 
cohort of 31 healthy and gynecological cancer serum samples. As serologically investigated 
targets for serum anti-glycan antibodies we used blood group antigens A/B trisaccharides as 
biological controls (12, 19-21) as well as the candidate P1 (Galα1-4Galβ1-4GlcNAcβ) which 
showed the highest discriminative power between a cohort of non-mucinous epithelial ovarian 
cancer patients and healthy controls. 
3.3.3 Material and Methods 
Clinical cohort 
Serum samples were prospectively collected from 31 women at the Department of 
Gynaecology, University Hospital Zurich, after written informed consent was given. Ethical 
approval for this study was granted by the appropriate Ethical Board in 2006 (SPUK, Canton 
of Zurich, Switzerland). Two venous blood samples (12ml) were collected per patient pre-
operatively in EDTA blood tubes (BD Vacutainer®, 0.184M EDTA, BD Diagnostics, Franklin 
Lakes, US) and stored on ice until further processing. Blood samples were centrifuged at 
3000xg at 4°C for 10 minutes, and aliquots of the supernatant plasma frozen at –80 °C. All 
collected serum samples were processed within the same protocol within 3 hours.  
Coupling of Suspension Array 
Biotinylated glycopolymers were coupled with fluorescence labeled carboxylated beads 
of 5.5 µm diameter with #25, 35 and 45 spectral “addresses” (bead regions) (Bio-Rad 
Laboratories). The stock of beads (1.25×107 beads/ml) was vortexed for 30 sec and sonicated in 
a water bath sonicator for 30 sec before use. The bead suspension (100 µl; 1.25×106 beads, 0.2 
nmol –COOH groups in total, according to supplier’s information) was centrifuged for 4 min, 
14,000 g at RT. The pellet was resuspended in washing buffer (100 µl; Bio-Plex amine 
coupling kit, Bio-Rad Laboratories) by vortexing and sonication and washed by centrifugation. 
The pellet was resuspended in 80 µl of microsphere activation buffer (Bio-Plex amine coupling 
kit, Bio-Rad Laboratories) by vortexing and sonication. The S-NHS solution (50 mg/ml Sulfo-
N-hydroxysuccinimide sodium salt and the EDC solution (50 mg/ml 1-ethyl-3-[3,3-
dimethylaminopropyl] carbodiimide hydrochloride (Pierce Biotechnology) were prepared just 
before use, then 10 ul of each solution were added to the microsphere suspension and vortexed 
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for 30 sec. The beads were incubated on a vertical rotor in the dark for 20 min at RT and 
subsequently centrifuged. The pellet was washed once with 500 µl of activation buffer and 
resuspended in 150 µl Biotin-solution (0.1 M NaHCO3, pH 8.3, containing 1 µg (≈ 2 nmol) of 
biotin-NH(CH2)6NH2 (Lectinity Holding, Moscow)). The suspension was rotated with medium 
speed in the dark for 2 h at RT. The biotinylated beads were centrifuged and resuspended in 
150 µl blocking-solution (50mM Ethanolamine (Sigma-Aldrich) in 0.1 M NaHCO3, pH 9.0) to 
block unbound sites. The beads were agitated in the dark on a rotator for 30 min at RT and 
centrifuged. The pellet was washed twice with 500 µl PBS (pH 7.4) and resuspended in the 
streptavidin-solution (400 pmol streptavidin (Bio-Rad) in 150 µl PBS per 100 µl of beads). The 
suspension was vortexed and agitated on a rotator in the dark for 12 h at 4°C. The beads were 
washed twice by centrifugation in 500 µl PBS. The Glyc-PAA-biot1-solution (20 pmol biotin 
(conjugate of Glyc with poly[N-(2-hydroxyethyl) acrylamide in ddW) with a single end biotin 
group (∼30 kDa, Glyc contents - 20%mol) (18)) and 1.25×106 streptavidin-coated beads in 150 
µl PBS was added and agitated in the dark on a rotator for 6 h at RT. The modified beads were 
centrifuged and supernatant removed. The beads were washed twice with 500 µl storage buffer 
(Bio-Rad Laboratories), centrifuged and resuspended in 100 µl of storage buffer (define the 
buffer). The bead concentration was determined by a hemocytometer (Roth AG). The samples 
were stored protected from light at 4°C 
Antibody binding suspension assay (SA) 
A Bio-Plex Suspension Array System (Bio-Rad) which identifies and quantifies the 
specific reactions based on bead color and fluorescence was used for bead-based suspension 
assays. Data analysis was performed by Bio-Plex Manager 4.1 software. A 96-well Multiscreen 
HTS filter plate (Millipore) were rewetted for 5 min with 100 µl of antibody diluent (PBS-0.05 
M Tris, pH 7.2, 0.25% BSA, Sigma-Aldrich). Antibody diluent incorporating (50 µl/well and 
2000 beads) was added. The plate was washed three times with 100 µl washing-buffer (PBS-
0.05 M Tris, pH 7.2) using a vacuum manifold (Bio-Rad). Human serum samples were diluted 
with antibody diluent 1:40 (50 µl/well) and added to the wells, shaken at 1,100 rpm for 30 sec 
on a microplate shaker and incubated in the dark for 1 h at RT on the shaker (200-300 rpm). 
The samples were washed three times with washing-buffer and incubated in the II antibody-
mix (R-phycoerythrin conjugated goat anti-human Ig (25 ng/well IgM+IgG+IgA, H+L; 
Southern Biotechnology) on a shaker in the dark for 30 min. The samples were washed three 
times with washing-buffer and the beads were resuspended and diagnosed by the Bio-Plex-
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Array reader. The data were acquired in by the internal software package (Bio-Plex Manager 
4.1; Bio-Rad). The results were reported as median fluorescence intensities (MFI). 
Direct ELISA 
Immunoplates 96-well NUNC MaxiSorp (Thermo Fisher Scientific) were coated with 
the coating-solution (10µg glycans bound to poly[N-(2-hydroxyethyl)acryl amide] carrier 
(Glyc-PAA) (Lectinity Holdings, Moscow) per 1 ml 50mM Na2CO3/ NaHCO3, pH9.6) for 12 h 
at 4°C. Carbohydrate-free PAA was applied as negative control. The plates were blocked with 
1% (w/v) BSA (Sigma-Aldrich) in PBS for 40 min at 37°, washed three times with PBS 
containing 0.5% (v/v) Tween20. Blood serum samples were diluted 1:1000 in incubation 
buffer (PBS, 0.3% (w/v) BSA, 0.02% (v/v) Tween20) and incubated for 60 min at 37°. The 
plates were washed three times with PBS containing 0.5% (v/v) Tween20. Bound anti-glycan 
antibodies were detected by 60 min incubation at 37° in goat anti-human IgA + IgG + IgM 
conjugated (0.16µg/ml in incubation buffer) to long chain biotin (Pierce, Rockford), three 
times washed and incubated in streptavidin horse radish peroxidase conjugate (0.083µg/ml 
HRPO in incubation-buffer, Southern Biotechnology Associates) diluted in incubation buffer 
for 1h at 37°C. The samples were washed three times was before development by chromogen 
substrate 3,3’,5,5’-tetramethylbenzidine (TMB) (Sigma-Aldrich). After 5min of incubation the 
peroxidase reaction was stopped by equal volume of 1M H2SO4. Optical density was measured 
by 450nm ELISA reader (Tecan Spectrafluor Plus, Tecan). The serum samples were set up in 
duplicates. For the statistical analysis their mean was used. 
Printed glycan array (PGA) 
Printed glycan array slide fabrication and high-throughput profiling was performed as 
previously described (11, 12). Briefly, monomeric glycans of 95-98% purity (Lectinity 
Holdings, Moscow) were diluted in 300mM phosphate buffer pH 8.5 containing 0.005% 
Tween 20 and printed by robotic pin deposition on N-hydroxysuccinimide activated glass 
slides (Nexterion Slide H, Schott, Jena, Germany). Glycans were printed in 50µM 
concentration in eight replicates. Free N-hydroxysuccinimide activated groups were blocked 
with 50mM ethanolamine in 50mM borate buffer at a final pH of 9.2. Slides were then rinsed 
with deionized water, dried and stored at room temperature in a desiccator. Each serum sample 
was diluted 1:15 in PBS (0.1% v/v Tween20 and 3% w/v BSA), vortexed for 15 seconds and 
incubated at 37°C for 15 min. Samples were transferred to the array slides and gently rocked in 
a sealed humidified incubator for 2h at 37°C. Unbound sample components were washed with 
a series of 0.1% and 0.001% Tween 20 in PBS. Antibody-solution, goat anti-human IgA + IgG 
+ IgM conjugated to long chain biotin (Pierce Biotechnology) was diluted 1:100 in PBS with 
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0.1% Tween20 and 3% BSA and was added. Slides were incubated at RT in a humidified 
chamber for 45 min and then washed. Bound antibodies were visualized by incubating slides 
with fluorescent dye streptavidin-solution (Alexa Fluor555 Molecular Probes 1:1000 in 
PBS/0.1% Tween20) at RT for 30 min. Fluorescence signals corresponding to glycan-bound 
antibodies were measured and quantified using ImaGene analysis software version 6.1 and 7.5 
(BioDiscovery). Signals were measured as total signal intensity (medTSI) per glycan and were 
expressed as median across eight within-array replicates. 
Statistical Analysis 
Combined graphical and statistical interpretations of method-comparison studies were 
performed (22) and included scatter plots combined with correlation and regression analysis 
(23). Difference Bland-Altman plots were combined with calculation of the 2s limits of the 
differences between individual methods (24, 25). To solve the problem of different data values, 
all data sets were standardized as follows: z = (xi – xmean) / xsd. Standardized data (z) were 
generated for each vector data set (xi) by subtraction by their mean (xmean) and division of their 
standard deviation (xsd), and were called standardized antibody measurements (SAM). Data 
analysis, including calculation of mean, median, standard deviation and coefficient of variation 
was performed using the open source statistical programming language R (http://CRAN.R-
project.org/, version 2.8.1). Statistically significant differences were proved for each method by 
Wilcoxon rank sum test. Concordance correlation coefficients (CCC) (26) which evaluate the 
degree to which pairs of observations fall on the 45° line through the origin, were calculated 
and compared within all independent methods (R package epiR). Direct comparison of two 
methods was performed using linear regression (27, 28). Median signals among all known 
blood groups were measured using the Kruskal-Wallis rank sum test (R package stat). All p-
values < 0.05 were taken as significant and the tests were performed on the 5% significance 
level. For comparison of high versus low anti-glycan antibody levels in correlation with known 
blood groups, sensitivity, specificity (R package ROCR (29)) and area under the curve (AUC) 
were calculated for each method. The best cut-off between observed false negative and false 
positive rates was determined as “precision-recall break even point” (29), the point at which 
precision equals recall and predictions are made due to the prevalence within the given data. 
3.3.4 Results 
Controls and validation procedures used in glycan-based immunoassays. 
Αlpha-rhamnose was used as a “positive biological control” in PGA experiments due to 
the known high expression levels in healthy control individuals (30). Aminoglucitol, an opened 
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reduced form of D-glucose which is not present as a structural component of regular 
glycosylation, was shown to be negative for anti-glycan binding at similar values to the 
technical background (12). We therefore used it as a negative biological control for PGA and 
SA, where median fluorescence intensities (MFI) signals for aminoglucitol binding did not 
exceed 200 MFI and were close to the technical cut-off in all individual samples (data not 
shown). An empty polymer structure (PAA) was used in ELISA as a control for non-specific 
binding and displayed in all cases lower signals than the lowest signals for Glyc-PAA coating 
(data not shown). 
The effectiveness of glycopolymer coupling to the fluorescent microspheres in SA was 
tested by human anti-glycan antibodies against A/B blood group antigens and P1, purified from 
pooled human sera by affinity chromatography as described before (16). It both SA and 
ELISA, polyclonal anti-glycan antibodies bound to cognate glycans in a dose-dependent 
manner displayed no or very low cross-reactivity to other glycans. 
Glycan-based immunoassay examination within AB0 blood group antigens 
Antibody profiles for Atri (GalNAcα1-3 (Fucα1-2)Galβ) and Btri (Galα1-3(Fucα1-
2)Galβ) blood group antigens were performed using SA, ELISA and PGA on 31 individual 
blood serum samples. Raw data were acquired for all technologies in different units; values 
varied from 74 to 13595 (MFI, SA), from 0.152 to 2.305 (OD, 450nm, ELISA) and from 0 to 
51.28*105 (medTSI, PGA). Anti- A/B antibody levels were calculated as distribution of 
median of 31 serum samples and additional median absolute deviation. Using PGA, we 
observed generally higher antibody binding levels to Btri than to Atri (p=0.0358), with higher 
individual variability of the latter, consistent with literature (12). The same pattern was 
observed in ELISA (p=0.0406), followed by lower individual variability of both anti-glycan 
antibodies, indicated by median absolute deviation.  
In contrast to PGA and ELISA, data generation by SA revealed no significant 
difference between general levels of anti-A and anti-B antibody binding, accompanied by 
higher individual variability in anti-A antibody binding. 
The appropriate distribution of the data of three immunoassays in the same units and on 
the same scale was achieved by standardization. PGA data were pre-processed (12) and SA 
skewed distributed raw data were log-transformed to improve interpretability and visualization. 
Next, SA, ELISA and PGA data were standardized as described above (Materials and 
Methods). Standardized data were further used for all statistical models, presented hereafter. 
Closest relationship between SA and PGA in detection of anti A/B antibodies  
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Direct binary comparisons of three methods, based on scatter plots and linear regression 
model revealed a pattern of positive correlations, ranged from moderate to high (Figure 17). 
Moderate CCCs were observed for SA and ELISA in Atri and Btri antigen (CCC 0.68 and 0.71, 
respectively, Table 11). These positive correlations were displayed by the proximity of linear 
regression lines to the equality line (Figure 17) for both antigens (Atri and Btri, Table 11). The 
highest correlation was observed between SA and PGA (Figure 17), with CCC 0.83 for Atri and 
0.70 for Btri (Table 11). The weakest correlation was observed between ELISA and PGA 
(Figure 17), with a CCC of 0.54 (Atri) and 0.41 (Btri) (Table 11). Observed correlation patterns 
for all three comparisons validated by F-statistics showed significant p-values (p<0.05). This 
supported the hypothesis that anti-glycan antibody levels across the three methods correlated to 
each other. No significant difference was found for both linear regression models in 
comparison of Atri versus Btri (p> 0.05) in all three binary comparisons, which indicated subject 
(here: glycan)-independent observations. 
Correlation characteristics for A antigen were comparably more distinctive than for B 
antigen (in SA versus PGA and PGA versus ELISA, Table 11) 
Additionally, the correlations between methods were examined (Figure 18) and proved 
glycan independent observations. It also demonstrated similar tendencies within both SA and 
PGA, showing the smallest absolute standard deviation (2*s.d.) for Atri (1.16SAM) and a 
bigger absolute standard deviation for Btri (1.54SAM) (Figure 18). The most pronounced 
difference was observed between PGA and ELISA with 1.91SAM for Atri and 2.16 SAM for 
Btri (Figure 18). None of the immunoassays showed any difference in the detection of anti-A/B 
antibodies, although Atri had a more distinctive distribution pattern compared to Btri. 
All immunoassays reflect adequately the standard serological distribution of AB0 blood types 
The well known AB0 blood group carbohydrate antigens were used for measurement of 
assay capacity in the detection of anti-glycan antibodies. AB0-specific antibodies 
(isohaemagglutinins) belong to a group of naturally occurring antibodies (31) which can be 
determined by haemagglutination test, ELISA (15, 17) and FACS (32). To define how applied 
assays distinguish between blood groups we performed non-parametric tests for all three data 
sets. All ‘glycan-based immunoassays’ were able to distinguish blood groups (A (n=13), AB 
(n=2), B (n=6) and O (n=10)) adequately (Figure 19). As expected, highly significant 
differences (p<0.01) between known blood group antigens Atri and Btri were found in each 
applied method (SA, ELISA and PGA). Strong discrimination of antibody levels for Atri was 
observed in all three methods with highest in SA (p<0.0001). Less significant discriminators 
were achieved for antigen Btri (SA, p=0.0058; PGA, p=0.0065). Distribution of anti-A/B 
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antibodies using a pool of immunoglobulin subtypes (IgG, IgA, IgM) determined by all three 
immunoassays were concordant with classical haemagglutination data (33). 
High diagnostic performance in all glycan-based immunoassays  
The accuracy of applied assays to discriminate between expected anti-glycan antibody 
levels was evaluated by ROC. Data from blood groups with low anti-Atri antibody levels (BG 
A and AB) were combined, as were the data from BG with higher anti-A antibody levels (BG 
B and O). SA revealed the best discrimination character between low and high anti-A antibody 
levels with excellent selectiveness (sensitivity 93.3%, specificity 93.7%, AUC 0.96). Equal 
AUC values were achieved by ELISA (0.95) and PGA (0.93) (Figure 20). 
Interestingly, the overall pattern changed for anti-B antibody levels and sensitivity, 
specificity and AUC values decreased in PGA, SA and ELISA (AUC 0.85, 0.87 and 0.78, 
respectively) (Figure 20). 
Glycan-based immunoassays showed diverse expression for P1 (Galα1-4Galβ1-4GlcNAcβ)  
Based on the findings that anti-A/B antibody profiles represent an assay independent 
pattern we further investigated potential ovarian cancer biomarker, antigen P1 (Galα1-4Galβ1-
4GlcNAcβ). ‘Glycan-based immunoassays’ were plotted against each other and their 
relationship determined by linear regression analysis (Figure 21). In comparison to the A/B 
blood group-based assays, anti-P1 correlations across the three assays appeared to be much 
weaker. Best relationships with moderate correlation (CCC 0.49) were detected between SA 
and ELISA assays. Almost no relationship could be observed comparing of PGA versus 
ELISA and PGA versus SA (CCC 0.35 and 0.27, respectively), which is consistent with the 
findings that SA and ELISA do not generate the same results as PGA. Within cancer samples, 
the CCC as well as the linear regression line was inverted in the comparisons PGA versus 
ELISA or SA (Figure 21). Within the healthy controls the correlation coefficient revealed at 
least moderate or low correlations (CCC 0.52 (SA versus PGA) and 0.29 (PGA versus 
ELISA)). Anti- P1 antibody levels between healthy and malignant cases showed only 
significant discrimination character in the PGA experiment (p=0.01) (Figure 22). 
3.3.5 Discussion 
In the present study we statistically measured and compared the efficacy and selectivity 
of three custom-developed immunoassays in profiling of anti-glycan antibodies in individual 
human serum samples. Two of the investigated glycans belonged to the subpopulation of AB0 
blood group antigens and one was previously described as potential ovarian cancer biomarker. 
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With the use of different statistical models we have shown, that all glycan 
immunoassay results for anti-A/B antibodies were positively correlated, from moderate to high 
correlations, and demonstrated the same tendencies for both blood group antigens independent 
of method used. For all methods the correlation patterns for A antigen were comparably more 
distinctive than for B antigen. 
All three methods adequately reflected known serological isohaemagglutinin 
distribution within four blood groups and showed high diagnostic performance in 
discrimination of blood groups, but best for SA and PGA. 
However, in comparison to the A/B blood group-based assays, anti-P1 correlations 
across the three assays considerably changed. PGA demonstrated a discrimination power 
between cancer and healthy serum samples whereas the other two methods did not result in 
reproducible results. This could reflect a true cancer association of P1 antibody levels, but 
because of the cohort size strong conclusions cannot be drawn. Differences in the various assay 
conditions like different concentrations of glycans as well as serum dilutions (Table 10) have to 
be drawn into consideration. Whilst this finding is of interest, our main aim in this study was to 
compare three ‘glycan-immunoassays’ on their expression of well known AB0 blood group 
anti-glycan antibodies. Our results indicate a stronger relationship among these assays were 
much stronger in case of AB0 blood group antigens than in case of P1. This could be explained 
by their strong biological importance, or high affinity for anti- A/B antibodies (21). Although 
the affinity and biological importance of anti-P1 antibodies was not investigated, they might 
comprise rather a subpopulation of anti-glycan antibodies with lower affinity (and/or 
specificity). As in the case of PGA glycans are presented as monomers in a highly organized 
manner with limited flexibility (and possibly restricted accessibility) (Table 10), presumably 
only a subpopulation of anti-P1 specific antibodies but not all the spectrum of possible P1 
binders was detected. In contrast to PGA, SA and ELISA are assays based on polymeric glycan 
presentation which allows multivalent binding between glycans and glycan directed antibodies 
(Table 10). We assume that SA and ELISA reflect a broader spectrum of glycan-antibody 
interactions. SA provides more degree of freedom than in PGA as flow conditions and 
polymeric glycan presentation contribute to the binding and interaction (Table 10) (13, 14). As 
a result, ELISA and SA might be more susceptible than PGA to non-specific binding, like the 
direct binding of heterophilic serum antibodies. Binding of heterophilic antibodies (rheumatoid 
factor IgMs) was previously reported for SA and ELISA, could interfere data readout causing 
false positive or negative results (34, 35) On the other hand, assay based on multivalent and 
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polymeric ligand presentation seem therefore to be closer to natural or in vivo conditions, 
which was shown by a good discrimination power for anti-A/B antibodies. 
We conclude that for biomarker research the use of only one assay with appropriate 
sensitivity, specificity and reproducibility might be sufficient to identify a specific disease. In 
contrast, it is not relevant to draw crucial conclusions based on data from one assay in the case 
of basic research, as each glycan, showing important physiological patterns in one assay, 
should be confirmed by other approaches. Each method is specific to describe glycan binding 
patterns (12), glycan binding partners (36) or motif-based analysis of specify glycan-binding 
proteins (37). For investigations into glycan-protein interactions the cumulative approach based 
on the use of several methods for better data interpretation seems more preferable, similar to 
cDNA or oligonucleotide microarrays being validated using RT-PCR as well as Northern 
blotting on the basis of gene expression levels. 
Based on our findings, the usefulness of each glycan-immunoassay strongly depends on 
the task, taking into account the advantages and limitations of each method. SA is better than 
ELISA in consuming a lower amount of glycopolymers (picomolar versus micromolar amounts 
per experiment), whilst SA is more suitable than PGA due to a greater range of flexibility and 
assay reconfiguration. On the other side, PGA is exceptionally convenient for high-throughput 
screening of big glycan libraries whereas ELISA is restricted in this aspect. Thus, an adequate 
usage of all discussed glycan-based immunoassays broadens the methodological flexibility in 
the area of glycobiology. 
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3.3.8 Figures 
 
Figure 17 Comparison of 'glycan-based immunoassays' by scatter plot. 
Methods were plotted against each other among all possible combinations. The x- and y- axis shows the 
standardized signals (see “Results”) for each method. Dashed lines indicate linear regression model for 
blood group antigen Atri (black) and blood group antigen Btri (grey). Black line indicates intercept of 0 
and slope of 1. Each dot is represented by two-method measurement of one serum sample (n=31). 
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Figure 18 Binary comparison of 'glycan-based immunoassays' by Bland-Altman plot. 
The averages of each two methods standardized data (e.g. [SA– ELISA]/2) are plotted on x- axis, and y 
axis refers to the absolute difference between each two methods ([SA– ELISA]). Upper and lower 
dashed lines indicate 95% limit of agreement for blood group antigen A (black) and blood group 
antigen B (grey). Black line indicates the absence of absolute difference between two methods. Each 
dot indicates the value of difference between two methods in each serum sample (n=31). 
 
Figure 19 Binding of serum anti-A/B antibodies to Atri and Btri in SA, ELISA and PGA. 
Boxplots demonstrate the distribution of anti-glycan antibodies directed to glycans Atri (plotted as 
SA_A; ELISA_A; PGA_A) and Btri (SA_B; ELISA_B; PGA_B) within each blood group (A, B, AB 
and O). The median per blood group is indicated by the horizontal black bar in a box. The bottom and 
the top of a box represent the lower and upper quartile, respectively. The length of a box is designated 
as interquartile range. The length of dotted lines, whiskers, is within 1.5 times of interquartile range. 
The data outside the whiskers are considered as outliers and are represented by empty circles. Blood 
groups are shown on x-axis. Standardized signals for each method are presented on y-axis. Kruskal- 
Wallis p-value indicates the equality of population medians among blood groups. 
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Figure 20 ROC curves for anti- A/B antibodies. 
Data from BG with expected low anti-A antibody levels (BG A and AB), as well as data from BG with 
higher anti-A antibody levels (BG B and O), were combined to assess the binary classification test 
characteristics (ROC curves) for antigen A in comparison of three methods. In reverse, the data from 
BG B +AB versus BG A+O were also combined for comparison of three methods, based on antigen B. 
 
Figure 21 Scatter plots for anti-P1 antibody levels in SA, ELISA and PGA. 
Methods were plotted against each other to describe the relationship of measurements (n=31). SA 
versus ELISA revealed best assessing agreement (CCC 0.49). No correlation could be detected between 
SA or ELISA versus PGA (CCC 0.27 or 0.35, respectively). Grey quadrates represent serum samples 
from healthy donors and black triangles refer to samples from donors with gynecological malignancies. 
Linear regression is indicated by black line for all serum samples (n=31), dashed grey line for healthy 
samples (n=22) and black dashed line for sera of malignant cases (n=9). The x- and y- axis shows the 
standardized values of each method. 
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Figure 22 Binding of anti-P1 antibodies in SA, ELISA and PGA. 
Boxplots demonstrate the distribution of anti-glycan antibodies directed to P1 measured by three 
immunoassays. Benign (n=22) and malignant (n=9) cases are plotted separately. 
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conc.: 
1st detection 0.16 µg/ml 20 µg/ml 25 ng/well 
conc.: 
2nddetection 0.083 µg/ml 2 µg/ml n/a 
data 
acquisition 
TMB as substrate; 
peroxidase reaction; 
450nm 
Fluorescent 
measurement at 
533 nm 
Fluorescent  
measurement at 
533 nm 
technical 
read out 
optical density at 
450nm 
median fluorescent 
total signal intensities 
of eight replicate 
median fluorescent signal 
intensity (within 100 beads) 
assay 
conditions static static flow 
Table 10 Methodological description of three ‘glycan-based immunoassays’. 
 
 
SA versus ELISA SA versus PGA PGA versus ELISA 
 
A B A B A B 
CCC 0.68 0.71 0.83 0.70 0.54 0.41 
95% CI 0.43-0.83 0.49-0.85 0.68-0.91 0.46-0.84 0.24-0.75 0.08-0.67 
R-squared 0.46 0.51 0.69 0.49 0.296 0.175 
F-test p-
value 
<0.001 <0.001 <0.001 <0.001 0.001 0.019 
Table 11 Relationship between 'glycan-based immunoassays'. 
Concordance correlation coefficient (CCC); A (Atri); B (Btri); printed glycan array (PGA); suspension 
array (SA); confidence interval (CI). 
Francis Jacob  Discussion 
 108 
4 Discussion 
4.1 High-Throughput Profiling for Epithelial Ovarian Cancer Biomarker Detection 
Epithelial ovarian cancer is the fourth most common cause of cancer death in women in 
the Western world and the leading cause of death from gynaecological malignancies worldwide 
(1). Due to unspecific symptoms like bloatedness or abdominal distension, 75% of women get 
diagnosed in advanced stage disease with a five-year survival of 10 to 30% (2). Despite 
advances in surgery and chemotherapy relapse rates are as high as 50% after six cycles of 
standard Carboplatin/ Paclitaxel chemotherapy, with a median survival after recurrence of only 
two years (1, 3). 
There is thus a high demand to utilize molecular expression profiles for the 
classification of ovarian tumors into distinct, clinically relevant subtypes and for the prediction 
of individual clinical outcomes by generating a personal “biosignature” (4). Transcriptional 
genome profiling technologies allow the analysis of the expression of thousands of genes of a 
specific biological system in only one experiment (5). Gene expression profiles of two RNA 
samples that are simultaneously hybridized onto a microarray chip can be compared and allow 
investigators to address important biological questions that could not be answered with 
traditional expression-based technologies as Northern blots, in situ hybridization, or real time 
PCR. Since the first ovarian cancer transcriptomic studies in 1999 (6-8), a rapid development 
of microarray technology has taken place, including the development of SEREX as the first 
high-throughput technology which examined protein expression (9). Meanwhile a linear 
increase in high-throughput profiling studies in the field of ovarian cancer has taken place (10). 
The immense amount of data gained through these experiments has enabled some insight into 
the heterogeneity of ovarian cancer and has shown some biomarkers which could evolve as 
new diagnostic, prognostic or therapeutic targets in the future. A summary on all high-
throughput technologies published from 1999 to 2007 in the field of ovarian cancer (10) has 
displayed important findings but also numerous limitations which need to be overcome in 
future studies. 
4.1.1 Current Limitations and Future Integrative Research 
High-throughput expression profiling studies in the field of genomics and proteomics 
(proteogenomics) allow the detection of thousands of genes and proteins from very small 
samples of tissue, cell lines, blood or other body fluids, and have thus revolutionized our 
knowledge and understanding of ovarian cancer. During the last eleven years this technology 
Francis Jacob  Discussion 
 109 
has been extensively used to unravel the ovarian cancer genome, transcriptome, and proteome, 
thus changing various paradigms, which were manifest for decades. A linear increase in 
profiling studies has left us currently with over 237 studies published between 1999 to 2007, 
which have used various platforms and clinical samples as well as having addressed numerous 
questions (10). The growing diversity of study questions during the recent years clearly 
demonstrates three major problems in high-throughput ovarian cancer profiling, namely the 
need 
a) to define homogenous subtypes of ovarian cancer and its adequate normal 
controls, 
b) to develop assays which are easy performable, reliable, comparable and 
reproducible, 
c) to openly distribute study results. 
Transcriptomic profiling, involving RNA molecules in a given cancer, is a widely used 
technology for the generation of gene expression data on a genomic scale with many 
significant results derived by several microarray platforms. Oligonucleotide arrays and cDNA 
microarrays are increasingly used by researchers interested in broad gene expression patterns, 
allowing them to compare the current activity of thousands of genes in specific tissues and cell 
lines under various study conditions, namely with and without genetic defect, or with and 
without treatment. Nowadays, the main problems regarding comparability occur due to data 
management and pre-processing, statistical analysis, distribution and storage of datasets. 
A large degree of variability has been found in gene expression patterns investigated in 
tissues (48.3%), even within supposedly genetically identical individuals. Causes were 
identified in the time of day the experiments were performed and patient characteristics like 
age, physiological state, menstrual status, response to disease (10), demonstrating that the 
robustness of the method is not given. Additionally, the heterogeneity of the disease and its 
potential precursor lesions have to be defined before any biomarkers with high sensitivity and 
specificity can be detected. Improvements could be achieved by standardized collection and 
storage of specific databases. Therefore, we have developed a specific database (PEROV, 
Peritoneal and Ovarian Cancer data base, Microsoft Access) which allows the storage of 
clinical patient characteristics as well as translational research results per patient. This database 
links both personal and clinical parameters, biochemical measurements such as CA125 and 
experimental work. It therefore enables the evaluation of translational research experiments by 
linking antibody profiles to individual tumor characteristics. 
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Another well known problem in gene expression profiling is the broad spectrum of 
available techniques. Requirements for fabrication, cross-hybridization, target redundancies, 
and ultimately the use of common platforms which are reproducible and compatible have to be 
recommended (11). It has been shown that different public databases, e.g. GEO (12) and 
ArrayExpress (13) differ in availability and assessment of data in their raw format, so that not 
sufficient quality data are available to enable meta-analyses (14). In the majority of publicly 
available datasets the raw data were not found (14). A possible solution was suggested by 
Brazma et al. in 2001, who published a proposal for guidelines describing the minimum 
information about a microarray experiment (MIAME). These days most scientific journals 
require the deposition of microarray derived data for independent verification studies (15). Due 
to these requirements data are increasingly available for the reproduction of previous findings, 
comparison and combination of other datasets or to test new applied bioinformatical tools and 
relevant mathematical procedures. Microarray data have been used to build secondary 
databases like the Arabidopsis genome based GENEVESTIGATOR (16), the cancer 
microarray database ONCOMINE (17), or the ArrayExpress Gene Expression Atlas (13). 
Based on our analysis in ovarian cancer proteogenomic studies, raw data of transcriptomic 
based high-throughput studies (63.7%) were only in 12% available within the MIAME 
guidelines (10). Unfortunately, most of the remaining studies published only gene lists of 
limited utility for integration analysis. 
Meta-analyses have emerged in the field of clinical investigations as the gold standard 
for the comparison and combined analysis of existing studies. It is well accepted that only 
meta-analysis can circumvent the problems inherent to studies with low statistical powers due 
to low samples sizes (18). Such analyses performed on cancer microarray data are only feasible 
by independent studies which investigated the same set of genes and the same clinical aim. In a 
meta-analysis performed by us we combined datasets of five publicly available raw data sets 
(19-23) and generated a list of consistently and significantly de-regulated genes which are 
potentially associated with ovarian cancer (unpublished data). This list included 25 most 
significantly up-regulated genes, including previously identified and validated ovarian cancer 
biomarkers like HE4 and DDR1. Both have been described, serum protein (sandwich ELISA) 
HE4 as potential tumor marker in ovarian cancer (24-26), and tissue protein 
(immunohistochemistry) DDR1 as marker of early ovarian oncogenesis (27). The second most 
significantly up-regulated gene identified in our meta-analysis was Growth arrest-specific 6 
(GAS6), and showed in our immunohistochemical studies an association with ovarian cancer 
survival (unpublished data). 
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The fast growing diversity of experimental designs and analytical technologies 
complicates the discovery and evaluation of experimental microarray data. Based on MIAME 
guidelines, concepts of reporting standards have been expanded to other high-throughput 
technologies, prevalent in proteomic experiments: a) the minimum information about 
proteomics experiments (MIAPE) (28), b) in situ hybridization and immunocytochemistry- 
Minimum Information Specification For In Situ Hybridization and Immunohistochemistry 
Experiments (MISFISHIE) (29, 30), c) and biomedical investigations- The Minimum 
Information for Biological and Biomedical Investigations (MIBBI) (31). These minimum 
information checklists can promote transparency in experimental reporting, enhance 
accessibility to data and support effective quality assessment, increasing the general value of 
the experimental data (31). The next era of high-throughput profiling research will rely on 
comparative analytical data generated from various data sets to answer questions related to 
causality and association (32), molecular function and regulation (33). 
4.1.2 Heterogeneity of the Disease 
It is becoming increasingly clear that epithelial ovarian cancer (EOC) is a 
heterogeneous disease. The way it is currently classified is by histopathology, however, the 
future might be by molecular profiling and might ultimately define the clinical outcome. 
Reviewing all published proteogenomic profiling based publications in EOC, we focused on 
the histology, stage and grade of ovarian tumors and revealed within this group various 
genetically distinct diseases. Different gene expression patterns separated low grade versus 
high grade SOC, early versus late stage EOC, EOC with local disease versus omental 
metastatic disease, or EOC with high likelihood to relapse early (10). Although high-
throughput profiling technologies are promising, further improvements in technology and study 
design combined with pathway analysis are necessary to target innovative molecular therapy 
(34). A low disease incidence and substantial molecular heterogeneity among EOC subtypes 
hamper the speed of elucidating new insight. In consistence with recent observations (10), 
changes between the different histological subtypes seem to be associated with specific genetic 
expression patterns regardless of the substage and grade of the disease. As to tumor 
morphology, it should be noted that the histological origin of the different ovarian cancer 
subtypes is still a matter of debate. 
Historically, the choice of treatment was based on pathological characteristics of the 
cancer, such as histology, invasion, tumor grade, size and nodal status. There is an observable 
trend which seems to accept that in the future cancer treatment will depend on an individual 
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patients molecular signatures (35). This implies a linkage between molecular diagnostics and 
therapeutics for the benefit of individualized therapy at each point in disease progression (36). 
Depending on the question addressed, the method used to screen for the molecular answer will 
decide the quality of the results. Whilst subtype analyses to distinguish between different 
genetic backgrounds might be answered using genomic profiling, diagnostic or prognostic 
marker detection needs to be addressed differently. Based on our analysis we conclude that 
genomic profiling experiments in ovarian cancer might be insufficient to investigate questions 
related to the etiology of ovarian cancer or to define new biomarkers, as physiological effects 
will depend on the relative distribution of gene products and its interaction with other genes 
(10, 34). As the biological effect cannot be determined on genomic or proteomic level, post-
translational modification screening will facilitate the most information for clinical practice 
and should therefore be included into our current screening approaches (34, 37). 
4.1.3 Ovarian Cancer Biomarker Research 
Various potential biomarkers have been discovered for early detection as well as post-
treatment monitoring using proteogenomic profiling strategies. Classical transcriptional high-
throughput technologies are limited by the detection of single biomarkers instead of a group of 
identifiers. Some of the detected and validated biomarkers are already under clinical evaluation 
using specifically designed sandwich ELISA, e.g. the most promising candidate human 
epididymis protein 4 (HE4) (24-26, 38, 39) or osteopontin (OPN) (40, 41). To our knowledge, 
however, there is no single biomarker which is superior to the current standard tumormarker 
CA125. This could be caused by technical limitations and the natural complexity or individual 
variability of gene and protein expression signatures. The heterogeneity of the disease also 
influences the detection of biomarkers of high performance, thus, new strategies have been 
proposed to identify more significant markers of early detection. 
Meta-analytical approaches were chosen to combine individual tumor markers for the 
benefit of improved significance and specificity. Whilst this requires complete raw datasets, we 
developed an automated overlapping ovarian (OLOV) database to integrate and intervalidate 
the results of cDNA microarray- and oligonucleotide array-based transcription profiling studies 
(10, 27). The gene with the highest significant number of overlaps within studies OI4 
(COL1A2, collagen, type I, alpha 2), followed by VEGF, a gene whose protein is targeted via 
mAb bevacizumab (Avastin®) and is currently under examination in clinical trials (42). The 
up-regulated bone morphogenetic protein 7 (BMP7) has been shown to be a potential inhibitor 
of transforming growth factor-beta (TGF-beta) which is involved in ovarian cancer signaling 
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(43). In ovarian cancer, heavily glycosylated MUC1 (44) was identified and its protein is 
known to show similar significance and specificity as CA125 and HE4 (26, 38). All of these 
proteins seem to be directly or indirectly linked to ovarian carcinogenesis. Other potential 
candidates which are overexpressed in ovarian cancer have already treatment options available, 
like Gleevec® (inhibit a family of tyrosine kinases) or Iressa® (targets EGFR family), which 
have shown a cytotoxic effect in recurrent cancers and are currently in phase two and three 
clinical studies in combination with or without Carboplatin and Paclitaxel as first line therapy. 
Gene therapies targeting p53, BRCAI, erbB2 are already in phase I to III clinical trials (45), 
however, new prognostic and predictive markers have not yet shown improved sensitivity and 
specificity compare to the current tumor marker CA125. 
Since genomic studies lack sensitivity and specificity in detection of single biomarkers 
new proteomic-based high-throughput profiling techniques were developed. Proteome analysis 
of body fluids, including serum, ascites and pleural effusions (10) can provide the link between 
gene sequence and cellular physiology (46). Blood serum is the main subject of biomarker 
research due to its accessibility. It also allows a dynamic and accurate reflection of the intrinsic 
genetic status of a cell and its environment (47). Initial proteomic approaches in ovarian cancer 
biomarker research have used SELDI-mass spectrometry or immobilized metal affinity 
chromatography (IMAC)-nickel chip surface to investigate a sub-proteome of metal-binding 
proteins for detection of biomarkers, and has shown better sensitivity and specificity compared 
to CA125 (48-50). No individual candidate protein which were identified in these studies has 
shown better sensitivity and specificity compared to CA125. The bioinformatically combined 
use of selected biomarkers and CA125 yielded a comparable or slightly higher sensitivity and 
specificity than CA125 alone. Nevertheless, to our knowledge no single biomarker identified 
by proteome-based profiling has shown better sensitivity and specificity compared to CA125. 
Despite a broad spectrum of technologies, identified single biomarkers seem to reach a 
sensitivity and specificity plateau which is similar to CA125. Multivariate logistic regression 
analysis on various combinations of markers aimed to overtake the performance of CA125, and 
various studies have used a panel of markers with or without CA125. Multivariate combination 
of three biomarkers combined with CA125 gained a higher sensitivity and specificity than 
CA125 alone (51). Classification regression trees have been developed, and a combination of 
five markers (CA125, OVX1, LASA, CA15-3, CA72-4) detected by ‘Classification and 
regression tree analysis’ reached a high sensitivity (90.6%) and specificity (93.2%) (52), whilst 
discrimination of malignant from benign pelvic mass by artificial neural network analysis 
(ANN) revealed an even increased test specificity due to only four (CA125, LASA, CA15-3, 
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CA72-4) of these markers, reaching 20% higher specificity and similar sensitivity as CA125 
alone (53). 
In our biomarker discovery approach using printed glycan array, CA125 showed 
comparable sensitivity and specificity with the detection of a naturally occurring AGA 
recognizing P1 glycan. We also used a multivariate selection model to search for potential 
glycans that could be combined to improve our differentiation rate. The highest ranked glycans 
were therefore further combined in a linear discriminant model and the performance was 
investigated by ROC analysis. Panels of AGA did not, however, reach a better sensitivity and 
specificity than 84%. When using a combination of eight candidates containing the structure 
Galβ1-4GlcNAcβ in the top ten selected glycans, a sensitivity of 83.3% and specificity of 
87.8% could be reached, which is clearly better than CA125 (76%/ 73.9%, respectively) in the 
same cohort. As our results are generated from one single Swiss cohort, we will next validate 
these findings in a second independent Australian cohort of over 350 patients with 
gynaecological adenocarcinoma. 
Other more clinically-based models like the ‘risk of malignancy index’ (RMI) (54) 
were using menopausal status, ultrasound and CA125 measurements in combination. The RMI 
is the product of CA125 measurement, ultrasound scan results (expressed as a score of 0, 1 or 
3) and the menopausal status (1 if premenopausal and 3 if postmenopausal). RMI has been 
shown to be able to distinguish benign and malignant cases better than CA125 alone (54). 
Another study investigated preoperative serum levels of HE4 and CA125, combining them in a 
logistic regression algorithm with pre- and postmenopausal status (25). This algorithm 
classified patients into low and high risk groups with an accuracy of 93.8% (25). Although 
these clinical tests can be used to triage patients for gynaecological oncology centres in the 
presence of a palpable pelvic mass, there is no benefit given from screening asymptomatic 
women with either ultrasound or CA125. 
4.2 Biological and Technical Complexity of Saccharides 
4.2.1 High-Throughput Glycan Arrays 
One of the current frontiers in “omic” sciences these days is the detection of the 
glycome, namely carbohydrate structures which are linked to proteins and lipids within an 
individual organism. High-throughput profiling of glycan-binding biomolecules by 
carbohydrate based microarrays allows determination of specificities of glycan-binding 
proteins (GBP) (55), examination of microbiologically relevant glycans (56), and the study of 
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carbohydrate-processing enzymes (57) and anti-glycan immune response (58, 59). Microarray-
based analysis of GBP in complex biological fluids are complicated but of highest biological 
and clinical relevance. To date, only few publications investigate a small cohort of glycans or 
glycoconjugates within a specific biological system (59), screening of AGA within human 
serum for diagnostic purposes or detecting the immune response to bacterial pathogens (58). 
The printed glycan array platform used in our discovery approach has been fabricated 
according to the technique of the Consortium for Functional Glycomics 
(www.functionalglycomics.org), and comprises about 200 mono- and oligosaccharides 
including the observed terminal oligosaccharides of mammalian N- and O-glycoprotein chains, 
glycolipids, and their related cores. About twenty of these oligosaccharides are thought to be 
tumor-associated (60), and therefore thought to be synthesized by cancer cells in a more 
intense way than by normal cells. 
4.2.2 Complexity of Glycan Array Fabrication 
Various biological systems consist of a high diversity of glycans from monosaccharides 
up to 500’000-mer saccharide structures (61). Glycosylation processes include more than 50 
glycosyltransferases, glycosidases and sugar nucleotide transporters (62). With only ten 
monosaccharides as a basis, 15x106 tetramers (63) and 1.05x1012 hexamers can be built, thus 
demonstrating the complexity of the glycome (64). This enormous natural complexity is 
currently investigated by new technologies which are able to profile glycans and their binding 
partners. 
Two major obstacles have hindered the recent development of glycan arrays, namely 
the difficult process of carbohydrate synthesis and the technique of immobilizing these 
structures onto an appropriate surface. A library of glycans for use in a high-throughput glycan 
array can be created by either carbohydrate synthesis or isolation of glycans from natural 
sources. Synthesis of carbohydrates can be achieved hereby with either automated solid-phase 
synthesis (65-67) or programmable “one spot” approach (68, 69). In case of enzymatic 
synthesis, glycosyltransferases and glycosidases are used (70), however, specific glycan 
processing enzymes are restricted in their availability due to their limited identification, 
characterization and their adaptability to synthesize carbohydrates enzymatically. The printed 
glycan array which we used for our discovery approach was based on monosaccharide and 
complex oligosaccharide structures synthesized by unique bioorganic pathways, thus achieving 
a final oligosaccharide purity of approximately 98% (71-73) (Lectinity Holdings, Moscow). 
Each glycan has been synthesized by a special and novel multi-step procedure, and was 
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confirmed by thin layer chromatography with the final product being characterized by nuclear 
magnetic resonance spectroscopy and mass spectrometry. 
Glycan-based microarrays utilize different ways of glycan immobilization such as 
NHS-activated glass slides or nitrocellulose. Carbohydrate structures can be linked to different 
platforms by various chemical bonds and spacers and can be coupled covalently or non-
covalently, specific or non-specific, and directly to the chemical surface or indirectly via 
glycoconjugates (74). As a type of planar surface, type NHS-activated hydrogel-coated glass 
slides were used in the printed glycan array to bind covalently amine-modified saccharides (75, 
76). Using covalent printing, all monomeric glycans were attached in known and identical 
orientations; however, in contrast to polymeric presentation this arrangement limits probably 
anti-glycan antibody binding sites. 
4.2.3 Problems of Standards and Controls 
Tumor marker CA125 has been established for the detection of EOC for more than 20 
years. It is a heavily glycosylated mucin identified by a murine mAb that lacks standardization 
based on poor purification, which is why all CA125 immunoassay results are expressed in 
U/mL. To increase performance of CA125 detection, a sandwich ELISA using two mAb was 
developed (77). An epitope-mapping workshop conducted by the International Society of 
Onco-Developmental Biology and Medicine investigated the binding characteristics of mAb 
reactive with CA125 and found that the binding affinity can be segregated into two major 
regions, OC125-like and M11-like epitopes (78). CA125 antigen is represented by a 
heterogeneous mixture of glycoproteins ranged in their molecular weight from 200 to 
1000kDa, probably related to differences in glycosylations. It is expected that mouse and rat 
mAb preferentially bind to peptide epitopes located at the C-terminus of the protein. Based on 
non-existing standards and controls it is difficult to study glycan-protein interactions in this 
setting, which is a well known problem in glycobiology. 
We used α-rhamnose as the biological positive control in our discovery approach. High 
expression levels of anti- α-rhamnose antibodies were observed in an IgG affinity-purified pool 
of 10’000 healthy individuals (79). Moderate to high levels of anti- α-rhamnose antibodies of 
immunoglobulin subtypes IgG, IgA and IgM were found in 200 individual healthy serum 
samples (79), consistent with our results. Fluorescence signals regarding α-rhamnose are within 
the 30% of highest glycan signals. The use of α-rhamnose as a positive biological control is 
further supported by findings that related antibodies have moderate biological variability of 
approximately 50% and a low coefficient of variation (80, 81). 
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Aminoglucitol has been suggested as negative biological control. It is an opened 
reduced form of D-glucose which is not present as a structural component of regular 
glycosylation. It has also been negative for anti-glycan binding at similar values to the 
technical background binding control (82), and was found in our study within the 18% lowest 
glycans. Glycan array technology has not established yet any standardized controls and the use 
of the described positive and negative biological controls are therefore only the best possible 
controls as to the literature. 
4.2.4 Reproducibility of Glycan Arrays 
Reproducibility of glycan array data was so far not studied except in one single 
publication where experimental variability, inter-individual biological variability and intra-
individual temporal variability was investigated (80). An overall coefficient of variation (CV) 
of 10.8% and variation across multiple batches of slides and days of 28.5% was found, which 
is consistent with our results, despite different platforms and presentation of glycans to human 
antibodies. We also examined intra-slide variability using the glycan Fucα1-2(GalNAcβ1-
3)Galβ, presented twice in two different positions on the array platform. A CV of less than 
10% was observed in each experimental set up, demonstrating excellent reliability of results. 
Despite indications of a good adaptability of glycan arrays, further efforts must be undertaken 
to study human AGA. This includes further studies on clinical parameters into dependency of 
AGA patterns, studying antibody glycan-binding and data processing. 
4.3 Naturally Occurring Anti-Glycan Antibodies 
4.3.1 Studying Glycan Binding Motifs 
Most glycan-binding proteins are able to recognize epitopes including two or three 
monosaccharides (83), and the non-glycan moiety of glycoconjugates seem to be involved in 
this binding. The study of GBP is a major field of glycobiology which is necessary to 
understand molecular recognition events. Measurements of glycan binding specificities is 
usually performed by molecular biological methods like affinity chromatography (62, 84, 85) 
and carbohydrate arrays (61, 74). One obvious disadvantage of affinity chromatography over 
glycan microarrays is the use of high amounts of glycans, including the enormous amount of 
time taken to synthesize carbohydrates to probe numerous glycan-protein interactions. High-
throughput technologies allow profiling of GBP to a broad spectrum of glycans but are still 
challenging from the point of data interpretation and determination of specific complex 
carbohydrate binding motifs. 
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So far, only a few publications have studied glycan-binding motifs. Only one 
systematic analysis was performed to study the complexity of oligosaccharides, multiple 
specificities of GBP and the nature of glycan array data (86). Hereby, glycan motifs that are 
critical for binding were studied by bioinformatics using data sets produced by the Consortium 
for Functional Glycomics (86). First, lectin binding to each glycan was analyzed in terms of the 
motifs in order to identify motifs that are selectively present in glycans bound by the lectin. 
Two different methods to calculate the motifs were compared and validated using three 
different lectins; Vicia villosa lectin recognizes terminal GalNAc, Concanavalin A recognizes 
terminal mannose containing structures, and wheat germ agglutinin which usually binds to a 
broad and not yet fully understood spectrum of oligosaccharides. Both the ‘motif segregation 
method’ and the ‘intensity segregation’ identified accurately the primary binding specificities 
and secondary specificities of all three lectins. The feasibility of these systematic methods led 
to further investigations on motif specificities of plant and human lectins and the results 
revealed unexpected carbohydrate ligands (86, 87). 
Only a few attempts were made to investigate the binding motifs of naturally occurring 
AGA. Motif specificities of AGA revealed higher cross-reactivity and a broader spectrum of 
glycan-binding motifs (86). Another study confirmed these finding by screening 27 well-
defined AGA bound to 80 different glycans and glycoconjugates on a microarray platform. 
More than a half of the profiled monoclonal AGA bound not only with designated antigens but 
demonstrated a high degree of cross reactivity. (88). In our experiments human polyclonal 
AGA seemed to preferentially bind to specific core structures. We observed that binding 
affinity or motif specificity of AGA seemed higher in the case of such core structures, for 
example GalNAcα-, Galβ1-4GlcNAc- or Galβ1-4Glcβ-. In contrast, no binding motifs could be 
observed on monosaccharide components possibly related to an overlay of unspecific binding. 
Unfortunately, a pre-processing of glycan microarray data into biological motifs has 
been performed and thus does not allow the comparison of data to our results (86). Glycan-
recognition epitopes show anti-Leb- antibodies (25LE) binding to Leb, Lea and terminal Fucα1-
4 (86). Strong signals can be also found for anti-Leb antibodies to core structures, terminal 
GlcNAcβ as well as GlcNAcβ1-6Gal which is not primarily presented at the terminal part of 
Leb oligosaccharide (88). Moreover, high cross-reactivities of AGA observed in both studies 
(86, 88) are in concordance to our observations. 
Specific AGA binding was used to monitor the expression of carbohydrate antigens, 
primarily on tissue sections to modulate their biological activity, and to target specific 
carbohydrates for clinical applications. Conclusions based on these findings are frequently 
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based on the perception that AGA are highly specific for their listed glycan antigens. Using 
glycan arrays we have shown that naturally occurring AGA of different immunoglobulin 
subtypes do not have such glycan-binding specificities. We are the first suggesting that 
naturally occurring AGA seem to bind epitope structures mostly located at the core of a 
complex carbohydrate chain. 
4.3.2 Anti-Glycan Antibodies Bind to Specific Carbohydrate Core Structures 
Various functional studies have examined naturally occurring AGA and their binding 
patterns to glycans, namely anti-α-galactosyl antibodies (89, 90), antibodies bound to 
negatively charged glycans (82, 91), and GlcNAc-terminated carbohydrate chains (82, 92). 
Carbohydrates are exposed on the cell surface and on secreted proteins, acting as sensors for 
biochemical signals (93). In a previous study, human naturally occurring AGA recognized 
short inner core structures for glycolipids (Galβ1-4Glc) and glycoproteins (GalNAcα) (82). The 
core structure is defined as a carbohydrate fragment located at the onset of a complex 
oligosaccharide, namely, the first carbohydrate structure at the linkage to a related glycolipid or 
–protein. We identified a panel of AGA core structures which occur in specific patterns and 
could describe 21 key core carbohydrate structures consisting of a monosaccharide (e.g. 
GalNAcα) up to a tetrasaccharide (e.g. Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ). Terminally located 
monosaccharides (e.g. Galα1-3(Fucα1-2)Galβ) or terminal modifications (e.g. 6’-O-Su-Galβ1-
4GlcNAc) seem to be able to influence binding of AGA to core structures. These 
monosaccharides are important for cell-cell interactions, as has been shown in host-pathogen 
recognition (94) and terminally located αGal (89, 90). Interestingly, comparison of healthy 
controls and non-mucinous EOC serum samples by multivariate analysis revealed a panel of 
glycans with similar core patterns responsible for significant discrimination between both 
subgroups. By analysing the first ten ‘top candidate’ structures, 8 out of 10 oligosaccharides 
contained the inner core structure -Galβ1-4GlcNAc and 2 oligosaccharides contained -
GalNAcα. These observations led us to propose that the majority of human AGA 
immunoglobulin subtypes IgA, IgG and IgM recognize inner core structures of cell surface 
glycosylations including N-, O-linked glycosylation and glycolipids. In non-malignant 
conditions inner core structures of glycosylation trees are occupied by interactions of different 
types of membrane-associated proteins and other carbohydrate structures (Figure 23 A). At this 
stage, inner core structures are encrypted and the binding of naturally occurring AGA seem to 
be limited to these potential cell surface carbohydrate core structures. In contrast, oncogenic 
transformation results in rearrangement of extra-cellular matrix and their associated molecular 
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components. Thus, encrypted binding sites could become available for circulating AGA, thus 
decrypting inner core structures (Figure 23 B). Alteration in glycan presentation signalizes the 
status of the cell towards the innate immune system; mainly to B1 cells which produce 
naturally occurring AGA. 
 
Figure 23 Anti-glycan antibody binding to inner core structures of membrane associated 
oligosaccharide chains. 
In non-malignant cell surface membranes (A) binding of AGA to core epitopes (red line) is not possible 
due to occupation of surrounding proteins (grey, black) - inner core structures are encrypted. During 
oncogenic transformation cell surface composition changes (B) and core carbohydrate structures are 
recognizable by circulating AGA- inner core structures are decrypted. EM= Extracellular Matrix  
4.3.3 Influence of Monomeric versus Polymeric Presented Glycans 
The presentation of glycans is of major importance for the investigation of naturally 
occurring AGA binding specificities. Most studies investigated glycan-binding patterns using 
one examination platform, which in our opinion bears danger for conclusions. In one of our 
studies we applied three independent custom-developed ‘glycan-based immunoassays’ to 
detect human AGA for methodological and statistical comparison of assays and to be able to 
interpret the biology based on AGA detection. We compared PGA, a high-throughput approach 
(76, 82), to multiplex flow cytometric suspension array (SA) and standard ELISA. PGA has the 
advantage of high sensitivity, low background signals, screening of an unlimited repertoire of 
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natural and synthesized glycans, speed and small reagent consumption. Multiplex flow 
cytometric SA (95) incorporates fluorescent microspheres with distinct spectral addresses as a 
solid support for glycans (58). This type of assay combines the flexibility of routine ELISA 
with simultaneous detection of multiple ligands in one sample and minimal reagent 
consumption. ELISA is widely used in most immunochemical studies (96-99), is affordable 
and well established method for screening of limited number of ligands. 
Binding of antibody subtypes IgA, IgG and IgM to specific glycans was measured in all 
three immunoassays, and signals detected using different detection methods; streptavidin 
HRPO and TMB (ELISA), Streptavidin Alex Fluor555 (PGA), and R-phycoerythrin labeled 
secondary antibodies (SA). Although all techniques aim to measure the same chemically 
synthesized glycans presented to AGA, they are captured differently, monomeric on flat 
surface/ 2-dimensional (PGA), polymeric on microspheres/ 3-dimensional (SA), and polymeric 
on flat surface/ semi 2-dimensional (ELISA). In our comparative analysis, distribution of AGA 
to blood group related trisaccharides showed comparable binding parameters. The pattern of 
AGA binding changed when screening for the PGA derived ovarian cancer biomarker 
trisaccharide P1 which was measured in all three techniques. The marked discrepancy in 
detecting P1 in all methods could be caused by various factors: a) potential cancer association 
of P1 antibody levels as observed in our previous study, b) low number of serum samples in 
study cohort, c) differences in assay conditions like glycan concentration and serum dilution. 
Concordance correlation coefficient among assays was much stronger in the case of AB0 blood 
group antigens than in the case of P1. This could be explained by the strong biological 
association and high specificity of anti- A/B antibodies (100). Affinity and biological 
significance of anti-P1 antibodies has not yet been clearly investigated, however, they 
obviously represent a subpopulation of AGA with lower affinity compared to anti-A/B 
antibodies. In the case of PGA, glycans are presented as monomers in a highly organized 
manner with limited flexibility; only a subpopulation of anti-P1 specific antibodies could be 
possibly detected. Thus, it is necessary to highlight that in contrast to PGA, SA and ELISA are 
assays based on polymeric glycan presentation which means that multivalent binding between 
glycans and high-affinity AGA can here possibly reflect a broader spectrum of glycan antibody 
interactions (58, 95). Non-specific binding such as direct binding of heterophilic serum 
antibodies in SA and ELISA could interfere with specific signals, as previously stated (101, 
102). We proposed that the assays based on multivalent and polymeric ligand presentation 
seem to be more close to natural or in vivo conditions. For biomarker research, in order to 
identify markers of disease, the advantage of using one assay with appropriate sensitivity, 
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specificity and reproducibility might be sufficient. For a rather functional approach into the 
biology of detected AGA, each glycan detected should be investigated further using also other 
immunoassays. Glycan-binding interactions can also be studied nuclear magnetic resonance 
spectroscopy of affinity-purified antibodies or by advanced surface plasmon resonance 
technology as a real time measurement. 
4.4 The Impact of Carbohydrates in Biomedical Research 
Glycans have been underestimated by the scientific community for a long time, whilst 
research focused on nucleotides, DNA, peptides and proteins. This can be explained by the 
complexity of carbohydrate synthesis and the fact that glycans are products of non-template 
driven processes because they are products of a network of glycosylation-related enzymes. 
With an increasing interest in glycobiology during the last couple of years an increasing 
number of publications in the field of organic chemistry, biochemistry, molecular biology, and 
biomedicine have arisen. As glycans play a major role in many biological processes, a large 
interest has driven the development of (1) new technologies to study carbohydrate-biomolecule 
interactions, (2) new potential diagnostic and therapeutic agents, (3) eventually clinical 
applications (Figure 24). 
Glycans are ubiquitous and represent the most abundant class of molecules in the 
nature. They coat all cell surfaces in a broad complexity to act as recognition molecules and 
therefore are involved in pathological phenotypes such as inflammation, cancer, and infectious 
diseases. There is a recognized need for glycobiology-driven therapeutic applications, thus the 
investigation of functional carbohydrate epitopes and its protein receptor (e.g. lectin, AGA) is 
eminent. Technologies allowing such investigations include nuclear magnetic resonance 
spectroscopy which determines the exact binding conformation and X-ray crystallography of 
the carbohydrate ligand, co-crystallized to its GBP. Synthesized glyco-mimicry structures of 
currently approved drugs are glycosidase inhibitors that prevent the digestion of carbohydrates 
for the prevention of influenza virus infections (Relenza, Tamiflu), the treatment of diabetes 
(Glustat, Zavesca, Glyset, Glucobay), and sulphated glycosaminoglycans which function as 
anticoagulants by binding to antithrombin III for the treatment of thrombosis (Arixtra) (103). 
Successful conjugations of carbohydrates to nanoparticles have attracted significant interest in 
recent years due to their specific properties. In addition to the unique properties originating 
from their quantum structure, nanoparticles display a large surface area and thus provide an 
ideal platform that can be conjugated with biomolecules for targeted approaches for cancer 
diagnostics, therapeutics and imaging (104). Carbohydrate-functionalized magnetic 
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nanoparticles were also used to detect the endothelial markers E-/ P-selectins, which are 
associated with acute inflammation of the cerebral endothelium (105). Imaging of metabolic 
carbohydrates to localize or distinguish the target from the surrounding components by using 
spectroscopic probes is becoming increasingly important. Whilst currently genetically encoded 
tags such as GFP are routinely used for protein trafficking, studies have demonstrated the use 
of metabolically labelled cell-surface sialic acids (106). 
The role of carbohydrate structures conjugated to cancer vaccines has been studied 
intensively. An overexpression of ganglioside GD3 has shown to be associated to melanomas, 
but gangliosides were of poor immunogenicity. Therefore, GD3 has been conjugated to an 
immunogenic carrier, keyhole limpet hemocyanin (KLH), demonstrating stronger antibody 
immune responses in immunized mice (107). For enhancement of the immune response, 
applications of adjuvants can significantly increase the immune response of patient to a co-
administered antigen (108). A purified plant extract derived from soap bark tree Quillaja 
saponaria (QS-21) was the most effective adjuvant and shows good adaptability to the IgM 
and IgG antibody response against MUC1 and GD3 (109), currently being under clinical 
evaluation as adjuvant for trial vaccines including HIV, malaria and cancer. 
 
Figure 24 Overview of biomedical applications of synthetic carbohydrates. 
Synthetic carbohydrates are multi-faceted tools; glycans were applied as glycan-mimetic drugs, coupled 
to nanoparticles for in vivo imaging of GBP (108), and are useful as adjuvants to enhance human 
immune response. Glycan-based vaccines (113) as well as metabolic labeling of glycans has recently 
been documented (109). 
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5 Future Prospects 
5.1 Cross-Validation of Printed Glycan Arrays 
Tumor associated carbohydrate antigens (TACA) are known to trigger an immune 
response resulting in the generation of anti-glycan antibodies (AGA). Based on literature and 
our previous results we hypothesize that the immune activity against certain tumor-associated 
antigens is a natural defense mechanism targeting malignant cells, and that the identification of 
corresponding naturally occurring antibodies could provide a predictive screening tool. Printed 
glycan array will be used in a separate cohort as previously described (1, 2). For validation 
purposes, AGA will be measured in an independent cohort established by the same research 
team, consisting of an equivalent cohort size but from another continent. An Australian cohort 
was prospectively established and includes over 360 patients with both gynaecological cancers 
and healthy control patients. The advantage of this validation approach is the fact that both the 
biobank generation and the PGA experiments are performed by the same personnel in both 
cohorts. 
5.2 Investigation of Specific Glycan Interactions 
Aberrant glycosylation of proteins and lipids during malignant transformation results in 
the appearance of specific glycan structures. These glycans are known as TACA and can be 
found on cell surfaces and in serum components (3). TACA are therefore promising targets for 
new diagnostic biomarkers as well as anti-cancer vaccines (4). Altered glycosylation of tumor 
cells is mainly the consequence of changes in cellular glycosyltransferase activities (5) and is 
found in almost 100% of cancers, as compared to the expression of oncogenes which is found 
in less than 30% of cancers (3). Glycan arrays allow determination of the specificities of 
glycan-binding proteins (GBP) (6), examination of microbiologically relevant glycans (7), 
study of carbohydrate-processing enzymes (8), and anti-glycan immune responses. 
To date, only a few studies investigated a small cohort of glycans and glycoconjugates 
within a specific biological system (9), by screening AGA within human serum for diagnostic 
purposes (10, 11) or detecting the immune response to bacterial pathogens (12). In contrast to 
this, printed glycan array was used to identify specific ovarian cancer AGA patterns. P1 
(Galα1-4Galβ1-4GlcNAc) a member of the P blood group system differentiated most 
significantly between the cancer and the control cohort. The physiological function of the P 
blood group system in general is still unknown. The detection of AGA to P1 as a potential 
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ovarian cancer associated carbohydrate antigen could imply that, similarly to mesothelioma 
cells (13), ovarian cancer cells contain a P1 epitope recognized by the human immune system. 
5.2.1 Hypothesized Strategy 
Glycans presented on eukaryotic cells are known targets for AGA as well as other GBP, 
such as galectins or siglecs. They are able to specifically recognize and interact with 
carbohydrates. GBP are involved in biological processes such as immune recognition and 
regulation, inflammatory responses, cytokine signaling, and cell adhesion. It is therefore 
important to further investigate and understand the glycobiological and immunological impact 
behind the identification of P1 as an ovarian cancer–specific carbohydrate structure with 
antigenicity. 
Our main aim for future studies will therefore be the examination of GBP and glycan-
presenting proteins (=glycosylated proteins) in order to understand the biological function of a 
specific carbohydrate structure in ovarian carcinogenesis. To investigate the role of specific 
glycans and their immune recognition biomolecules it is necessary to synthesize appropriate 
carbohydrates of high purity. Synthesized and biologically validated carbohydrates will then be 
used to affinity purify specific binding partners from pooled ascites, blood serum samples or 
ovarian cancer cell lines (Figure 25/1). After established affinity purification, eluted GBP will 
be validated based on their protein content by SDS-PAGE and silver staining. In parallel, 
Western blot analysis will be used to control the presence of human AGA of immunoglobulin 
subtype IgA, IgG and IgM. Eluates after affinity purification should contain immunoglobulins 
and are therefore additional controls for affinity purification. Identification of potential GBP 
will be performed by liquid chromatography mass spectrometry. The specificity and binding 
affinity of identified GBP will be studied by printed glycan array as well as custom-made 
suspension array and ELISA using commercially available mAb. Immuno-blotting will be 
performed to evaluate identified GBP and to test their presence in applied positive and negative 
controls. 
Glycosylation is an enzymatic process that links various saccharides to produce glycan 
structures. This product is attached to proteins, lipids and other organic molecules. 
Glycosylated proteins serve in membranes and in secretions for a variety of structural and 
functional roles (14). Specific glycans (e.g. P1) have been identified as recognisable by the 
adaptive innate immune system and can therefore potentially serve as ovarian cancer-
associated carbohydrate antigen. If this antibody-glycan interaction is cancer-specific and 
which underlying glycan-presenting proteins are involved, is yet unclear. In our case, glycan-
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presenting proteins are defined as proteins which are post-translationally modified by a specific 
glycan structures such as P1. 
In a second approach we aim to study glycan-presenting proteins by using nanoparticle-
antibody conjugations (15). Two classes of nanoparticles will be used: (A) fluorescent dye-
loaded silica and (B) magnetic (Fe3O4) nanoparticles in order to localize and purify 
glycosylated proteins containing glycans of interest. AGA covalently coupled to nanoparticles 
will be tested on corresponding chemically synthesized Sepharose-PAA-glycan and on cell 
lines. Purified, validated and fluorescence-nanoparticle labeled AGA will then be used to 
localize specific glycan structures in paraffin-embedded patient tissues (A). Magnetic-
nanoparticle labeled AGA will be used to bind glycosylated proteins (B). Captured proteins 
will then be purified via a magnetic column and eluted prior to structural analysis with mass 
spectrometry (Figure 25/2-4). 
 
 
Figure 25 Strategy for identification of ovarian cancer candidate-associated GBP. 
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5.2.2 Preliminary Data 
5.2.2.1 Synthesis of Glycosorbents 
Cognate adsorbent (glycosorbents) structures were produced for affinity 
chromatography Sepharose6FF and coupled to polymer presenting glycans. The synthesized 
glycosorbents were generated in two major steps: (1) synthesis of polymeric 
neoglycoconjugates by activated polymer reaction with ω-aminoalkylglycosides (16), and (2) 
synthesis of final glycosorbents. Chemically synthesized glycans of high purity, end-labeled by 
a monomeric spacer and terminated by an activated amine group were coupled to polymer 
polyacrylamide (PAA). After blocking with ethanolamine the reaction was verified by thin 
layer chromatography followed by Ninhydrin treatment for the detection of free amine groups. 
Sepharose6FF was added to PAA-glycan at pH 8.5 adjusted by triethanolamine. Incubation 
with Sepharose6FF-PAA-glycan was blocked by ethanolamine and the reaction verified by thin 
layer chromatography and phosphorous acid reaction for the detection of carbohydrates. 
5.2.2.2 Verification of Synthesized Glycosorbents 
As a proof of principle, chemically synthesized carbohydrates were studied in their 
binding ability towards human antibodies by incubation of glycosorbents containing blood 
group A trisaccharide (Atri), a minimal AB0 blood group determinant. Pooled serum of 10 
healthy controls with blood group 0 was applied to Sepharose6FF-PAA-Atri, and bound human 
anti-Atri antibodies were visualized using Tetramethyl Rhodamine Iso-Thiocyanate (TRITC) 
labeled goat anti-human IgA, IgG & IgM (Figure 26). The negative control was not incubated 
with human serum and showed no signal (Figure 26). Pooled samples of blood group A with 
expected low or no antibodies to Atri were incubated with Sepharose6FF-PAA-Atri. Low signals 
were detected with fluorescence microscopy (data not shown), which could also be due to 
cross-reactivity or unspecific binding of AGA. Verification of synthesized glycosorbents 
revealed that chemically synthesized carbohydrates are suitable for further functional studies. 
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Figure 26 Serum containing anti-Atri antibodies bound to Sepharose6FF-PAA-Atri. 
Blood group 0 containing Atri binding antibodies (A) were visualized by goat anti-human IgA, IgG, IgM 
conjugated TRITC (A/TRITC), in contrast to control without serum (B/TRITC) with no fluorescence 
signal. (TRITC) Tetramethyl Rhodamine Iso-Thiocyanate labeled goat anti-human IgA, IgG and IgM; 
Brightfield images at same glass slide position. 
5.2.2.3 Verification of P1- Affinity Purified Eluates 
Affinity chromatography was performed to isolate specific GBP. Sepharose conjugated 
P1 (Galα1-4Galβ1-4GlcNAc-PAA-Sepharose) was selected as first glycan of interest. A pool of 
ascites from 17 ovarian cancer patients was preprocessed as source of potential P1- binding 
proteins. Performing 1D SDS-PAGE in combination with silver staining, we visualized several 
affinity purified protein bands. These bands appeared in different eluates and ranged from 
25kDa to 100kDa in molecular size (Figure 27/1). Additionally, immuno-blotting using anti-
human IgA, IgG and IgM biotin streptavidin detection system revealed immunoglobulins 
bound to P1 (Figure 27/2). These first experiments using after affinity purification confirmed 
can be seen as proof of principle and show the presence of AGA as well as other GBP. 
 
Figure 27 Validation of P1 affinity purified glycan binding proteins. 
Collected eluates of affinity purified samples were separated by SDS-PAGE and proteins visualized by 
silver nitrate staining procedure (1) along with the standard marker (M; Precision Plus Protein Marker 
[Bio-Rad]) and positive control 1:500 diluted ascites pool (A). Eluates 2 to 9 separated by SDS-PAGE 
and AGA of immunoglobulin subtypes are detected by goat anti-human IgG, IgA and IgM biotin-
streptavidin system (2). 
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5.2.2.4 Validation of Affinity Purified Anti- Glycan Antibodies 
Following affinity purification we measured the total protein content and presence of 
human AGA using Western blotting and AGA bound to P1 using direct ELISA. Cross-
reactivity of purified AGA was studied in a self-made ELISA using non-related P1 glycan 
structures. 
ELISA revealed a high optical density for glycan P1 and low or no cross-reactivity to 
other glycans such as AB0 blood group antigens or rhamnose, a glycan whose corresponding 
antibodies are present in high amounts in serum across all humans (17) (Figure 28, A). As 
would be expected, low signals were detected in control samples containing unspecific AGA 
(Sepharose6FF-PAA, without glycan) (Figure 28, B). This indicates a highly specific 
purification of anti-P1 antibodies, which is essential for our further experiments. This 
experiment therefore shows promising results in that AGA bound to Sepharose6FF-PAA-P1 
was highly affinity purified with low cross-reaction to other carbohydrate structures. 
 
Figure 28 Affinity purified anti-glycan antibodies against P1 validated by ELISA. 
Different eluates (2-9) arising from Sepharose6FF-PAA-P1 (A) and Sepharose6FF-PAA (B) were 
subjected to Rha, Btri, Adi, Atri and P1 and are presented as cumulative bar graphs. High specificity of P1-
purified AGA was achieved in eluates 3 to 7 (A) with low signals to other applied glycan structures. 
Overall low signals were observed in control samples (B). In A, decreasing signal intensity to P1 refers 
to increasing volume of elution buffer. Low-AGA binding was observed in eluate 1 and 2. 
5.2.2.5 Mass Spectrometry to Identifies Glycan-Binding Proteins 
Mass spectrometry was used to identify potentially interacting binding partners to 
identified glycans; P1 affinity purified proteins were solubilized for better susceptibility of 
enzymatic cleavage by RapiGest™ SF Surfactant. Remaining inter- and intra-molecular 
disulfide bonds were reduced by Tris (2-carboxylethyl) phosphine hydrochloride (TCEP HCl) 
and samples were alkylated by iodocetamide and digested overnight with trypsin. To avoid 
contamination, digested peptides were purified with ultramicro spin column and redissolved in 
0.1% formic acid for injection into the mass spectrometer. 
A B 
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Liquid chromatography mass spectrometry analysis of P1-affinity purified samples was 
performed on a Thermo Fourier Transformed-LTQ mass spectrometer, connected to an 
electrospray ionizer. Acquired MS scans were searched against the human International Protein 
Index (IPI) protein database. Final identification revealed 53 potential P1-binding proteins. 
Beside a broad spectrum of detected immunoglobulin subtypes, other non-immunoglobulin 
related proteins were identified (Table 12). Most of the identified proteins are associated to 
immune response processes. Interestingly, beside expected P1 related immunoglobulins, known 
GBP such as Ficolin 2 (a serum lectin p35) and complement-associated protein SP-40 
(Vitronectin) were identified. Whilst these both proteins are only known to bind carbohydrate 
structures, we identified a third protein T-kinin (Kininogen) which is known to be involved in 
ovarian cancer. 
Due to unspecific binding and cross-reactivity, our preliminary experiments revealed 
that the polymer polyethylenglycol could cause high background signals. The presence of this 
polymer could be explained by the Tween 20 washing steps which might have washed off 
loosely or unspecifically bound reactants, or unstable polymer coming from the glycosorbent. 
The presence of polyethylenglycol could possibly enhance unspecific binding and will be 
avoided in further experiments. As an additional control, PAA on Sepharose6FF will be used 
in affinity chromatography to identify unspecific binding proteins. Nevertheless, our 
preliminary data of P1 affinity purified ascites samples revealed specific AGA and GBP which 
are known to be associated to ovarian cancer as well as glycan-binding activity. 
Uniprot 
accession 
Gene 
Symbol 
Protein Description 
protein 
probability 
sequence 
coverage 
[%] 
number 
unique 
peptides 
total 
number 
peptides 
P01024 C3 Complement C3 precursor 1 37.6 72 92 
P01031 C5 Complement C5 precursor 1 8 13 13 
P13671 C6 
Complement component C6 
precursor 
1 9.9 9 9 
P10643 C7 
Complement component C7 
precursor 
1 5.5 4 4 
P00739 HPR 
Haptoglobin-related protein 
precursor 
1 27.9 6 6 
P22692 IGFBP4 
Insulin-like growth factor binding 
protein 4 precursor 
1 23.3 4 4 
P01042 KNG1 Kininogen precursor 1 19.9 9 9 
P04004 VTN Vitronectin precursor 1 6.7 3 3 
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P01028 C4 Complement C4 precursor 1 1.1 2 2 
O43866 CD5L CD5 antigen-like precursor 1 27.7 9 11 
P27918 CFP Properdin precursor 1 27.1 10 12 
P00751 CFB Complement factor B precursor 1 23 19 19 
Q15485 FCN2 Ficolin 2 precursor 0.9985 6.4 2 2 
P02765 AHSG Alpha-2-HS-glycoprotein precursor 0.9913 5.4 1 1 
P61769 B2M Beta-2-microglobulin precursor 0.9913 8.4 1 1 
Q02413 DSG1 Desmoglein 1 precursor 0.987 1.3 1 1 
P10909 CLU Clusterin precursor 0.9819 3.6 1 1 
P00747 PLG Plasminogen precursor 0.9817 3 2 2 
P49908 SEPP1 Selenoprotein P precursor 0.976 2.6 1 1 
Q9BXR6 CFHR5 
Complement factor H-related 
protein 5 precursor 
0.976 1.8 1 1 
P01034 CST3 Cystatin C precursor 0.9752 6.2 1 1 
P04003 C4BPA 
C4b-binding protein alpha chain 
precursor 
0.9743 1.7 1 1 
P81605 DCD Dermcidin precursor 0.9522 10 1 1 
P02753 RBP4 
Plasma retinol-binding protein 
precursor 
0.9333 5.5 1 1 
P61626 LYZ Lysozyme C, type P precursor 0.9401 9.2 1 1 
Table 12 P1 binding proteins identified via mass spectrometry. 
P1-binding proteins enriched by affinity chromatography revealed 53 P1-binding partners. The first 25 
potential GBP are listed, in bold are identified proteins with known glycan binding activity or ovarian 
cancer association. 
 
5.3 References 
1. Blixt O, et al. (2004) Printed covalent glycan array for ligand profiling of diverse 
glycan binding proteins. Proc Natl Acad Sci U S A 101(49):17033-17038. 
2. Huflejt ME, et al. (2009) Anti-carbohydrate antibodies of normal sera: findings, 
surprises and challenges. Mol Immunol 46(15):3037-3049. 
3. Hakomori S (2001) Tumor-associated carbohydrate antigens defining tumor 
malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol 491:369-
402. 
4. Fuster MM & Esko JD (2005) The sweet and sour of cancer: glycans as novel 
therapeutic targets. Nat Rev Cancer 5(7):526-542. 
5. Chandrasekaran EV, Xue J, Neelamegham S, & Matta KL (2006) The pattern of 
glycosyl- and sulfotransferase activities in cancer cell lines: a predictor of individual 
cancer-associated distinct carbohydrate structures for the structural identification of 
signature glycans. Carbohydr Res 341(8):983-994. 
Francis Jacob  Future Prospects 
 138 
6. Moller I, et al. (2008) High-throughput screening of monoclonal antibodies against 
plant cell wall glycans by hierarchical clustering of their carbohydrate microarray 
binding profiles. Glycoconj J 25(1):37-48. 
7. Disney MD & Seeberger PH (2004) The use of carbohydrate microarrays to study 
carbohydrate-cell interactions and to detect pathogens. Chem Biol 11(12):1701-1707. 
8. Park S & Shin I (2007) Carbohydrate microarrays for assaying galactosyltransferase 
activity. Org Lett 9(9):1675-1678. 
9. Krishnamoorthy L & Mahal LK (2009) Glycomic analysis: an array of technologies. 
ACS Chem Biol 4(9):715-732. 
10. Dotan N, Altstock RT, Schwarz M, & Dukler A (2006) Anti-glycan antibodies as 
biomarkers for diagnosis and prognosis. Lupus 15(7):442-450. 
11. Wandall HH, et al. (2010) Cancer biomarkers defined by autoantibody signatures to 
aberrant O-glycopeptide epitopes. Cancer Res 70(4):1306-1313. 
12. Bovin NV & Huflejt ME (2008) Unlimited glycochip. Trends Glycosci. Glycotechnol. 
20(115):245-258. 
13. Spitalnik SL, et al. (1986) Glycolipid antigen expression in human lung cancer. Cancer 
Res 46(9):4751-4755. 
14. Varki A, et al. (1999) Essentials of Glycobiology (Cold Spring Harbor Labartory Press, 
Plainview (NY)) p p.41. 
15. Thierry B, Al-Ejeh F, Brown M, Majewski P, & Griesser HJ (2009) Immunotargeting 
of advanced functional nanostructures for cancer diagnosis and treatment. Advanced 
Materials 21:541-545. 
16. Bovin NV, et al. (1993) Synthesis of polymeric neoglycoconjugates based on N-
substituted polyacrylamides. Glycoconj J 10(2):142-151. 
17. Dotan I, et al. (2006) Antibodies against laminaribioside and chitobioside are novel 
serologic markers in Crohn's disease. Gastroenterology 131(2):366-378. 
 
 
 
Francis Jacob  Summary 
 139 
6 Summary 
Epithelial ovarian cancer (EOC) has the highest mortality in gynaecological cancers with a 
5-year survival of only 20% due to detection of 2/3 of cases in advanced stage disease. Based 
on proteogenomic studies during the last 10 years a paradigm shift has taken place with the 
increasing insight that this is a biologically heterogeneous disease. The identification of type-
specific genetic patterns or protein markers will contribute to the identification of disease 
origin, and allow early detection, prediction and targeted treatment. We performed the first 
comprehensive overview on all published studies using functional proteogenomics in EOC, to 
critically evaluate findings including genetically heterogenous subtypes of EOC, and to 
develop research questions not yet been addressed. Between 1999 and 2007, 237 studies were 
published as revealed by systematic online database screening, including Pub Med, Cochrane 
library and Medline. Most studies were using transcriptomic approaches (63.7%), followed by 
proteomics (20.3%) and other methods. Although a variety of research questions were 
addressed, most studies concentrated on the identification of biomarkers for early detection, 
independent of platform used. Later studies seemed to realize the technical limitations and 
therefore concentrated rather on molecular patterns to distinguish treatments, drug resistance, 
metastases and technical microarray limitations. As a result of our summary we found that the 
main limiting factors remain the low reproducibility and the heterogeneity, mainly of samples, 
array platforms, bioinformatical analyses, and the disease of EOC in total. 
The decision was therefore made to study a more homogeneous group of non mucinous 
EOC and to use a robust microarray technology which concentrates rather on post-translational 
modifications, an approach which has not been performed so far. Whilst studies on high-
throughput profiling in the field of glycobiology have been published in small numbers, no 
study on EOC profiling for specific anti-glycan antibodies (AGA) has been performed 
previously. AGA incorporate a vast and yet insufficiently investigated subpopulation of 
naturally occurring and adaptive antibodies in humans. Glycan-antibody interactions mediate 
many important biological processes, such as innate immune responses, recognition of 
malignant transformation, autoimmune diseases, neurological disorders and host-versus-graft 
rejections. Due to the complexity and heterogeneity of glycan structures, as well as 
peculiarities of antibody-glycan binding in vivo, many important aspects of these interactions 
are still poorly understood. 
Our main aim was to investigate the potential of AGA in the diagnosis of well-defined 
non-mucinous EOC using a novel printed glycan array (PGA) discovery approach. PGA is the 
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first high-throughput glycan array containing as many as 203 glycan structures, synthesized to 
a purity of approximately 98%. We found high reproducibility in measuring AGA which also 
showed a signal towards blood groups as known from literature. Significant discrimination 
between healthy controls and cancer samples was found in 24 glycans, with P1 (Galα1-4Galβ1-
4GlcNAcβ; p<0.001) being the most significant candidate. Higher sensitivity and specificity 
than currently applied biomarker CA125 was achieved by a panel of multivariate selected and 
linear combined AGA signals (83.3% and 84.8%, respectively). 
To understand the biological properties of AGA it is necessary to study their binding 
properties. We therefore performed cluster analysis and found AGA which specifically bound 
to core glycan structures reflected by 21 unique clusters, including N- and O-linked glycans. To 
study AGA bindings in greater depth, we developed two compatible ‘glycan-based 
immunoassays’ (multiplex suspension array, ELISA), where the same glycans were presented 
chemically and spherically in different forms. Whilst screening for blood group AB0 antigens 
A and B trisaccharide, all three assays revealed the same reproducibility and results, in contrast 
to PGA. Based on these findings we then investigated a previously PGA identified ovarian 
cancer glycan P1. Interestingly, among all three methods the overall AGA binding pattern 
decreased in this setting. PGA showed a significant discriminative power between cancer and 
healthy serum samples in the patient cohort which the other two methods did not seem to be 
able to reproduce. This could be influenced by differences in the various assay conditions like 
different concentrations of glycans as well as serum dilutions. 
Using a PGA discovery approach, we detected AGA which could detect non mucinous 
EOC with a higher sensitivity and specificity than the current tumor marker CA125. These 
findings indicate that ‘glycoarrays’ have a large potential for the development of a new 
generation of biomarkers in EOC. It also demonstrates that tumor-associated glycans are 
recognized by the immune system. To investigate the glycobiological role of EOC-associated 
glycans, we are aiming to next purify detected AGA and to validate and quantify them further. 
Mass spectrometry will be used to identify AGA subtypes as well as potential glycan-binding 
proteins, which will promote our understanding of role of the identified antibodies. 
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7 Zusammenfassung 
Das epitheliale Ovarialkarzinom (EOC) ist die fünfthäufigste maligne Erkrankung bei der 
Frau weltweit. Innerhalb der gynäkologischen Krebserkrankungen zeigt es die höchste 
Sterblichkeit. Dies beruht darauf, dass 75% der Patientinnen erst in einem fortgeschrittenen 
Stadium diagnostiziert werden und somit die 5-Jahres-Überlebensrate auf nur 20% sinkt. 
Innerhalb der letzten 10 Jahre kam es aufgrund proteogenomischer Studien zu einem 
Paradigmenwechsel, so dass EOC heute als biologisch heterogenes Krankheitsbild verstanden 
wird. Zur besseren Früherkennung, Prognose und gezielten Behandlung ist es von großer 
Bedeutung, spezifische molekulare Marker zu identifizieren. 
In der vorliegenden Arbeit wurden alle bisherigen Publikationen, die eine Analyse des 
Genoms oder Proteoms beim EOC zum Inhalt hatten, analysiert. Ziel war es herauszufinden, 
welche Fragestellungen mit welchen Forschungsplattformen und klinischen Proben 
durchgeführt wurden. In dem Zeitraum von 1999 bis 2007 konnten anhand einer 
systematischen Online-Datenbank-Analyse in PubMed, Medline und Cochrane 237 Studien 
identifiziert werden. Die meisten Studien untersuchten das menschliche Transkriptom (63,7%), 
nur 20.3% hingegen das Proteom. Trotz einer Vielzahl von Fragestellungen beschränkten sich 
frühe Studien auf die Identifizierung von Biomarkern zur Früherkennung, unabhängig von der 
verwendeten Plattform. Spätere Studien hingegen konzentrierten sich auf die Untersuchung 
technischer Grenzen, molekularer Muster, Behandlungsunterschiede, Tumorresistenzen und 
Metastasen. Zusammenfassend konnte somit gezeigt werden, dass die geringe 
Reproduzierbarkeit und Heterogenität der Proben, sowie verschiedene Array-Plattformen, 
bioinformatische Analysen, und das heterogene Krankheitsbild die größte Limitierung für die 
Tumormarker-Entwicklung darstellen. Eine geringe Anzahl von Studien verwendete 
Hochdurchsatzmethoden im Bereich der Glykobiologie, jedoch gab es keine solche Studie 
beim EOC. Zudem wurde bislang keine Studie publiziert, welche spezifische Anti-Glykan 
Antikörper (AGA) untersucht, obgleich diese eine große und noch unzureichend untersuchte 
Subpopulation von natürlich vorkommenden und adaptiven Antikörper beim Menschen 
darstellt. Aufgrund der Analyse bisher publizierter Studien beim EOC wurde in der 
vorliegenden Arbeit ein Ansatz verfolgt, welcher eine homogene Gruppe von nicht muzinösen 
EOC und gesunden Kontrollen mit einer robusten Microarray- Technologie kombinierte. 
Glykan-Antikörper-Interaktionen vermitteln eine Vielzahl biologischer Prozesse, 
welche während der Immunantwort, Erkennung der malignen Transformation, 
Autoimmunerkrankungen, neurologischen Störungen und Graft versus Host Disease 
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(Transplantat-Abstoßung) von Bedeutung sind. Aufgrund der Komplexität und Heterogenität 
der Glykanstrukturen, sowie Besonderheiten der Antikörper-Bindung in vivo, sind diese 
Interaktionen noch weitestgehend ungeklärt. Ziel der vorliegenden Arbeit war es, das Potenzial 
der AGA im Blutserum bei der Diagnose einer homogenen Gruppe von EOC mit Hilfe eines 
neuartigen Printed Glycan Array (PGA)-Ansatzes zu untersuchen. Der PGA umfasst 203 
komplexe Glykanstrukturen welche mit einer Reinheit von 98% chemisch synthetisiert wurden. 
Die Resultate zeigten eine hohe Reproduzierbarkeit der AGA-Signale, welche auch mit dem 
bekannten AB0- Blutgruppen-System übereinstimmten. Signifikante Unterschiede zwischen 
gesunden Kontrollen und Karzinom-Patientinnen konnten bei 24 Glykan-assoziierten AGA 
Signalen mit dem Topkandidaten P1 (Galα1-4Galβ1-4GlcNAcβ; p <0,001) identifiziert werden. 
Eine höhere Sensitivität und Spezifität im Vergleich zum heute verwendeten EOC Biomarker 
CA125 wurde durch eine multivariate Kombination der AGA-Signale (83.3% bzw. 84.8%) 
erreicht. 
Um ein besseres Verständnis der biologischen Eigenschaften der AGA zu erhalten, 
wurden Antikörper-Glykan-Bindungseigenschaften genauer untersucht. Eine Clusteranalyse 
mit den PGA Daten wurde durchgeführt, wobei sich herausstellte, dass AGA spezielle Kern-
Glykanstrukturen binden, welche sich in 21 einzigartigen Clustern widerspiegeln, 
einschließlich N- und O- Glykosylierungen. 
Zur weiteren Untersuchung der AGA-Bindungseigenschaften wurden zwei kompatible 
"Glykan-basierte Immunoassays" entwickelt. Alle drei Methoden (Multiplex Suspension 
Array, ELISA, PGA) verwenden hierbei die gleichen chemisch synthetisierten Glykane, 
präsentieren diese jedoch sphärisch in verschiedenen Formen. Die Untersuchung von AB0 
assoziierten A- und B-Trisacchariden zeigte in allen drei Methoden ähnliche Ergebnisse. 
Basierend auf diesen Resultaten wurde eine weitere Analyse des zuvor identifizierten Top-
Kandidaten P1 durchgeführt. Hierbei stellte sich heraus, dass die AGA Bindungsmuster in ihrer 
Konkordanz reduziert waren. Der PGA zeigte das deutlichste Diskriminierungs-Potential 
zwischen dem Serum Gesunder und Karzinom-Patientinnen. Dies könnte durch 
unterschiedliche Testbedingungen, wie verschiedene Glykankonzentrationen oder 
Serumverdünnungen beeinflusst worden sein. 
Spezifische AGA für nicht muzinöse EOC erreichten eine höhere Sensitivität und 
Spezifität als der aktuelle Tumormarker CA125. Neben dem Potenzial für eine neue 
Generation von Tumormarkern konnte weiterhin gezeigt werden, dass tumor-assoziierte 
Glykane vom Immunsystem erkannt werden.  
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In weiterführenden Untersuchungen soll die Rolle glykobiologischer, EOC-assoziierter 
Glykane durch Aufreinigung von AGA, deren Validierung und Quantifizierung zugrunde 
gelegt werden. Des Weiteren sollen Massen-spektrometrische Methoden zur Identifizierung 
von AGA Subtypen sowie potenziellen Glykan-bindenden Proteinen eingesetzt werden, um das 
Verständnis ihrer biologischen Bedeutung zu verbessern. 
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8 Contributions 
8.1 Manuscript published in Biomarkers in Med (2009) 3(6), 743-756 
The special report published in Biomarker in Medicine 2009 with the title 
“Proteogenomic studies in epithelial ovarian cancer: established knowledge and future 
needs” summarizes important findings based on high-throughput technologies in the field of 
epithelial ovarian cancer from 1999 to 2007. This project was designed and given to me by my 
supervisor Dr. Viola Heinzelmann-Schwarz. The systematic literature search was performed 
completely by Francis Jacob. This includes the development of a strategy and search machine 
for publications as well as data analysis. The development of aims and the analysis of the data 
generated was performed by Francis Jacob under supervision of Dr. Viola Heinzelmann-
Schwarz. The OLOV database was previously designed by Dr. Matthias Heinzelmann and 
published in a publication (Heinzelmann-Schwarz V et al, Cancer Res 2004). In this study, 
however, we updated OLOV with up-regulated genes within all identified transcriptomic 
approaches, hereby highlighting the most promising ovarian cancer-associated genes/ proteins. 
Further support for this study was given from the statistical point of view by our collaborator 
Dr. Darlene Goldstein. 
8.2 Manuscript in preparation (1) 
The second manuscript entitled ”Serum anti-glycan antibody detection of non-
mucinous ovarian cancers using printed glycan array” represents the main part of this PhD 
thesis. This study was designed by the supervisor Dr. Viola Heinzelmann-Schwarz, including 
the setup of a large biobank, national and international collaborations and financial grant 
acquisition for this project. The main aim was the use of a new technology (printed glycan 
array), available via a collaboration with the Scripps Institute in San Diego to study the 
technical and biological distribution of anti-glycan antibodies in serum of healthy and ovarian 
cancer patients. The whole experimental procedure included the establishment of a large 
biobank after ethical approval (performed in parts by Francis Jacob), the experiments around 
the printed glycan array and the bioinformatical analysis (both parts performed by Francis 
Jacob under supervision). The printed glycan array experiments included (1) in-house printing 
of custom glycan arrays, (2) experimental development and screening of human serum samples 
and (3) mathematical data pre processing. All three steps were performed by Francis Jacob 
under guidance of the San Diego team Dr. Margaret Huflejt and Prof. Marko Vuscovic. The 
use of technical and biological relevant glycans was suggested by Francis Jacob. 
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Bioinformatical data analysis merging the clinical bio-databank PEROV (designed by Dr. M. 
Heinzelmann) to the printed glycan array data was performed by Francis Jacob under direct 
supervision of Dr. Darlene Goldstein. The whole project from its initial planning phase to the 
written manuscript was managed and supervised by Dr. Viola-Heinzelmann Schwarz. 
8.3 Manuscript in preparation (2) 
The third manuscript presented in this PhD thesis entitled “Comparison of three glycan-
based immunoassays: suspension array, ELISA and printed glycan array in the detection 
of human anti-glycan antibodies” describes three in-house developed glycan-based assays. In 
this publication we aim to investigate methodological as well as biochemical dependencies of 
glycan presentation to human anti-glycan antibodies. Results previously generated by printed 
glycan array (manuscript 2) were compared to two independent glycan-based assays which 
were developed within the Translational Research Group (TRG) at the University Hospital 
Zurich; Dr. Viola Heinzelmann-Schwarz). Bead-based suspension array as a technology was 
primarily developed by Dr. Tatiana Pochechueva whilst still being a Post-doctoral fellow in 
Prof. Nicolai Bovin’s laboratory in Moscow. The specific suspension array which is described 
within this paper, however, was developed by Dr. Pochechueva whilst being a Post-doctoral 
Fellow under Dr. Viola Heinzelmann-Schwarz. She was supported in these experiments by 
Francis Jacob. The third method, glycan-based ELISA was established and the experiments 
performed by Francis Jacob. Human serum samples of benign and malignant gynaecological 
cases were selected and anti-glycan antibody levels measured and analysed per each glycan-
based assay. As biological validation AB0-blood group related A and B trisaccharides were 
selected and anti-glycan antibody binding studied. In addition, the top candidate from 
publication 2, trisaccharide P1, was selected and profiled in the same cohort. 
Clinicopathological extracts from the PEROV database (Dr. Matthias Heinzelmann) were 
correlated to the experimental findings and statistical analysis performed by Francis Jacob 
under supervision of Dr. Darlene Goldstein. The whole project was designed, planned and 
supervised from the financial acquisition till the manuscript preparation by Dr. Viola 
Heinzelmann-Schwarz. Prof. Nicolai Bovin has supervised partially the suspension array part 
and has been involved in the manuscript writing due to his expertise in this field. 
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10 Appendix 
10.1 Abbreviations 
®  registered trade mark 
µl  microliter 
µM  micromolar 
2D PAGE Two-Dimensional Poly-Acrylamid 
Gel Electrophoresis 
AGA  Anti-Glycan Antibodies 
ANN  Neural Network Analysis 
Asn  asparagine 
Atri  GalNAcα1-3(Fucα1-2)Galβ 
AUC  Area under curve 
BCG  bacille Calmette-Guérin 
BG  blood group 
BL  borderline 
BMP7  bone morphogenetic protein 7 
BRAF  v-raf murine sarcoma viral 
oncogene homolog B1 
BRCA1  gene breast cancer 1, early onset 
BRCA2  gene breast cancer 2, early onset 
BSA  Bovin Serum Albumin 
Btri  Galα1-3(Fucα1-2)Galβ- 
CA125  mucin 16 (MUC16), cell surface 
associated 
CA15-3  Carbohydrate Antigen 15-3 
CA19-9  Carbohydrate Antigen 19-9 
CA72-4  Cancer Antigen 72-4 
CD43  leukosialin 
CD5+  Lymphocyte antigen T1/Leu-1 
cDNA  complementary DNA 
CFG  Consortium for Functional 
Glycomics 
CFR-1  cystein-rich fibroblast growth 
factor receptor 
CGH comparative genomic 
hybridization 
ClCOC  clear cell ovarian cancers 
cm  centimeter 
CTNNB1 catenin (cadherin-associated 
protein), beta 1, 88kDa 
CV  Coefficient of Variation 
DDR1  discoidin domain receptor tyrosine 
kinase 1 
DMH  differential methylation 
hybridization 
DNA   deoxyribonucleic acid 
EGFR  epidermal growth factor receptor 
ELISA  Enzyme-Linked Immunosorbent 
Assay 
EM  extracellular matrix 
EMA  epithelial membrane antigen 
EnOC  endometrioid ovarian cancers 
EOC  epithelial ovarian cancers 
ERBB2  v-erb-b2 erythroblastic leukemia 
viral oncogene homolog 2 
ESI electrospray ionization 
FA2  agalactosyl biantennary glycan 
FIGO  International Federation of 
Gynecology and Obstetrics 
Fuc  fucose 
Gal   galactose 
GalNAc  N-acetyl galactosamine 
GALNT1 UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N 
acetylgalactosaminyl transferase 1 
GAS6  growth arrest-specific 6 
GATA1  GATA binding protein 1 (globin 
transcription factor 1) 
GATA2  GATA binding protein 2 
(endothelial transcription factor 
GATA 2) 
GBP  Glycan-Binding Proteins 
GD3  Neu5Aca2-8Neu5Aca2-3Galβ1-
4Glcβ 
Glc   glucose 
GlcA  glucuronic acid 
GlcNAc  N-acetyl glucosamine 
Globo H  Fucα1-2Galβ1-3GalNAcβ1-
3Galα1-4Galβ1-4Glcβ 
Glyc Glycan 
GM2  Neu5Aca2-3(GalNAcβ1-4)Galβ1-
4Glcβ 
GPI glycophosphatidylinositol 
GRP78  glucose-regulated protein, 78kDa 
GT3  Neu5Acα2-8Neu5Acα2-
8Neu5Acα2-3Galβ1-4Glc 
H type 1 Fucα1-2Galβ1-3GlcNAc 
H type 2  Fucα1-2Galβ1-4GlcNAc 
HE4  WAP four-disulfide core domain 2 
(alias WFDC2, WAP5) 
HGSC  high-grade serous carcinoma 
HMFG-IIIC12 milk fat globule-EGF factor 8 
protein 
HOXA7  homeobox A7 
HOXB7  homeobox B7 
HRPO  horseradish peroxidase 
IdA  iduronic acid 
IgA  Immunoglobulin A 
IgD  Immunoglobulin D 
IgG  Immunoglobulin G 
IgM  Immunoglobulin M 
IL-8  interleukin 8 
IMAC  immobilized metal affinity 
chromatography 
INHA  inhibin, alpha 
INHB  inhibin, beta 
kDa  kilodaltons 
KLK8  kallikrein-related peptidase 8 
KRAS  v-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog 
LASA  lipid-associated sialic acid 
LC  liquid chromatography 
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Leb  Fucα1-4(Fucα1-2Galβ1-
3)GlcNAcβ 
Lex  Galβ1-4(Fucα1-3)GlcNAβ 
Ley  Fucα1-3(Fucα1-2Galβ1-
4)GlcNAcβ 
LGSC  low-grade serous carcinoma 
LMP  low-malignant potential 
L-PHA  leukocytic phytohemagglutinin 
mAb  monoclonal antibody 
MALDI  matrix-assisted laser 
desorption/ionization 
Man  mannose 
MCF-7  Michigan Cancer Foundation-7 
cell line 
medTSI median total signal intensity 
MFI median fluorescence intensity 
MGED  Microarray Gene Expression Data 
MIAME  Minimal Information About 
Microarray Experiments 
MIAPE  Minimal Information About 
Proteomics Experiments 
MISFISHIE Minimum Information 
Specification For In Situ 
Hybridization and 
Immunohistochemistry 
Experiments 
ml  milliliter 
MOC  mucinous ovarian cancers 
MS  Mass Spectrometry 
MSLN  mesothelin 
MUC1  mucin 1, cell surface associated 
n  number 
Neu5Ac  neuraminic acid 
Neu5Gc  N-glyconeuraminic acid 
NHS  N-hydroxysuccinimide 
NSAID  non-steroidal anti-inflammatory 
drugs 
OD optical density 
OI4  collagen, type I, alpha 2; 
osteogenesis imperfecta type IV 
OLOV  OverLapping OVarian data base 
OSE  ovarian surface epithelium 
OVCAR-3 human ovarian cancer cell line 3 
OVXI  mAb recognizes modified Lewis X 
determinant on mucin 
P1  Galα1-4Galβ1-4GlcNAc 
p53  gene for tumor protein p53 
PAA  polyacrylamide 
PBS phosphate buffered saline 
PCR  polymerase chain reaction 
PEROV  Peritoneal and Ovarian Cancer 
data base 
PGA  printed glycan array 
PIK3CA  phosphoinositide-3-kinase, 
catalytic, alpha polypeptide 
Pk  Galα1-4Galβ1-4Glc 
PTEN  phosphatase and tensin homolog 
PTM  post-translational modification 
QS-21  Quillaja Saponaria 21 
RFU  relative fluorescence unit 
Rha  Rhamnose 
RMI  Risk of Malignancy Index 
RNA  ribonucleic acid 
ROC  Receiver Operating Characteristics 
S100A7  S100 calcium binding protein A7 
SA   Suspension Array 
SAX2  Strong Anion Exchanger 2 
SELDI  Surface-Enhanced Laser 
Desorption and Ionization 
SEM  scanning electron microscopy 
Ser  serine 
SEREX  serological analysis of 
recombinant cDNA expression 
sLea  Neu5Acα2-3Galβ1-3(Fucα1-
4)GlcNAcβ 
sLex  Neu5Acα2-3Galβ1-4(Fucα1-
3)GlcNAβ 
SNP single nucleotide polymorphism 
SOC  serous ovarian cancers 
SSEA3  Galβ1-3GalNAcβ1-3Galα1-
4Galβ1-4Glcβ1-1Ceramide 
sTn  Neu5Acα2-6GalNAcα 
T antigen Thomson-Friedenreich antigen 
TACA  tumor-associated carbohydrate 
antigen 
TCEP HCl Tris (2-carboxylethyl) phosphine 
hydrochloride 
TCOC  transitional cell ovarian cancer 
TF  Thomson-Friedenreich antigen 
TFCP2  transcription factor CP2 
TGF-beta transforming growth factor-beta 
Thr  threonine 
TMB  3,3′,5,5′-Tetramethylbenzidine 
Tn  GalNAcα 
TOF  Time of Flight 
TRITC  Tetramethyl Rhodamine Iso-
Thiocyanate 
U  Units 
v  version 
VEGF  vascular endothelial growth factor 
VTCN1  V-set domain containing T cell 
activation inhibitor (alias B7-H4) 
WCX2  Weak Cation Exchanger 2 
WHO  World Health Organization 
Xyl  xylose 
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